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Summary 
 
   
SUMMARY 
 
To allow the correct functioning of an organism and to adapt to physiological and 
environmental changes, the expression of a specific subset of genes in each different cell 
type has to be tightly regulated. Nuclear factor κB (NF-κB) is a family of inducible 
transcription factors able to drive the transcription of hundreds of genes implicated in the 
regulation of several cellular processes such as innate and acquired immunity, cell 
proliferation and apoptosis. The aim of this thesis was to investigate how acetylation of 
p65, the best-studied subunit of NF-κB, affects NF-κB-driven transcription. 
Our results indicate that p65 is acetylated by p300 in vitro and in vivo at lysines 
310, 314 and 315. Acetylation of p65 does not influence nuclear-cytoplasmic shuttling, 
DNA binding or cell viability in response to TNFα. Genome-wide gene expression 
analysis revealed that p65 acetylation seems to play a role in NF-κB-dependent gene 
expression. Real-time RT-PCR analysis of specific genes suggest that acetylation at lysine 
310 is required for full activation of a subset of genes, while acetylation at lysines 314 and 
315 is needed for the decreased expression of another group of genes.  
We also identified SIRT2 as a novel p65 deacetylase. SIRT2 belongs to the family 
of NAD+-dependent deacetylases called sirtuins. Deacetylation assays performed in vitro 
or in HEK 293T cells with overexpressed proteins revealed that SIRT2 deacetylates p65 at 
all three lysines 310, 314 and 315. Furthermore, p65 is hyperacetylated at lysine 310 in 
Sirt2-/- MEFs after TNFα stimulation in vivo. Both endogenous proteins interact in the 
cytoplasm of Jurkat T-cells under basal conditions. While p65 shuttles to the nucleus in 
response to TNFα stimulation, SIRT2 stays in the cytoplasm, implying that SIRT2 
deacetylates p65 in the cytoplasm. Furthermore, gene expression of Mpa2l, a gene found 
to require acetylation of p65 at K310 for its proper expression, was misregulated in Sirt2-/- 
MEFs.  
In addition, we studied the role of CARM1 as a transcriptional coactivator of NF-
κB. A subset of NF-κB-dependent genes that require CARM1, but not its enzymatic 
activity, for their proper expression was identified. 
Together, our data suggests that p65 acetylation regulates the expression of 
specific NF-κB-dependent genes and that this is in part controlled by SIRT2-mediated p65 
deacetylation. 
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ZUSAMMENFASSUNG 
 
Damit ein Organismus korrekt funktioniert und sich an Umwelteinflüsse und intrazelluläre 
Veränderungen anpassen kann, muss die Expression spezifischer Gene in jedem Zelltyp fest 
reguliert sein. Nukleärer Faktor κB (NF-κB) ist eine Familie von induzierbaren 
Transkriptionsfaktoren, welche die Expression von Hunderten von Genen steuern kann, die 
in verschiedenen zellulären Prozessen wie der angeborenen und erworbenen Immunität, der 
Zellvermehrung sowie der Apoptose, beteiligt sind. Das Ziel dieser Doktorarbeit war es zu 
untersuchen, wie die Acetylierung von p65, einer der wichtigsten Untereinheiten von NF-κB, 
die Funktion von NF-κB beeinflusst. 
 Unsere Ergebnisse zeigen, dass p65 von p300 in vitro und in vivo an drei Lysinen 
310, 314 und 315 acetyliert wird. Die Acetylierung von p65 hatte keinen Einfluss auf die 
Translokation von p65 in den Nukleus, auf die DNA Bindung oder auf das Überleben der 
Zellen nach Stimulierung mit TNFα. Eine genom-weite Genexpressionsanalyse deutete 
darauf hin, dass die Acetylierung von p65 eine wichtige Rolle in der Modulierung der NF-
κB-abhängigen Genexpression spielt. Real-time RT-PCR Analysen von verschiedenen 
Genen zeigen, dass die Acetylierung von Lysin 310 für die vollständige Expression einiger 
Gene erforderlich ist, während die Acetylierung von Lysin 314 und 315 für die reduzierte 
Expression anderer Gene benötigt wird. 
 Zusätzlich haben wir SIRT2 als neue p65 Deacetylase identifiziert. SIRT2 gehört zu 
den Sirtuinen, einer Familie von NAD+-abhängigen Deacetylasen. Deacetylierungs-
experimente in vitro oder in Zellen mit überexprimierten Proteinen zeigten, dass SIRT2 p65 
an allen drei Lysinen 310, 314 und 315 deacetyliert. Ausserdem war p65 an Lysine 310 in 
Sirt2-/- MEFs nach Stimulierung mit TNFα hyperacetyliert. Endogenes p65 und SIRT2 
interagierten im Zytoplasma von unstimulierten Jurkat T-Zellen. Während sich p65 nach 
Stimulierung mit TNFα in den Nukleus translozierte, blieb SIRT2 im Zytoplasma. Dies 
deutet darauf hin, dass SIRT2 p65 im Zytoplasma deacetyliert. Die Genexpression von 
Mpa2l, für dessen richtige Expression die Acetylierung von p65 an K310 benötigt wird, war 
in Sirt2-/- MEFs dereguliert.  
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Zusammengefasst sprechen unsere Ergebnisse dafür, dass die Acetylierung von p65 
die Expression von bestimmten NF-κB-abhängigen Genen reguliert und dass dies zum Teil 
durch SIRT2-vermittelte Deacetylierung von p65 kontrolliert wird. 
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ABBREVIATIONS 
 
aa   Amino acids 
acetyl-CoA   Acetyl coenzyme A  
ADP   Adenosine diphosphate 
ATP   Adenosine triphosphate 
ATPase  Adenosine triphosphatase 
BAFF   B-cell activating factor  
bp   Base pair 
Brd4    Bromodomain containing 4 
CARM1   Coactivator-associated arginine methyltransferase 1 
CBP   cAMP-response element-binding (CREB) binding protein 
CDK   Cyclin-dependent kinase 
ChIP   Chromatin immunoprecipitation 
CK2   Casein kinase 2  
CMV   Cytomegalovirus  
CTD    Carboxy-terminal domain of Pol II 
C-terminal  Carboxy terminal 
DNA   Deoxyribonucleic acid 
FoxO   Forkhead box O  
GCN5   General control non-derepressible 5 
GDH   Glutamate dehydrogenase  
GSK3β   Glycogen synthase kinase 3β 
GTFs   General transcription factors 
H   Histone 
HAT   Histone acetyltransferase 
Hda1   Histone deacetylase A 1 
HDAC   Histone deacetylase 
HDACi  Histone deacetylase inhibitor 
HIF-1α   Hypoxia-inducible factor 1, alpha subunit 
HIV-1   Human immunodeficiency virus type 1 
HP1   Heterochromatin protein 1 
IFN   Interferon 
IκB   Inhibitor of NF-κB  
IKK   IκB kinase  
IL-1β   Interleukin-1β  
IRF   Interferon regulatory factor 
K   Lysine 
kB   kilo bases 
kDa   kilo Dalton 
LPS   Lipopolysaccharides 
LTβ   Lymphotoxin-β 
MEFs   Mouse embryonic fibroblasts 
mRNA   Messenger RNA 
MSK1/2  Mitogen- and stress-activated protein kinase 
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MYBBP1a  Myb binding protein 1a 
NAD+   Nicotinamide adenine dinucleotide  
Nam   Nicotinamide  
N-CoR   Nuclear receptor corepressor 
ncRNA  Non-coding RNA 
NEMO   NF-κB essential modulator 
NES   Nuclear export signal  
NF-κB   Nuclear factor κB 
NLS   nuclear localization signal  
N-terminal  Amino terminal 
OAADPr   2’-O-acetyl-ADP ribose  
p300   E1A-associated protein of 300 kDa 
PARP1   Poly(ADP-ribose) polymerase 1 
PCAF    p300/CBP-associated factor  
PHD   Plant-Homeo domain 
PIC   Pre-initiation complex 
PKA   Protein kinase A  
Pol II   RNA polymerase II 
PRMT   Protein arginine N-methyltransferase 
P-TEFb   Positive transcription elongation factor b 
rDNA   ribosomal DNA  
RHD   Rel Homology Domain  
RNA    Ribonucleic acid 
Rpd3   Reduced-potassium-dependency gene 3 
RSK1    Ribosomal S6 kinase 1 
RT-PCR  Reverse transcriptase polymerase chain reaction 
SIR   Silent information regulator 
SIRT   Sir2-related protein (sirutin) 
SMRT   Silencing mediator of retinoic acid and thyroid hormone receptors 
SRC-1   Steroid receptor co-activator 1 
TAD   Transactivation domain  
TAFs   TBP-associated factors 
TBP   TATA box binding protein 
TFII   Transcription factor of Pol II 
Tip60   Tat interacting protein 60 kDa 
TNFα   Tumor necrosis alpha 
TSA   Trichostatin A  
TSS   Transcription start site 
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INTRODUCTION 
 
1 RNA polymerase II dependent transcription 
 
The execution of biological processes such as development, differentiation and proliferation, 
requires the precise and orchestrated expression of genes. The genetic information of DNA is 
transcribed into different forms of RNA in a highly coordinated process known as 
transcription (reviewed in [1]). The cellular enzymes responsible for this synthesis are RNA 
polymerases (Pol). Three main RNA polymerases have been identified in higher eukaryotes, 
including RNA Pol I, II and III [2]. Pol I is primarily implicated in transcribing 18S and 28S 
ribosomal RNAs, whereas Pol II is responsible for all messenger RNA (mRNA) synthesis in 
eukaryotes [3], and Pol III is involved in the synthesis of cellular 5S sRNA, tRNAs and 
adenovirus VA RNAs [4].  
In eukaryotes, transcription of protein-coding genes by Pol II proceeds through 
multiple steps that include the formation of a pre-initiation complex (PIC), initiation, 
promoter clearance, elongation and termination of transcription [5]. The expression of 
protein-coding genes is not only regulated at the level of transcription, but also through 
mRNA processing and transport, translation and mRNA stability (reviewed in [1]). The 
major regulatory step is thought to occur at the level of transcriptional initiation. 
Eukaryotic Pol II dependent transcription usually requires several factors classified 
into three groups: general transcription factors (GTFs), promoter-specific transcription 
factors, and cofactors, which will be discussed in the following sections. 
 
1.1 The general transcription machinery  
To achieve accurate transcription in vitro, a minimum number of proteins is required, 
including Pol II and general transcription factors (GTFs) (reviewed in [4]). 
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1.1.1 RNA polymerase II 
The polymerase that synthesizes protein-coding messenger RNA (mRNA) in eukaryotes is 
Pol II. Yeast and human Pol II consists of 12 different subunits, designated RPB1 to RPB12 
[6]. In higher eukaryotes, the carboxyl terminal domain (CTD) of RPB1, the largest subunit 
of Pol II, contains a tandem repeat of the heptapeptide sequence YSPTSPS, with 52 copies in 
mammals and 26 to 29 in yeasts [7]. Posttranslational modifications in CTD are crucial for 
transcriptional regulation at multiple steps. For example, CTD phosphorylation at mainly 
serines 2 and 5 constitutes a major regulation step in transcription: Pol II involved in PIC 
assembly is unphosphorylated, whereas highly phosphorylated CTD is required for transcript 
initiation, elongation and termination (reviewed in [5]). More specifically, Pol II 
phosphorylation at serine 5 associates with promoter-proximal regions of transcribed genes, 
whereas phosphorylation at serine 2 increases toward the 3’-end of the gene. Several stress-
associated and cyclin-dependent kinases (CDK) have been described to phosphorylate CTD: 
serine 5 is phosphorylated by CDK7 present in TFIIH and by CDK8 found in Mediator, 
while serine 2 is phosphorylated by CDK9 associated with positive transcription elongation 
factor b (P-TEFb). A recent study shows that unphosphorylated CTD binds to DNA, and that 
this complex is recognized by CDK7, which can then phosphorylate CTD at serine 5 [8]. 
Upon phosphorylation, CTD dissociates from DNA, allowing transcriptional activation. The 
CTD then becomes accessible to CDK9 to phosphorylate serine 2, resulting in transition to 
transcription elongation. Phosphorylation at serine 7 has been recently shown to be important 
for small nuclear RNAs (snRNAs) maturation [9]. 
Unlike prokaryotic enzymes, eukaryotic Pol II is not able to recognize the promoters 
by itself and to drive transcription in vitro [10]. For site-specific initiation, additional 
proteins, called the general transcription factors (GTFs), are necessary. 
 
1.1.2 General transcription factors 
Recruitment of Pol II to the transcription start site (TSS) is facilitated by GTFs, known as 
TFIIA, -B, -D, -E, -F and –H, which assemble at the core promoter in a stepwise manner to 
form a pre-initiation complex (PIC) [10, 11]. Early in vitro experiments determined that 
GTFs are required for correct initiation of Pol II transcription, being TFIID usually the first 
factor to bind DNA by recognizing the TATA box, initiator (Inr) and/or downstream 
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promoter element (DPE) found in most core promoters. TFIID is a multiprotein complex 
containing TBP (TATA box binding protein) and approximately 14 TBP-associated factors 
(TAFs), which are important for promoter recognition rather than activation [12]. After 
TFIID association with DNA, TFIIA and TFIIB are recruited to stabilize the promoter-bound 
TFIID. Pol II and TFIIF are then recruited, followed by TFIIE and finally by TFIIH. TFIIH 
has three enzymatic functions required for transcription: ATPase involved in transcription 
initiation and promoter clearance, ATP-dependent helicase to unwind the DNA, and CTD 
kinase. Alternatively, Pol II can also exist as a preassembled holoenzyme complex consisting 
of Pol II, a subset of GTFs and other proteins. Once PIC is assembled, Pol II escapes from 
the promoter in a process known as promoter clearance, to start with mRNA elongation. 
Meanwhile, a scaffold structure composed of TFIID, TFIIE, TFIIH and Mediator remains on 
the core promoter for subsequent reinitiation of transcription, which is a much faster process 
than the initial round [13].  
 
1.2 Transcription factors and cofactors 
Formation of the PIC is sufficient for a basal level of transcription in vitro. However, 
transcriptional activity is greatly stimulated by transcription factors and coactivators. In the 
cells, a tight regulation of transcription is in part achieved by transcription factors (activators 
and repressors) and cofactors (coactivators or corepressors). 
 
1.2.1 Transcription factors 
In general, promoter-specific transcription factors bind DNA in a sequence-specific manner 
upon activation. The recognition sites of transcription factors are usually upstream of the core 
promoter, either in proximal promoters or enhancers [14]. Depending on the cellular context, 
these proteins can either activate or repress transcription. Several signaling pathways control 
the activities of transcription factors [1]. 
DNA-bound activators are thought to stimulate transcription by recruiting histone-
modifying enzymes and remodeling complexes to generate local chromatin decompaction, 
thus allowing the binding of the transcription machinery; activators also influence 
transcription by interacting directly with GTFs and Pol II to allow targeting of them to gene 
12
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promoters [15]. Conversely, repressors can influence transcription in a negative way either by 
blocking the binding of a nearby activator, by directly competing for binding to the same site, 
by establishing a ‘closed’ chromatin structure or by inhibiting PIC assembly [16]. In some 
cases, an activator can become a repressor by differential cofactor recruitment.  
 
1.2.2 Transcription cofactors 
Typically, cofactors are proteins that regulate transcription without binding directly to DNA; 
they are rather recruited through protein-protein interactions with a DNA-bound transcription 
factor. Like transcription factors, transcription cofactors can either stimulate (coactivators) or 
inhibit (corepressors) transcription by linking transcription factors with GTFs, by modifying 
chromatin and by stimulating PIC formation (reviewed in [17]). Many transcriptional 
cofactors are enzymes that directly modulate the chromatin structure by remodeling 
nucleosomes or by modifying histones (discussed in more detail in sections 2.2 and 2.3 
respectively) [1]. A general feature of coactivators is that they can stimulate transcription 
synergistically. 
Mediator is a key coactivator of Pol II, which is absolutely required for both basal and 
activator-dependent transcription in vitro and in vivo of almost all Pol II promoters from 
yeast to humans (reviewed in [18]). Mediator is a multi-protein complex with more than 20 
subunits that bridges the interaction between transcription factors at an enhancer and the 
transcription machinery at the promoter to stimulate the initiation of transcription [19]. But 
mediator does not only function as coactivator, it can also repress transcription [20].  
 
1.3 Transcriptional regulatory elements   
In order to modulate transcription, GTFs and transcription factors bind to regulatory 
sequence elements on the DNA, including core promoters, proximal promoters, enhancers, 
silencers and insulators. 
 
1.3.1 Core promoter elements 
Core promoter is the minimal portion of the promoter required to properly initiate 
transcription in vitro, since it is the platform for the assembly of transcription PIC. It 
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typically extends 40-50 bp up- and downstream of the TSS, thus defining the position of the 
TSS as well as the direction of transcription [21]. To date, seven core promoter elements 
have been identified, namely TATA box, the initiator (Inr), the downstream promoter 
element (DPE), the motif ten element (MTE), the downstream core element (DCE), the 
upstream TFIIB-recognition element (BREu) and the downstream TFIIB-recognition element 
(BREd) (reviewed in [22]). The TATA-box, which is recognized by the TBP subunit of 
TFIID, was the first core promoter element to be described.  
 
1.3.2 Proximal promoters, enhancers, silencers and insulators 
The proximal promoter is the region immediately upstream from the core promoter. It 
constitutes a few hundred bp long region where multiple binding sites for transcription 
factors can be found. Transcription factors can also bind DNA on enhancers to activate 
transcription. Enhancers are usually located far away from the core promoter, either up- or 
downstream of TSS, even in introns (reviewed in [23]). Many different transcription factors, 
coactivators and chromatin remodeling proteins assemble at enhancers and facilitate the 
recruitment of Pol II to the promoter of a gene located several kilobases (kB) away by DNA 
loop formation (Figure 1). Thus, enhancers regulate genes from a distance in a position- and 
orientation-independent manner (reviewed in [24]).  
Silencers, on the other hand, are sequence-specific elements that regulate transcription 
in a negative manner by binding repressors that prevent Pol II to initiate transcription. As for 
the enhancers, silencers can be located far away from the TSS.  
Insulators are genetic boundary elements that block genes from being affected by the 
transcriptional activity of neighboring genes by disrupting the communication between a 
regulatory sequence and a promoter  (reviewed in [25]). By doing so, insulators influence 
transcriptional regulation and global nuclear organization (reviewed in [26]).  
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Figure 1. Classical model of transcription activation in eukaryotes. The activator  (Act) binds to the distal 
enhancer (step 1) and recruits chromatin remodeling complexes (Rem) and histone acetyltransferases (HAT) to 
make the chromatin more accessible (step 2). TFIID can then bind to the core promoter to nucleate the assembly 
of the PIC (step 3). Mediator (Med) then bridges the interaction between the enhancer-bound activator and the 
transcription machinery at the promoter to recruit Pol II and initiate transcription (step 4) [27]. 
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1.4 Revision to the classical definitions of eukaryotic Pol II transcription 
The GTFs are considered ‘general’ because they were proposed to be required for the 
transcription of every Pol II dependent gene [28]. However, recent in vivo studies have 
shown that not all GTFs are present in every PIC, in part because certain GTFs are not 
expressed in every cell type of a given organism [29]. In addition, although TFIID was 
initially defined as a TATA-binding factor, it seems to act primarily through TATA-less 
promoters [30]. On the other hand, TBP binding to the TATA box is not a prerequisite for 
gene expression in vivo [31]. 
Several studies have shown that the core promoter elements may not be as universal 
as once thought neither. For example, the TATA box has been recently identified as being 
present in less than 30% of all human and yeast Pol II promoters [30, 32, 33]. Furthermore, a 
whole class of promoters has been described that contain multiple TSS over a region of 100 
bp, referred as broad-peak TSS-containing promoters [34]. They are much more abundant 
than single peak promoters and their regulation seem to be completely different. While single 
peak promoters contain usually a TATA box and are involved in the tight regulation of 
tissue-specific genes, broad peak promoters often harbor CpG islands, are TATA-less and 
associate with ubiquitously expressed genes. In addition to multiple TSS, alternative 
promoters of protein-coding genes have been also described, which are clearly separated by 
several hundred bp [35, 36]. These alternative promoters have been associated with a tight 
regulation of developmental genes. 
Recent in vivo studies have shown that Pol II recruitment to DNA is by far more 
complex than originally described. PIC assembly was initially described to occur at the core 
promoter. Recent studies have shown that Pol II and GTFs may also bind to enhancer and 
intergenic regions, though more weakly than to promoters (reviewed in [37]). Binding to 
enhancer regions has been observed as an early event in gene activation, thus playing a role 
in transcriptional initiation. Some enhancers have been proposed to function as nucleation 
centers for the PIC assembly to regulate the timing of gene activation during development, 
differentiation and the cell cycle  (reviewed in [27]). After formation of the PIC at some 
enhancers, the active PIC would be quickly transferred to the specific promoters when the 
cell receives the necessary signal. It is still not clear how general this event is, and whether 
the PIC is transferred from the enhancer to the promoter by DNA looping or by tracking. 
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Enhancers do not only localize in cis up to several hundred kB away from the 
regulated gene, they can also be confined to another chromosome, thus modulating 
transcription in trans [38]. Inter-chromosomal associations have been described to be 
involved in processes such as T lymphocyte differentiation, genomic imprinting, X 
inactivation and expression of odorant receptor in sensory neurons [39]. 
Several studies have shown that Pol II can accumulate at inactive or lowly expressed 
genes. For example, chromatin immunoprecipitation (ChIP) assays in Drosophila 
melanogaster revealed Pol II localization to proximal promoter of heat-shock genes already 
before heat-shock induction [40], which was a surprise since Pol II recruitment was thought 
to be the limiting step in transcription. Later, Pol II was found to be transcriptionally engaged 
at these promoters, though arrested after formation of a short nascent RNA molecule of about 
25 nucleotides [41]. These findings introduced the concept of ‘Pol II proximal promoter 
pausing’, which occurs at a variety of genes, is conserved from yeast to humans, and is 
thought to be required for full activation of genes (reviewed in [42]). Thus, in addition to PIC 
formation, mRNA elongation constitutes an important regulatory step of transcription as 
well.  
Genome-wide investigations showing Pol II pausing at proximal promoters have also 
reported transcription in the opposite direction of the sense RNA, referred to as antisense 
transcription. Though initially thought to be a rare event, several recent studies have shown 
that bidirectional transcription is a general feature of eukaryotic transcription [43-48]. 
Moreover, it correlates with active promoter regions rather than having a random distribution 
through the genome. However, while sense RNA tends to get elongated, antisense RNA 
transcription fails to proceed beyond promoters. Whether antisense transcription is a 
byproduct of sense transcription, or whether it is required for sense transcription is still not 
clear. 
The completion of the Human Genome Project on 2003 allowed the identification and 
analysis of functional elements in 1% of the human genome by the Encyclopedia of DNA 
Elements (ENCODE) project [49]. They identified previously unrecognized TSS, many of 
them hundreds of thousands of bases away from the known TSS. Additional exons from the 
protein-coding genes were also described, sometimes located thousands of bases away from 
the gene, sometimes even hidden in another gene. In addition, they found that approximately 
one forth of the recognized promoters is located at the end of the gene. One of the main 
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conclusions of this study was that the human genome is pervasively transcribed, since 80% of 
the bases studied were expressed. The majority of this transcription was shown to take place 
at non-coding DNA, consistent with the finding that only around 1% of the whole genome is 
protein-coding DNA [50]. Non-coding RNAs (ncRNAs) are known to regulate gene 
expression at different levels, including chromatin structure, transcription, RNA processing, 
RNA stability and mRNA translation (reviewed in [50] and [51]). In addition to ribosomal 
and transfer RNA, which constitute large part of all ncRNA, other ncRNAs have been 
identified in the last years. Some examples are small RNAs (small interfering RNA, 
microRNA and piwi-associated RNA) important for gene expression regulation, small 
nuclear RNAs involved in splicing of mRNA, Xist necessary for inactivation of the second X 
chromosome in females and telomerase RNA used as template for addition of telomeres [52-
56]. The ENCODE project allowed the discovery of numerous novel ncRNAs, whose 
functions have yet to be determined.  
The local environment of a gene such as nucleosome positioning and histone 
modifications heavily affects the transcription of a gene (reviewed in [57] and [58]). 
Furthermore, the formation of higher order structures of chromatin and the position of a gene 
in the nucleus also influences gene expression (reviewed in [59] and [60]). The impact of 
chromatin structure on transcription will be discussed in the following sections. 
 
 
2 Chromatin 
 
Genomic DNA has to be efficiently packaged in order to fit into a cell, given that DNA is 
considerably longer than the diameter of every cell. This compaction is achieved in 
eukaryotic cells by wrapping DNA around histone proteins, forming so a dynamic structure 
known as chromatin [61]. These core histones are highly conserved proteins that consists of a 
globular domain and an unstructured N-terminal “tail” that is subjected to several 
posttranslational modifications, generating different chromatin structures [58]. The relaxed 
structure permissive to transcription is called euchromatin and is often associated with active 
transcription of genes. In contrast, constitutive heterochromatin is tightly packed and 
inaccessible to transcription factors, thus it is poorly transcribed [62]. There exist an 
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intermediate state, facultative chromatin, which is condensed and repressed as constitutive 
heterochromatin, but can decondense to allow transcription under specific conditions 
(reviewed in [63]). 
 
2.1 Nucleosome 
The fundamental subunit of chromatin is the nucleosome, which consists of 147 bp of DNA 
wound around an histone octamer composed of two copies each of the four core histones 
(H3, H4, H2A and H2B) [64]. These core histones contain a globular domain involved in 
histone-histone interactions, and an N-terminal histone tail, which is approximately 15 to 30 
amino acids (aa) long and highly modified posttranslationally [65]. A chain of nucleosomes 
can coil in a regular manner to form a so-called 11-nm fiber (Figure 2). The next level of 
compaction is the 30-nm fiber, in which linker histone H1 is incorporated and the DNA is 
furthermore condensed in part due to the neutralization of the DNA charge by the positively 
charged histone tails [57].  
 
 
Figure 2. Chromatin structure. Schematic representation of the DNA wrapped around eight core histones in the 
nucleosome, forming “beads on a string” structure. The further coiling in condensed chromatin, the 30-nm fiber, 
inhibits transcription. 30-nm fibers form loops, increasing condensation yields “higher-order chromatin folding” 
[66]. 
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In general, chromatin creates a natural barrier for the binding of GTFs and 
transcription factors to their regulatory sequences on DNA [57]. Consistent with this, several 
genome-wide studies showed that nucleosome density at promoter regions is typically lower 
than in the coding region [67-69]. Nevertheless, some transcription factors, such as the 
glucocorticoid receptor, are able to bind to its DNA recognition sequences even when they 
are packaged into nucleosomes [70].  
The dynamic state of chromatin is mainly achieved by two distinct classes of 
mechanisms: ATP-dependent chromatin remodeling and posttranslational modifications on 
histones, which will be discussed in the following sections. 
 
2.2 Chromatin remodeling  
Chromatin remodeling complexes use ATP hydrolysis to alter the chromatin structure by 
disrupting or moving histone octamers along DNA [71]. By doing so, they can render 
nucleosomal DNA either accessible or inaccessible for regulatory proteins. Chromatin 
remodeling factors are divided into four main families according to their similarities in their 
ATPase subunit: SWI/SNF (switch/sucrose nonfermenting), ISWI (imitation of switch), INO 
(inositol), and CHD (chromodomain helicase/ATPase DNA binding protein) [65]. The 
ATPases are generally present in complexes with 4 to 12 other protein subunits [72].  
 
2.3 Posttranslational modifications of histones  
Both histone tails and globular domains are subject to multiple posttranslational 
modifications at several sites by many distinct classes of enzymes. These posttranslational 
modifications have a great impact on processes involved in DNA metabolism such as 
transcription [73]. Up to date, eight distinct types of modifications have been described on 
histones, including acetylation [74], methylation [75], phosphorylation [76], ubiquitination 
[77], ADP-ribosylation [78], sumoylation [79], deimination [80] and proline isomerization 
[81]. They influence the packaging of chromatin by two different mechanisms: recruitment of 
effector proteins that bind the modified histone and disruption of contacts between 
nucleosomes (reviewed in [58]).  
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Posttranslational modifications are dynamic; they can appear and disappear on 
chromatin within minutes. Thus, enzymes that remove the modifications have been 
identified. Methylation of histone tails was long believed to be stable and irreversible, until 
the discovery of the first demethylase, LSD1 [82]. Many of the enzymes that modify histones 
have non-histone substrates as well. 
Acetylation, methylation, phosphorylation and ubiquitination of histones have been 
implicated in gene activation, whereas methylation, ubiquitination, sumoylation, deimination 
and proline isomerization have a role in repression (Table 1).  
 
 
Table 1. Chromatin modifications. Shown are the various posttranslational modifications of histones, the 
transcriptionally relevant sites and the transcriptional outcome. DNA methylation was not a subject of this 
work. Table taken from [83]. 
 
 
Recent observations suggest that there is no clear division between active and repressive 
modification states [83]. For example, methylation of lysine 4 of histone H3 (H3K4) usually 
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correlates with transcriptional activation [84-86]. However, H3K4 methylation within the 
ribosomal RNA locus can lead to repression of Pol II transcription [87]. 
 
2.3.1 Crosstalk between different histone posttranslational modifications 
Different histone modifications might influence each other (reviewed in [88]). For example, 
one histone modification could promote the generation of another. This is the case of H3S10 
phosphorylation, which facilitates the binding of Gcn5 and the subsequent acetylation of 
H3K14 [89]. Conversely, one histone modification could impair the formation of another. 
Posttranslational modification at lysine residues are a good example for this: since lysines 
can be subjected to many different types of modifications including acetylation, methylation, 
sumoylation and ubiquitination, one type of modification excludes the others on the same 
lysine residue. Furthermore, deimination of histones converts arginines to citrullines, thus 
preventing arginine methylation [80]. Histone modifications could also direct the loss of 
particular modifications; for example, methylation of H3K36 promotes deacetylation of H3 
and H4 by Rpd3S deacetylase complex in yeast [90]. In addition, crosstalk can also occur 
between modifications on different histone tails; for example, H2B ubiquitination is required 
for H3K4 and H3K79 methylation in yeast [91]. 
 
2.3.2 The histone code 
It is thought that every histone modification leads to a specific biological outcome [58]. This 
has led to the proposal of the histone code hypothesis, which predicts that the 
posttranslational modifications of the histone tails, alone or in combination, can be “read” by 
proteins to modulate transcription and other DNA-template programs [92]. Increasing 
evidence indicates that the modified histones create binding sites for specific domains that 
are often associated with enzymes that modify or alter chromatin (Figure 3) [93, 94].  
For example, the bromodomain, a conserved motif found in many proteins that 
modulate chromatin structure, binds to acetylated lysine residues on histone H3 and H4 (see 
section 3.3) [95]. Furthermore, TAF3, a component of TFIID, binds to H3K4me3 via its plant 
homeodomain (PHD) finger [96]. H3K4me3 is a hallmark of active human promoters, thus 
this finding sheds light on why this histone modifications is important for gene activation. In 
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contrast, methylation of lysine 9 on histone H3 (H3K9me3/me2), a mark of heterochromatin, 
is recognized by the chromodomain of repressive heterochromatin protein 1 (HP1) [97]. This 
interaction leads to the structural formation of compacted chromatin, which represses 
transcription. But effector proteins may also recognize unmodified chromatin. For instance, 
the PHD finger of BHC80, a component of the LSD1 co-repressor complex, preferentially 
binds to unmethylated H3K4 compared to its methylated counterparts [98]. 
 
 
Figure 3. (A) Proteins are recruited to chromatin modifications via specific domains that recognize these modifications. 
Methylation (Me) is bound by chromo-like domains of the Royal family (chromo, tudor, malignant brain tumor (MBT)) 
and plant homeodomain (PHD) domains; acetylation (Ac) of lysines (K) is recognized by bromodomains (Bromo), and 
phosphorylation (P) of serines (S) by a domain within 14-3-3 proteins. (B) Some examples of proteins known to interact 
with modified chromatin via their specific domains: bromodomain PHD finger transcription factor (BPTF), 
chromodomain helicase DNA binding protein 1 (CHD1), inhibitor of growth family member 2 (ING2), heterochromatin 
protein 1 (HP1), 14-3-3, remodels the structure of chromatin (Rsc4), polycomb (PC), EPEC adherence factor (EAF3), 
Crumbs homolog 2 (CRB2), Jumonji 2 (JMJD2) and bromodomain containing 2 (Brd2) [58]. 
 
It is important to keep in mind that the histone code is not as strict as the genetic code: 
one specific posttranslational modification on histone tails does not always correlate with the 
same outcome [99]. The cellular context plays an important role in determining the functional 
readout of a posttranslational modification during a specific cellular response to an 
extracellular or intracellular stimulus. 
 
 
3 Nε-acetylation of proteins 
 
In contrast to co-translational N-terminal α-acetylation of many proteins, Nε-acetylation is a 
reversible, posttranslational modification that consists of the transfer of an acetyl group from 
acetyl coenzyme A (acetyl-CoA) to the ε-amino group of a lysine in the target protein (Figure 
4) [100]. This reaction is also different from the newly described protein O-acetylation, 
which competes with phosphorylation [101, 102]. Up to date, only lysines have been 
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demonstrated to be Nε-acetylated. Because lysine acetylation was first described in histones, 
the enzymes responsible for the catalysis of acetylation are often referred as histone 
acetyltransferases (HATs) and the ones performing the reversed reaction as histone 
deacetylases (HDACs). The dynamic equilibrium of these two classes of enzymes in the cells 
results in a rapid turnover of acetylation [103].  
 
 
 
Figure 4. Acetylation and deacetylation reaction. Histone acetyltransferases (HATs) transfer the acetyl moiety 
from acetyl Coenzyme A (acetyl-CoA) to the amino group of internal lysine residues on histone or other non-
histone proteins. The reversed reaction is catalyzed by histone deacetylases (HDACs) [100].  
 
Acetylation was first discovered in histones more than 40 years ago, whereas the first 
HAT was identified only a decade ago [104-106]. Of all the posttranslational modifications, 
acetylation has the most potential to achieve decompaction of chromatin because it partially 
neutralizes the positive charge of histones and thus weakens intra- and inter-nucleosomal 
interactions of the chromatin fiber [107, 108]. It was the first modification of chromatin to be 
described and to be correlated with increased gene activation [105, 109]. All four core 
histones (H2A, H2B, H3 and H4) can be acetylated, though H3 and H4 modifications are 
mainly responsible for gene activation. Deacetylation of histones, in contrast, is associated 
with repression [100]. Thus, it is no surprise that certain histone deacetylases (HDACs) are 
part of repressor complexes, while some transcriptional coactivators possess intrinsic histone 
acetyltransferase (HAT) activity [74, 110]. 
Fifteen years after histone acetylation was discovered, acetyl lysine residues were 
found in high-mobility group protein 1 (HMG1) [111]. More importantly, the first non-
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histone target of HAT was reported only a decade ago: p53 [112].  Since then, many other 
non-histone proteins have been described to be acetylated [113]. It is now well established 
that acetylation is a quite common posttranslational modification in eukaryotes, virus and 
bacterial proteins [114]. It has been described in numerous proteins, among them more than 
80 transcription factors, many other nuclear regulators and several cytoplasmic proteins 
[113]. In eukaryotic cells, most acetylated proteins are localized to the nucleus. However, this 
posttranslational modification is also important for regulating different cytoplasmic 
processes, such as cytoskeleton dynamics, energy metabolism, endocytosis, autophagy and 
signaling from the plasma membrane [115]. 
Once a protein is acetylated, its biological function may be affected in different ways. 
For instance, protein acetylation neutralizes the positive charge of lysines. As a result, the 
electrostatic properties of the protein are strongly modified, thus influencing the interaction 
with other proteins, DNA or RNA [113]. Alternatively, lysine acetylation can impair the 
ability to form hydrogen bonds, which may be important for processes such as 
oligomerization [116]. Furthermore, in addition to acetylation, lysines are subject to other 
posttranslational modifications, including methylation, ubiquitination and sumoylation. Thus, 
any of these modifications would preclude the other ones and their functional consequences. 
As in histones, acetylation of a lysine residue might affect modification of a neighboring 
residue in non-histone proteins as well, which let to the proposal of extending the ‘histone 
code’ to a more general term such as the ‘protein modification code’ [115]. The biological 
function of a protein may be further influenced by interaction with bromodomain-containing 
proteins (described in more detail in section 3.4). 
 
3.1 Histone acetyltransferases 
HATs are enzymes capable of acetylating histones as well as non-histone proteins [117]. The 
first HAT to be identified was cytoplasmic Hat1 (Histone acetyltransferases 1) from S. 
cerevisiae [118]. The first nuclear HAT was discovered in the ciliate Tetrahymena 
thermophila and was found to be homologous to yeast Gcn5 (general control non-
derepressible 5), followed by the rapid identification of HAT activity on several known 
transcription-related proteins, such as TAF1 (TAFII250) and CBP [119-121]. HATs are 
evolutionary conserved from yeast to humans and present in multimeric complexes involved 
in transcription as coactivators [122]. In general, HATs have limited specificity by 
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themselves; the remaining subunits of the multimeric complexes allow the targeting of the 
HAT complex to the correct substrate and the regulation of the specific activity [123]. 
Interestingly, multiple HATs have been shown to acetylate the same substrate [114]. 
HATs can be divided into three main families on the basis of their catalytic subunit: 
GNATs (Gcn5-related N-acetyltrasnferases), p300/CBP (E1A-associated protein of 300 
kDa/CREB-binding protein) and MYST proteins [124].  
 
3.1.1 GNATs 
Gcn5, a protein present in all eukaryotes, is the founding member of the GNATs [125]. In 
yeast, Gcn5 is present in four distinct multiprotein complexes: SAGA (Spt-Ada-Gcn5-
acetyltransferase), ADA, SLIK and HAT-A2 [117, 126]. Mammalian PCAF (p300/CBP-
associated factor), a structurally similarly protein to yeast Gcn5, is also a member of this 
family of HATs [127]. Other HATs included in this family are yeast Elp3, Hat1, Hpa2 and 
Nut1 [117]. 
 
3.1.2 MYST 
Another group of HATs is the MYST family, named by he founding members: MOZ, Ybf2 
(Sas3), Sas2 and Tip60 [74]. Tip60 (Tat-interactive protein, 60 kDa) was the first human 
MYST member to be identified [128]. In addition to the founding members of this family, 
new HATs have been identified, including yeast Esa1, Drosophila MOF, and human HBO1 
and MORF. These enzymes are involved in the regulation of a wide range of cellular 
processes in diverse organisms, such as transcriptional silencing, cell cycle progression, 
dosage compensation, transcriptional activation and oncogenic transformation [74].  
 
3.1.3 p300/CBP 
p300 and CBP are two different nuclear proteins with high sequence homology and very 
similar cellular functions, which possess HAT activity [121, 129]. They are able to modify all 
four histones in vitro with little apparent specificity [129], as well as non-histone proteins. In 
addition, p300 and CBP have been shown to autoacetylate themselves to regulate their HAT 
activity [130]. 
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These very large proteins (around 300 kDa) are ubiquitously expressed proteins found 
only in metazoans [131]. p300/CBP are transcriptional coactivators that are able to mediate 
the communication between at least 40 different transcription factors and the basal 
transcription machinery [132]. Since they are thought to be present in limiting amounts in the 
cells, transcription factors have to compete for these pivotal co-activators. Knockout mice for 
p300/CBP dye at embryonic stage, reflecting how important these proteins have become for 
higher eukaryotes [133]. 
 
3.1.4 Other HATs 
In addition to the HATs mentioned above, over 10 other proteins have been described to 
possess intrinsic HAT activity. However, since they do not contain true consensus HAT 
domains, they are classified as an ‘orphan class’ of HAT enzymes [134]. Among these HATs 
is TAF1, the largest subunit of TFIID. It was shown to contain histone acetyltransferase 
activity in vitro, which may allow the formation of the PIC after acetylating histones at the 
TATA box [120]. Subunits of TFIIIC, a general transcription factor in the RNA pol III basal 
machinery, have also been shown to possess HAT activity [135]. The human nuclear receptor 
coactivators SRC-1 (Steroid receptor coactivator 1) and ACTR (Activator of retinoid 
receptor) are additional members of the ‘orphan class’ of HATs [136, 137]. In addition, 
CLOCK, a circadian rhythm protein, has been described as an acetyltransferase, too [138]. 
Yeast Rtt109 (regulator of Ty1 Transposition gene product 109) is a member of this family of 
HATs as well; it promotes genomic stability through the direct acetylation of H3K56 [139]. 
Several other proteins have been described as members of the ‘orphan class’ of 
HATs, including Elp3 (Elongator protein3), Eco1 (Establishment of cohesin 1), CDY 
(chromodomain on 1 chromosome), and TFIIB [124]. 
 
3.2 Histone deacetylases 
HDACs were first discovered in 1996 [140]. Mammalian HDACs are divided 
phylogenetically into four main classes based on their homology to enzymes first described 
in yeast: class I HDACs are homologues of yeast Rpd3 (reduced-potassium-dependency gene 
3), class II HDACs of yeast Hda1 (a subunit of histone deacetylase A complex) and class III 
HDACs of Sir2 (silent information regulator 2) [141]. The last identified HDAC, HDAC11, 
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has similar homology to both Rpd3 and Hda1 and is therefore grouped into a separate class; 
class IV [142, 143]. Class I, class II and class IV form together the ‘classical’ family of 
HDACs, whereas class III is also referred to as ‘sirtuins’. 
 
3.2.1 ‘Classical’ HDACs 
The ‘classical’ family of HDACs contains 11 members in humans: class I includes HDAC 1, 
2, 3 and 8; class II is composed of HDAC 4, 5, 6, 7, 9 and 10; and class IV includes only 
HDAC11 (depicted in Table 2) [141]. HDAC1, the orthologue of yeast Rpd3, was the first 
HDAC to be described [140]. Members of the ‘classical’ HDAC family are conserved from 
yeast to human and have a quite similar mechanism of action, since they all require zinc ion 
to hydrolyze the acetyl group [103].  However, additional cofactors are required for HDAC 
activity, since most recombinantly expressed enzymes are found to be inactive [103]. The 
‘classical’ HDACs are inhibited by trichostatin A (TSA). The majority of HDACs are found 
in multiprotein co-repressor complexes that act on specific regions of chromatin by 
deacetylating it, thus repressing transcription [141].  
 
 
HDAC  HDAC  Localization  Expression  Function  
group  members  
Class I  HDAC1, Nuclear   Ubiquitous  Involved in a variety of functions, such 
(Rpd3)  HDAC2,       as transcriptional repression and cell 
  HDAC3,       differentiation.  
  HDAC8  
 
Class II  HDAC4, Nuclear and   Tissue-specific Transcriptional repression, microtubule 
(Hda1)  HDAC5, cytoplasmic     regulation 
  HDAC6,      
  HDAC7,       
  HDAC9,  
  HDAC10  
 
Class IV HDAC 11 Nuclear  Tissue-specific  Immune tolerance 
Table 2. ‘Classical’ histone deacetylases. Adapted from [65]. 
 
All class I members are widely expressed proteins [144]. They, together with the class 
IV member, localize exclusively to the cell nucleus. In contrast to class I HDACs, class II 
HDACs members are expressed in a tissue-specific manner and described to regulate 
differentiation and development [144]. They are able to shuttle between nucleus and 
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cytoplasm in response to certain cellular signals [141]. Some of them are transcriptional 
repressors that are exported from the nucleus to allow transcriptional activation of genes 
[110].  
 
3.2.2 Sirtuins 
Yeast Sir2 has been implicated in DNA repair, recombination, replication and increased 
replicative lifespan [145]. Furthermore, Sir2 has been shown to silence transcription at 
telomeres, mating-type loci and ribosomal DNA (rDNA), through deacetylation of histones 
[146]. Sir2 is highly conserved from bacteria to higher eukaryotes and has seven homologues 
in mammals, called sirtuins (SIRT1 to 7), depicted in Figure 4. They share a conserved 
catalytic core domain of ∼250 amino acid (aa) residues in the central part of the proteins 
[147].  
 
 
Figure 4. Sirtuins. Shown are the cellular localizations, enzymatic activities and targets of the mammalian 
sirtuins [148]. The newly identified deacetylation target of SIRT6, H3K9, is not depicted in this figure. 
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In addition to deacetylate proteins, some sirtuins have been described to ADP-
ribosylate them. They require nicotinamide adenine dinucleotide (NAD+) as a cofactor in 
their deacetylation reaction unlike class I, II and class IV HDACs, which need zinc [146]. 
This NAD+-dependency links sirtuin proteins to the metabolic state of cells and helps to 
regulate sirtuins’ activity [149]. During the deacetylation reaction, nicotinamide (Nam) is 
cleaved from NAD+ and the acetyl group of the substrate is then transferred to NAD+, 
generating the novel metabolite 2’-O-acetyl-ADP ribose (OAADPr) [150]. Since Nam is a 
byproduct of the reaction, an excess of it in the cells inhibits sirtuins’ deacetylase activity. Up 
to date, all sirtuins have been described to have deacetylation activity except for SIRT4, 
which is able to ADP-ribosylate proteins, as well as SIRT6, SIRT2 and SIRT3 [151-155].  
SIRT1 is the best-characterized member of this family, given its higher homology to 
Sir2 [153]. As its yeast homologue, SIRT1 has been implicated in the formation of 
heterochromatin, as well as survival under stress, glucose homeostasis and aging. It is found 
predominantly in the nucleus, where it deacetylates histones H3K9, H4K16, and H1K26, as 
well as transcriptional regulators such as TAFI68, p53, p300, forkhead box O (FoxO) 
transcription factors and nuclear factor κB (NF-κB) [147, 156-159]. These are only some 
examples of the growing number of SIRT1 targets.  
SIRT2 has been described to regulate microtubule dynamics and possibly cell cycle 
progression [160-162]. It was originally identified as a cytoplasmic protein, but growing 
evidence indicates that it can also localize to the nucleus under specific conditions [162-164]. 
SIRT2 has been described to deacetylate α-tubulin and FoxO1 in the cytoplasm, while 
histone H4K16 and p300 were identified as its nuclear targets [161, 162, 165, 166].  
SIRT3, 4 and 5 are localized to the mitochondria, where SIRT3 and SIRT5 
deacetylate several proteins [163, 167]. SIRT4 inactivates glutamate dehydrogenase (GDH) 
by ADP-ribosylating it, thus regulating the levels of insulin [151]. SIRT6 is a nuclear protein 
able to ADP-ribosylate itself [152]. Recently, it has been shown to deacetylate H3K9, which 
modulates telomeric chromatin and represses NF-κB dependent genes [168, 169]. Lastly, 
SIRT7 is localized to nucleoli, where it activates transcription by RNA polymerase I [170]. 
p53 has also been described to be deacetylated by SIRT7 [171]. 
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3.3 Bromodomain as acetyl lysine binding module 
Acetylation regulates several cellular processes, specially chromatin compaction and gene 
expression. One way of doing so is by creating docking sites for bromodomain-containing 
proteins. The bromodomain was initially described as an evolutionary conserved domain of 
about 110 aa present in several proteins involved in transcriptional regulation, such as the 
HATs p300, CBP, GCN5, PCAF and TAF1, and other chromatin factors, listed in Table 3 
[114, 172]. After the discovery of the specific interaction between the bromodomain of 
PCAF and acetyl lysines [173], it was clear that this is a module on proteins that binds acetyl 
lysines.  
Many bromodomain proteins are part of multi-protein complexes, which after 
recruitment to the acetyl lysine execute their biological function. Therefore, bromodomains 
have important roles in persistent chromatin acetylation by HATs and acetylation-dependent 
nucleosome assembly and remodeling [114]. In addition, bromodomains bind to acetylated 
non-histone proteins. The binding specificity of different bromodomains to their specific 
interaction partners is determined by flanking residues of the acetyl lysine, which are also 
recognized by bromodomains [174]. In fact, acetyl lysine is necessary but not sufficient for 
efficient binding by bromodomains [114].  
Several bromodomain proteins have two of these modules. Interestingly, sequence 
alignment have revealed that when two bromodomains are present in the same protein, they 
share less similarity to each other than to similarly located bromodomains in other related 
proteins [172]. Thus, different bromodomain subunits may cooperate to recognize distinct 
acetylated sites on the same target. 
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Species/         #  bromo binding to Complex   Biological function  
Protein   acetyl lysine in 
 
S. cerevisiae  
Gcn5  1 H4 and H2A SAGA, ADA, HAT2, SALSA Acetylation, coactivator 
Spt7  1 nucleosome SAGA, SALSA   Coactivator 
Swi2/Snf2 1 nucleosome SWI/SNF   Chromatin remodeling 
Sth1  1   RSC    Chromatin remodeling 
Rsc1  2   RSC    Chromatin remodeling 
Rsc2  2   RSC    Chromatin remodeling 
Rsc4  2 H3K14  RSC    Chromatin remodeling 
Bdf1  2 H4  TFIID interaction, SWR  Anti-silencing 
Bdf2  2   TFIID interaction  
TBP7/YTA 1 
 
Mammals 
GCN5  1 H4K8  STAGA, TFTC   Acetylation, coactivator 
PCAF  1 H3, H4, Tat PCAF    Acetylation, coactivator 
p300  1 MyoD, STAT3     Acetylation, coactivator 
CBP  1 histones, MyoD,     Acetylation, coactivator 
   c-Myb, p53 
TAF1  2 H3, H4, p53 TFIID    Transcription initiation 
MLL  1   ALL-1 complex   Histone methylation 
MLL2  1       Homolog of ALL-1 
hASH1  1       Histone methylation 
Brm  1   BAF (hSWI/SNF)  Chromatin remodeling 
BRG1  1   BAF, PBAF, NUMAC  Chromatin remodeling 
Polybromo 6   PBAF    Chromatin remodeling 
BAZ1A  1   huCHRAC, hACF/WCRF, hNURF Chromatin remodeling 
BAZ1BF 1   WICH    Chromatin remodeling 
BAT2A  1   NoRC    Chromatin remodeling  
BAZ2B  1 
BPTF  1   hNURF    Chromatin remodeling 
Brd2  2 H4K12  Mediator   Coactivator 
Brd3  2  chromatin     Coactivator 
Brd4  2 H3, H4, p65     Coactivator  
Brd5  2 chromatin  
TIF1α  1   HP1 interaction   Corepressor 
TIF1β  1   HP1 interaction   Corepressor 
TIF1γ  1   HP1 interaction   Corepressor 
BR140  1 
Brd1  1 
Brd7  1       Transcr. coregulator 
Brd8  1   Tip60     Coactivator 
WDR9  2       Coactivator 
BS69  1       Corepressor 
PRO2000 1 
CECR2  2 
PRKCBP1 1 
 
Table 3. Bromodomain proteins in yeast and mammals. Adapted from [114]. 
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4 NF-κB family of transcription factors 
 
Cells have to continually adapt to changes in their environment. One way to achieve this is 
by activating inducible transcription factors that modify the pattern of gene expression in the 
cells. One well-known example of inducible transcription factors is nuclear factor κB (NF-
κB), which regulates the expression of a large number of target genes involved in several 
cellular processes such as immune and inflammatory response, apoptosis, cell proliferation, 
cell differentiation and survival [175]. Consequently, it is not surprising that a deregulation of 
this transcription factor would lead to several pathologies, such as inflammatory diseases, 
neurodegenerative disorders and cancer [176, 177]. In addition, NF-κB p65 subunit knockout 
mice dye at embryonic day 15.5 by massive degeneration of the liver, strengthening the fact 
that NF-κB is a key factor in the regulation of normal cellular events [178]. 
 
4.1 NF-κB family members 
First discovered 23 years ago [179], NF-κB is an ubiquitously expressed family of proteins 
found in every mammalian cell. It is conserved from the phylum Cnidaria to humans, 
although it is notably absent in yeast and C. elegans [180]. Three Rel proteins have been 
described in Drosophila called Dorsal, Dif and Relish; thus, NF-κB is an ancient signaling 
pathway and the major mediator of the immune system [181]. 
The mammalian NF-κB family consists of five members depicted in Figure 5A: p65 
(also known as RelA), c-Rel, RelB, p105/p50 (NF-κB1) and p100/p52 (NF-κB2) (reviewed 
in [182]). All NF-κB subunits share a highly conserved Rel Homology Domain (RHD) at the 
amino terminus of the protein that is approximately 300 aa long. This domain is important for 
DNA binding, dimerization of the family members, interaction with the inhibitor of NF-κB 
proteins (IκB) and nuclear localization. In addition, p65, c-Rel and RelB contain a C-terminal 
transactivation domain (TAD), required for induction of target genes. The other two 
members, p105 and p100, are the precursors of p50 and p52, respectively. These long 
proteins have to be processed by proteosome-mediated partial proteolysis to become active 
by loosing the ankyrin repeats at the C-terminal region of the proteins. While p100 is 
processed to p52 upon stimulation and activation of the NF-κB pathway, the majority of p50 
is constitutively generated during translation without having p105 as precursor [183].  
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Figure 5. Schematic representation of NF-κB, IκB and IKK proteins. Members of the NF-κB (A), IκB (B), and 
IKK (C) family are shown. The number of amino acids is shown on the right. Presumed sites of cleavage of 
p100 and p105 are indicated. In addition, phosphorylation and ubiquitination sites on p100, p105 and IκB 
proteins are shown. (RHD) Rel homology domain, (TAD) transactivation domain, (LZ) leucine zipper domain, 
(GRR) glycine-rich region, (HLH) helix-loop domains, (Z) zinc finger domain, (CC1/2) coiled-coil domains, 
(NBD) NEMO-binding domain, (α) α-helical domain. Picture taken from [182]. 
 
 
NF-κB family members form homo- or heterodimers with each other, which can then 
bind to DNA. Up to date, 12 distinct combinations have been described. The most abundant 
dimer is the one composed of p65 and p50. RelB does not form homodimers, but it can 
dimerise with p50 and p52. Homodimers of p50 and p52 are unable to induce gene 
expression because they lack a transactivation domain, and are found associated to silenced 
genes in unstimulated cells [184].  
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4.2 NF-κB signaling pathways 
There are two well-described signaling pathways that lead to NF-κB activation: the canonical 
or classical pathway and the non-canonical or alternative pathway, both depicted in Figure 6 
(reviewed in [185]). The canonical pathway is induced by pro-inflammatory cytokines such 
as tumor necrosis α (TNFα) and interleukin-1β (IL-1β), as well as viral and bacterial 
products.  
 
 
Figure 6. The classical and alternative NF-κB pathway. A simplified schematic representation of the two main 
signaling pathways of NF-κB, the classical (A) and the alternative (B) pathways. See text for detailed 
discussion. Picture taken from [182]. 
35
Introduction 
 
 
  In most unstimulated cells, NF-κB dimers containing p65 or cRel reside in the 
cytoplasm in an inactive form bound to IκBα or IκBβ [175]. IκB proteins possess multiple 
ankyrin repeat domains and bind to different combinations of NF-κB transcription factors, 
shown in Figure 5. The prototypical IκB protein is IκBα, which preferentially binds p50/p65 
heterodimers. This binding masks the nuclear localization signal (NLS) found in p65, leading 
to sequestration of the transcription factor in the cytoplasm. Nevertheless, a fraction of the 
cellular NF-κB/IκBα complexes shuttles between the nucleus and the cytoplasm due to the 
unmasked NLS of p50 and nuclear export signal (NES) of IκBα.  
Once a cell is stimulated, the IκB kinase (IKK) complex is activated and 
phosphorylates the IκB proteins at specific residues (serine 32 and 36 in IκBα). This event 
leads to ubiquitylation and subsequent degradation of IκBs by the 26S proteosome, which 
results in unmasking of the NLS present in p65, rapidly shifting the balance towards 
translocation of NF-κB to the nucleus. There it binds to specific sequences in promoter or 
enhancer region of genes, regulating so their transcription by recruiting co-activators and co-
repressors. One of the first genes to be induced is IκBα, generating a negative feedback loop: 
NF-κB is redistributed to the cytoplasm by the newly synthesized IκB protein [186]. Thus, in 
most cases, NF-κB is transiently activated. Though, since several transcription factors such 
as p53, c-myc and HIF-1α (Hypoxia-inducible factor 1, alpha subunit) are among its target 
genes, NF-κB can indirectly influence the expression of many more genes than just its direct 
targets [187-189]. In the presence of continual inducer, NF-κB activation is cyclical, with 
nuclear NF-κB binding to DNA appearing and disappearing over time. 
The IKK complex consists of two catalytic subunits, IKKα and/or IKKβ, and the 
regulatory subunit NEMO (NF-κB essential modulator, also known as IKKγ), shown in 
Figure 5C. IKKβ is mainly implicated in the canonical pathway, while IKKα homodimers 
are required for the non-canonical one, where they  phosphorylate p100 upon stimulation, 
resulting in its proteosomal processing to p52, depicted in Figure 6 [190]. This leads to 
liberation of RelB/p52 dimers that were sequestered in the cytoplasm by p100 [191]. The 
non-canonical pathway is mainly triggered by lymphotoxin-β (LTβ), B-cell activating factor 
(BAFF) and CD40, resulting in a transcriptional response with a much slower kinetics than 
the one from the canonical signaling pathway. While in the canonical pathway the induced 
genes play a role in the activation and regulation of the immune response, the non-canonical 
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pathway mainly regulates B-cell maturation and secondary lymphoid tissue formation. The 
two pathways may activate overlapping set of genes, although there are also specific genes 
[192, 193]. 
NF-κB can be activated through a less-known pathway, which is independent of IKK 
complex activation but still requires phosphorylation-dependent degradation of ΙκBα [194, 
195]. DNA damaging inducing agents such as UV irradiation and doxorubicin can trigger this 
third pathway. 
NF-κB signaling pathways can be activated by hundreds of stimuli such as cytokines, 
Lipopolysaccharides (LPS), growth factors and stress inducers [196]. As an ultimate result, 
NF-κB induces the expression of a large number of target genes in order to cope with the 
changing environment. Up to date, around 300 target genes have been described in 
mammalian genomes [196], (www.nf-kb.org). The set of genes that are regulated by NF-κB 
differ depending on the cell type and the inducing stimulus [197]. How does NF-κB mediate 
distinct cellular responses depending on the stimuli and the physiological context? There is 
no doubt that this can only be achieved through a tight regulation of NF-κB transcriptional 
activity. A key observation is that not all cell types are able to respond equally to a given 
stimulus, either because they miss the required receptor or the necessary signal transduction 
mechanism [198]. In addition, the expression of individual NF-κB subunits change in 
different types of mammalian cells, and this expression can be altered by environmental and 
developmental signals [199]. The specificity achieved during transcription is discussed in 
more detail in the next section. 
 
4.3 NF-κB-dependent transcription 
4.3.1 κB site 
NF-κB binds to chromatin in a sequence-specific manner to so called κB sites. The sequence 
of the canonical κB site for p65 is 5’ GGGRNNYYCC 3’ (R = purine, N = any base and Y = 
pyrimidine) [179]. It has been proposed that κB sites are often clustered and located in the 
proximal promoter. Nevertheless, there is more and more evidence that functional κB sites 
can also be located in intronic regions. In agreement with this, recent genome-wide studies 
have shown that only close to one third of p65 recruitment to DNA occurs within 5 kB 
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upstream of transcription start site (TSS) [200, 201]. κB sites are also present in some viral 
promoters such as human immunodeficiency virus type 1 (HIV-1) and cytomegalovirus 
(CMV) [202, 203]. Thus, if NF-κB is activated by a virus infection, it can transactivate the 
viral promoters as well as the host promoters, resulting in an enhanced viral transcription. 
Many studies have shown that the κB site sequence is highly degenerate, specially in 
the 3’ half of the site, and that some κB sites that deviate from the consensus sequence can 
anyway bind NF-κB dimers with high affinity [204]. The κB sites in many promoters are 
conserved throughout evolution, suggesting that the sequence plays an important role in 
selectivity. Whether κB site sequence determines which dimer will preferentially bind is still 
under debate. Initial in vitro studies suggested that this would be the case [205]. 
Nevertheless, with the exception of some cases, most κB sites do not show any clear 
specificity for a given dimer [206, 207]. In cells lacking individual NF-κB family members, 
no obvious correlation between κB site sequence and specific dimers have been found, 
though different NF-κB target genes have distinct requirements for NF-κB proteins [208]. 
Thus, promoter context rather than just the κB site sequence is important to accomplish 
specificity. 
Despite showing little relevance for dimer specificity, κB sites can influence which 
cofactor will interact with the bound NF-κB dimer [209]. In order to maximize the contacts 
with DNA, dimers adopt somehow different conformations depending on the κB site 
sequence, which influences the ability to interact with specific transcriptional co-regulators 
[210]. In addition, NF-κB binding to DNA is a very dynamic process which allows rapid 
exchange of dimers to fine-tune gene expression [211-213]. For example, ChIP-on-Chip 
experiments in monocytes have shown that p50 and p52 are recruited to a significant number 
of target genes in unstimulated cells. Upon LPS stimulation, other NF-κB subunits bind to 
several of these and other genes and, leading to an increase in RNA pol II occupancy and 
gene expression [213]. 
κB sites are not only located at the promoter region of target genes, but also on 
enhancers. For example, p65/p50 heterodimers have been shown to bind to an enhancer 
located in the second intron of the murine Mnsod gene upon TNFα stimulation, necessary for 
proper expression of Mnsod [214]. Another example of NF-κB binding to an enhancer 
element is at the IFN-β gene. In response to virus infection, NF-κB and other transcriptional 
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regulators bind to the enhancer located immediately upstream of the core promoter of IFN-β 
to form a multi-protein complex known as the IFN-β enhanceosome [215]. This coordinate 
assembly is required to allow RNA pol II binding to the core promoter and initiation of 
transcription. A recent study shows that NF-κB first binds to at least one of the three 
identified distinct genetic loci to subsequently bind to the IFN-β enhancer to nucleate 
enhanceosome assembly via interchromosomal associations [216]. Furthermore, NF-κB 
bound to the enhancer of murine CD80 gene has been shown to nucleate PIC assembly at this 
distal enhancer; PIC was then brought to within spatial proximity of the TSS by DNA 
looping to initiate transcription [217]. 
The crystal structure of RHD p50/p65 heterodimer bound to a κB site reveals an 
unusual conformation which resembles a butterfly, with the wings connected to a cylindrical 
body of DNA, shown in Figure 7 [210]. While the C-terminal domain of the two monomers 
interact with each other to allow dimerization, the DNA is wrapped around by the N-terminal 
domains in a way that positioning of the κB site into a nucleosome would constitute a sterical 
hinder.  
 
 
Figure 7. NF-κB conformation bound to DNA. The structure of the Rel Homology Domains (RHD) of p50/p65 
heterodimers bound to Ig-κB DNA sequence. p50 is depicted in green, p65 in red, the top strand of the DNA is 
in pink and the bottom strand is in yellow [210]. 
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4.3.2 Impact of chromatin structure on NF-κB-dependent transcription 
An additional level of transcriptional regulation is achieved by the chromatin environment 
surrounding the κB sites of the induced genes. An in vitro study shows that the affinity of 
NF-κB for its response element is not influenced by nucleosome positioning [218]. The 
situation might be different in vivo, if posttranslational modifications of histone tails and 
folding of chromatin into higher-order structures are considered as possible obstacles to NF-
κB binding. Interestingly, studies in macrophages have shown that NF-κB target genes can 
be divided into two groups depending on how fast they are induced. The first group of genes 
has constitutively and immediately accessible promoters resulting in fast gene expression 
while the other group has promoters that require stimulus-induced chromatin modification 
prior to gene induction [219]. Moreover, it has been shown in LPS-stimulated macrophages 
that chromatin-remodeling complexes are required for the induction of secondary response 
genes and primary response genes with delayed kinetics, but not for rapidly induced primary 
response genes [220]. These could be explained by at least two ways: either NF-κB binds to 
its response elements regardless of nucleosome positioning and then mediates the removal of 
inhibitory nucleosomes to allow the transcription machinery to bind, or chromatin-
remodeling complexes are first needed to increase the κB site accessibility. 
In any case, when p65 enters the nucleus it binds to a broader range of target genes 
promoters than those whose transcription is being regulated [200, 212]. Thus, although 
binding of NF-κB to chromatin is required for the activation of target genes, it is not 
sufficient to drive transcription. Indeed, NF-κB does not function alone, but it often 
cooperates with several other transcription factors to control gene transcription, such as Sp1 
[221], activator protein 1 (AP-1), interferon regulatory factors (IRFs) [222] and E2F1 [201]. 
The different transcription factors are present depending on cellular context and co-
stimulatory signals. This is strengthened by genome-wide mapping studies showing that 
around 50% of the p65 binding sites do not contain a canonical κB site [200, 201], meaning 
that either p65 binds to a yet unidentified sequence or that it binds trough interaction with 
other proteins that associate with DNA.  
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4.3.3 Cofactors of NF-κB in transcription 
NF-κB has been shown to interact with an increasing number of cofactors that can either 
activate (coactivators) or repress (corepressors) gene expression.  
In unstimulated cells, NF-κB target genes are basally repressed by p50 or p52 
homodimers bound to κB sites, which recruit co-repressor complexes. More specifically, p50 
homodimers have been reported to associate with HDAC1 at DNA, resulting in suppression 
of NF-κB transcription in unstimulated cells [223]. Other studies have shown that p50 
homodimers can tether other repressor complexes at the DNA consisting of SMRT (Silencing 
mediator of retinoic acid and thyroid hormone receptors) and HDAC3 or N-CoR (Nuclear 
receptor corepressor) and HDAC3 [224-226]. Upon stimulation of cells, these corepressor 
complexes are exported from the nucleus to allow transcription to occur, a process known as 
derepression. In addition, HDAC3 has been reported to repress NF-κB dependent 
transcription by directly deacetylating p65 after entry into the nucleus, resulting in 
termination of the NF-κB response [227]. HDAC1 and HDAC 2 have been shown to interact 
with p65 in the nucleus of unstimulated cells, resulting in a repression of basal as well as 
post-induction gene expression [228].  
SIRT-1 has been described as a potent NF-κB inhibitor, in part, by deacetylating p65 
at lysine 310 [159]. Furthermore, SIRT6 has been recently identified as a corepressor of NF-
κB for a subset of genes [169]. Additional reported repressors of NF-κB transcription are 
MYBBP1a (Myb binding protein 1a) [229] and copine-I [230]. 
Some of the identified NF-κB activators are p300/CBP [231, 232], PCAF [233], 
SRC-1 [234], TBP and TFIIB [235], TAF4b [236], TAF1 [237], Coactivator-associated 
arginine methyltransferase 1/ Protein arginine N-methyltransferase (CARM1/PRMT4) [238], 
Poly ADP-ribosylpolymerase 1 (PARP1) [239], RNA helicase A [240], P-TEFb  [241] and 
Brd4 (Bromodomain containing 4) [242]. The homologous proteins p300 and CBP were 
found to interact with p65 in response to TNFα and to increase NF-κB reporter gene 
expression [231, 232]. These two large multi-domain proteins are known to bridge the 
interaction between several transcription factors and components of the basal transcription 
machinery (reviewed in [243]). In addition, p300/CBP possess HAT activity and p300 have 
been reported to acetylate p65, which modulates NF-κB transcriptional activity [244, 245]. 
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PARP1 directly interacts with p300 and synergistically coactivates NF-κB-dependent 
transcription [239]. This is dependent on p300-mediated acetylation of PARP1 [246].  
Another coactivator of NF-κB is CARM1, which belongs to the family of protein 
arginine methyltransferases. CARM1 has been reported to be involved in transcriptional 
activation and mRNA stability/degradation through methylation of histones as well as several 
non-histone proteins [247]. This coactivator was shown to be required for the proper 
expression of a subset of NF-κB target genes upon TNFα or LPS stimulation [238]. 
P-TEFb, which consists of kinase CDK9 and cyclin T1, cyclin T2 or cyclin K, has 
also been described as an NF-κB coactivator. P-TEFb has been described to phosphorylate 
Pol II CTD, which is required for the elongation of mRNA [248]. To achieve this, P-TEFb is 
recruited to gene promoters through interaction with Brd4 [249], which is a bromodomain-
containing protein known to interact with various proteins to modulate transcription. P-TEFb 
has been shown to associate with NF-κB at the promoter of a subset of NF-κB dependent 
genes to stimulate transcriptional elongation by Pol II [241]. Interestingly, a recent study 
shows that Brd4 binds acetylated p65 through its two bromodomains resulting in increased 
transcription of a subset of genes [242]. Thus, Brd4 is thought to bridge the interaction 
between P-TEFb and acetylated p65 at the promoter of specific genes. 
In addition to all the aspects mentioned above, specificity of target genes is further 
achieved by posttranslational modifications of NF-κB, which may affect the interaction with 
transcriptional coactivators and corepressors [250, 251]. 
 
4.4 Regulation of p65 by phosphorylation and acetylation  
As histones and many other non-histone proteins, p65 can also be posttranslationally 
modified, resulting in an alteration of many of its biological functions. The possible 
modifications of p65 described until now are phosphorylation, acetylation, nitration, 
oxidation, proline isomeration, ubiquitination and methylation [250]. Many of these 
modifications are likely to vary between different cell type and stimuli. This section will 
focus on phosphorylation and acetylation of p65. 
p65 is phosphorylated at serine 276 by protein kinase A (PKA) in response to LPS 
[252] and MSK1/2 (mitogen- and stress-activated protein kinase 1/2) upon TNFα [253]. 
Other serine targets of phosphorylation are 536 by IKKα, IKKβ and RSK1 (Ribosomal S6 
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kinase 1); 468 by GSK3β (Glycogen synthase kinase 3β), IKKε and IKKβ [254-256]; 529 by 
casein kinase 2 (CK2) [257] , and 311 by PKCζ [258], which are reviewed elsewhere [250]. 
Threonine 435 has also been reported to be phosphorylated at p65 by an unidentified kinase; 
while dephosphorylation of this site by protein phosphatase 4 (PP4) occurs in response to 
cisplatin treatment [259]. From all these phosphorylation events, the ones on serine 276 and 
536 are required to allow the interaction between p65 and the transcriptional coactivators 
p300/CBP [260].  
Several lysines of p65 are subject to acetylation, mainly by p300/CBP. The Greene 
lab described acetylation at lysines 218, 221 and 310 by p300/CBP [244]. They showed that 
while acetylation of lysine 221 enhances DNA binding and, along with lysine 218, impairs 
interaction with IκBα; acetylation at lysine 310 is required for full transcriptional activity. In 
contrast, the Benkirane group reported that acetylation of p65 on other lysines (122 and 123) 
by both p300 and PCAF reduces DNA binding and thus promotes removal from DNA [261]. 
We have identified two additional acetyl acceptor sites upon TNFα stimulation, namely 
lysines 314 and 315, and confirmed lysine 310 acetylation [245]. Acetylation on these three 
lysines regulates the activation or repression of specific subset of genes, therefore providing 
specificity to NF-κB-dependent gene expression.  
Since phosphorylation of p65 on either serine 276 or 536 is needed to allow 
interaction with p300, it is also required for the subsequent acetylation at K310, thus leading 
to a crosstalk between these two posttranslational modifications [262, 263]. Because 
p300/CBP are essential coactivators of both p53 and p65, these two transcription factors 
compete for p300/CBP [264]. Interestingly, IKKα has been recently reported to 
phosphorylate CBP in a stimulus-dependent manner, which leads to an increased binding of 
CBP to NF-κB, resulting in p65 acetylation and NF-κB-mediated cell growth by activation of 
anti-apoptotic genes [265]. 
p65 can in turn be deacetylated by SIRT1 and HDAC3, which has been correlated 
with termination of the NF-κB response [159, 227, 261].   
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5 Aim of this thesis 
 
NF-κB is an inducible transcription factor known to regulate several cellular processes, 
including the immune response, apoptosis and cellular proliferation. To do so, it modulates 
the expression of specific genes selected from the more than 300 possible target genes. 
Because NF-κB has a pivotal role in the regulation of diverse cellular processes, a tight 
regulation of its activity is required. Posttranslational modifications, such as acetylation, are 
known to influence the activity of NF-κB. The aim of this thesis was to elucidate how p65 
acetylation affects NF-κB-driven transcription. 
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6 Published research articles 
 
6.1 Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of 
RelA/p65 
Authors:  Christine Buerki, Karin M. Rothgiesser, Taras Valovka, Heather R. Owen, 
Hubert Rehrauer, Monika Fey, William S. Lane and Michael O. Hottiger 
Journal: Nucleic Acids Research, Vol. 36, No. 5, March 2008 
Contribution: Planning and performance of the necessary experiments to show p65 
acetylation by p300 in cells, interaction between endogenous p300 and 
p65 in the different complemented cell lines, cell viability after TNFα 
treatment, gene expression analysis by real-time RT-PCR for a number of 
genes (Ccl-20, Ifi-44, Gbp-2) and of Ccl-7 protein levels. Helping in the 
experiment describing p65 acetylation at lysine 310 in vivo in response to 
TNFα stimulation, as well as in the analysis of results and the preparation 
of the figures and the manuscript. 
 
6.2 Deacetylation of p65 by cytoplasmic SIRT2 regulates NF-κB  
Authors:  Karin M. Rothgiesser, Susanne Waibel, Bernhard Lüscher and Michael O. 
Hottiger 
Journal:  Manuscript submitted 
Contribution: Planning and performance of all the experiments except cloning of the 
HA-SIRT2 wild type and mutant constructs. Analysis of all the results and 
preparation of the figures and the manuscript.  
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6.3 CARM1 but not its enzymatic activity is required for transcriptional coactivation of 
NF-κB-dependent gene expression 
Authors:  Sandrine Jayne, Karin M. Rothgiesser and Michael O. Hottiger 
Journal:  Manuscript submitted  
Contribution: Participation in the generation of custom microarrays specific for the study 
of NF-κB-dependent gene expression and standardization of this 
technique for our laboratory. 
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ABSTRACT
Nuclear factor kappaB (NF-iB) plays an important
role in the transcriptional regulation of genes
involved in immunity and cell survival. We show
here in vitro and in vivo acetylation of RelA/p65 by
p300 on lysine 314 and 315, two novel acetylation
sites. Additionally, we confirmed the acetylation
on lysine 310 shown previously. Genetic comple-
mentation of RelA/p65!/! cells with wild type and
non-acetylatable mutants of RelA/p65 (K314R and
K315R) revealed that neither shuttling, DNA binding
nor the induction of anti-apoptotic genes by tumor
necrosis factor a was affected by acetylation on
these residues. Microarray analysis of these cells
treated with TNFa identified specific sets of genes
differently regulated by wild type or acetylation-
deficient mutants of RelA/p65. Specific genes were
either stimulated or repressed by the acetylation-
deficient mutants when compared to RelA/p65 wild
type. These results support the hypothesis that site-
specific p300-mediated acetylation of RelA/p65
regulates the specificity of NF-iB dependent
gene expression.
INTRODUCTION
The inducible transcription factor family nuclear factor
kB (NF-kB) consists of dimeric proteins involved in many
diverse processes such as immune and stress responses and
the opposing processes of proliferation and apoptosis
(1–3). NF-kB is induced in almost all cell types by
different extracellular stimuli causing the activation of an
enormous array of target genes (4). Thus, it is not
surprising that the specificity of NF-kB responses is very
important for the fate of a cell. It has been shown that
abnormal NF-kB activity, which is not always associated
with genetic alterations, plays a role in different inflam-
matory diseases and cancer (5–7).
NF-kB specificity is regulated at different levels in
the cell (8). One level of regulation is the selective
activation of distinct NF-kB complexes after induction
by diverse stimuli. In mammals there exist five family
members, c-Rel, RelB, p65 (RelA), p105/p50 (NF-kB1)
and p100/p52 (NF-kB2) that can form a range of homo-
and heterodimers (9). After regulated IkB (inhibitor of
NF-kB)-dependent NF-kB translocation to the nucleus,
these dimers bind with variable affinities to consensus
NF-kB-binding sites in the promoter and enhancer regions
of their target genes, often cooperatively with other
transcription factors [e.g. IFNb promoter (10)]. This
integrates other signal transduction pathways with
the NF-kB pathway giving additional levels of specificity
and regulation to the transcriptional control of responsive
genes. The interaction with cell-type-specific co-factor
proteins has been shown to influence the transcriptional
potential of NF-kB (11). One of the co-factors of NF-kB
is the co-activator p300 and its homolog CBP (CREB-
binding protein). They have been shown to interact with
the RelA/p65 and the p50 subunit serving as molecular
bridges between NF-kB and the transcription machinery
(8,10,12–14). They contain intrinsic histone acetyltransfer-
ase activity catalyzing the acetylation of lysine residues
in histones and non-histone proteins (15,16). A growing
number of transcription factors are acetylated and
regulated by p300/CBP including p53 (17), GATA-1
(18), E2F-1 (19,20) and YY1 (21). Post-translational
acetylation influences different properties of these
transcription factors such as DNA binding, protein–
protein interactions, protein stability and transcriptional
potential (22).
NF-kB is subject to a variety of post-translational
modifications [e.g. phosphorylation (23), ubiquitination
(24) or prolyl-isomerisation (25)] that modulate
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its activity. Phosphorylation of the RelA/p65 subunit by
the PKAc, MSK1 and PKC! kinases enhances its
interaction with the co-activator p300/CBP and stimulates
the NF-kB transcriptional activity (26–28). In contrast,
ubiquitination of RelA/p65 on the promoter specifically
terminates the NF-kB response (24).
It has recently been shown that RelA/p65 and p50
are reversibly acetylated by p300 and PCAF (29–31).
Chen et al. identified lysine residues (K) 218, 221 and 310
of RelA/p65 as acceptor sites for p300 acetylation.
They reported that lysine 221 acetylation enhanced
DNA-binding activity of NF-kB in vitro and abolished
the interaction with IkBa leading to a prolonged NF-kB
response in the nucleus. The acetylation at lysine residue
310 was required for full transcriptional activity of RelA/
p65 (32). Kiernan et al. identified lysine 122 and 123 in
RelA/p65 as acetylation sites modified by both p300
and P/CAF. In contrast to K218, K221 and K310,
acetylation of K122 and K123 decreased the DNA
binding of RelA/p65 facilitating the removal of RelA/
p65 from the DNA and the export from the nucleus
by IkBa resulting in a faster termination of the NF-kB
response (30). Furthermore, a recent report presented
the TGF-b1 mediated acetylation of RelA/p65 at lysine
221 in vitro and in vivo enhancing the induced activation of
NF-kB by bacteria (33).
Together, these data question the precise functional
relevance of RelA/p65 post-translational acetylation
in NF-kB-dependent gene regulation in vivo. Thus, our
study aimed to identify the role of RelA/p65 acetylation
in vivo. We found that p300 efficiently acetylated RelA/p65
in vitro and in cells at lysine 314 and 315—two novel acetyl
acceptor sites. Additionally, our results confirmed the
acetylation of RelA/p65 at the previously reported site
of lysine 310 in vitro and in vivo. We generated acetylation-
deficient lysine to arginine substitution mutants of RelA/
p65 and stably complemented murine RelA/p65–/– cells
with these mutants. The nuclear-cytosolic shuttling and
the DNA binding of the acetylation-deficient mutants
were similar to that of wild type RelA/p65. Furthermore,
induction of anti-apoptotic genes by TNFa was not
affected by the non-acetylatable mutants of RelA/p65.
However, whole genome microarray analysis after TNFa
stimulation indicated that the expression of specific genes
was either positively or negatively affected by the K/R
mutations. Our results imply that although general
transcriptional activity of RelA/p65 was not affected by
acetylation at lysine 310, 314 and 315, the expression
of specific sets of genes was modulated by lysine-specific
acetylation of RelA/p65. Thus, site-specific acetylation
could serve as molecular mechanism to promote specificity
of NF-kB-dependent gene expression.
MATERIAL AND METHODS
Plasmids
hGCN5L, mP/CAF and hTip60 were cloned into
pFastBacHTb vector in frame with an N-terminal
6"His-tag. pph-CMV-Km-RelA/p65 wild type was pre-
viously described in (13). pph-CMV-Km-RelA/p65K310R
(K310R), pph-CMV-Km-RelA/p65K314/K315R (K314/
315R) and pph-CMV-Km-RelA/p65K310R/K314/K315R
(KTR) were generated by site-directed mutagenesis
according to the QuickChange protocol (Stratagene)
using the following oligonucleotides:
K310R: 50CGTAAAAGGACATACGAGACCTTCA
GGAGCATCATGAAGAAGAGTCC30,
50GGACTCTTCTTCATGATGCTCCTGAAGGTCT
CGTATGTCCTTTTACG30,
K314/315R: 50CCTTCAGGAGCATCATGCGGAGG
AGTCCTTTCAGCGGACCC30,
50GGGTCCGCTGAAAGGACTCCTCCGCATGA
TGCTCCTGAAGG30 (bold letters represent K/R muta-
tion). pphCMV-Km-RelA/p65K122/123R, pphCMV-
Km-RelA/p65K218/221R, pphCMV-Km-RelA/p65K218/
221/310R were generated using the QuickChange site-
directed mutagenesis protocol with pph-CMV-Km-RelA/
p65 wild type as template vector. The specific primer
sequences can be received upon request. The combina-
torial mutant pphCMV-Km-RelA/p65K218/221/310/314/
315R (KQR) was generated with the same protocol
using pph-CMV-Km-RelA/p65K310R/K314/K315R as
template vector. All introduced mutations were
confirmed by sequencing.
Reagents and antibodies
Mouse TNFa, Trichostatin A (TSA), Nicotinamide
(NAM), acetyl-Coenzyme A, calf thymus core histones
(H7755) and Trichloroacetic acid (TCA) were purchased
from Sigma. Sodium fluoride (NaF) and beta-glyceropho-
sphate were purchased from Flucka. 14C-labeled acetyl
Coenzyme A (MC269) was obtained from Moravek
Biochemicals. Most of antibodies were from Santa Cruz
Biotechnology: anti-RelA/p65 (C-20, sc-372), anti-a-tubu-
lin (TU-02, sc-8035), control mouse IgG (sc-2025) and
anti-PCNA (PC10, sc-56). The anti-p300 monoclonal
antibody was purchased from BD Pharmingen (554215).
The anti-p50 antibody was a generous gift from N. Rice
(National Cancer Institute, Frederick, MD). Anti-myc
9E10 antibody was either purified from hybridoma cells
according to standard protocol or purchased from Roche
Applied Science. The polyclonal anti-acetylated-Lysine
antibody was from Cell Signaling. A specific antibody
against acetylated lysine 310 of RelA/p65 was generated in
collaboration with Abcam. The anti-Ccl-7 antibody was
purchased from Abcam (ab9911).
Tissue culture, cell transfections
Complemented RelA/p65–/– NIH 3T3 mouse embryonic
fibroblasts (MEFs) and HEK 293T cells were maintained
in DMEM supplemented with 10% FCS, 100 units/ml
penicillin/streptomycin and non-essential amino acids
(GIBCO). Cells were transfected using the calcium
phosphate precipitation method.
Generation and purification of baculovirus expressed proteins
All recombinant proteins were expressed in Sf21 cells
using the Bac-To-Bac (GIBCO) or BacPAK (Clontech)
system. Recombinant His-tagged proteins were purified
over Ni2+-beads (ProBond, Invitrogen).
1666 Nucleic Acids Research, 2008, Vol. 36, No. 5
48
In vitro acetylation assay
One microgram of recombinant human wild type
or mutant RelA/p65 was incubated with 0.5–1 mg recom-
binant p300 or CBP or equimolar amounts of hGCN5L,
mP/CAF or hTip60 in HAT buffer (50mM Tris–HCl pH
8.0, 100mM NaCl, 10% glycerol, 1mM DTT, 1mM
PMSF, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml
leupeptin, 1mM sodium butyrate) supplemented with
1.5 nmol 14C-acetyl CoA for 45min at 308C. Reactions
were stopped by adding 10"Laemmli-buffer and proteins
resolved on SDS–PAGE with subsequent visualization
by Coomassie brilliant blue or SyproRuby staining.
The gel was immersed in 1M sodium salicylate for
20min at RT. After drying, the gel was exposed to
X-ray films (Contatyp) at –808C.
MS/MS
In vitro acetylated RelA/p65 was resolved on SDS–PAGE,
fixed and stained with Coomassie brilliant blue. The
corresponding protein band was then excised and washed
twice with 50% acetonitrile. After tryptic digestion the
protein sequence analysis was performed at the Harvard
Mass Spectrometry and Proteomics Resource Laboratory
by microcapillary reverse-phase HPLC nano-electrospray
tandem mass spectrometry (mLC/MS/MS) on a
ThermoFisher LCQ DECA XP quadrupole ion trap
mass spectrometer.
GST-pull down experiments
GST, GST-RelA/p65wt and GST-RelA/p65KTR proteins
were immobilized on glutathione beads (Amersham
Pharmacia) and incubated with purified his-p300 in
binding buffer (20mM Hepes pH 7.5, 60mM NaCl,
10% glycerol, 1.5mM MgCl2, 1mM DTT, 1mM PMSF
and 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin)
for 2 h at 48C rolling. Glutathione beads were washed
with binding buffer. Proteins were boiled, resolved on
SDS–PAGE and subjected to western blot analysis using
anti-his antibody (Qiagen).
Acetylation assay in cells
Myc-tagged RelA/p65 wild type, RelA/p65 acetylation-
deficient mutants or control empty vector were
co-expressed with p300 in HEK 293T cells. After 15 h of
transfection, cells were treated with HDAC inhibitors
(HDACi: 2mM TSA, 5mM NAM) alone or in combina-
tion with TNFa (30 ng/ml) for 30 or 45min, respectively.
Whole cell extracts were prepared (50mM Hepes pH 7.9,
420mM NaCl, 0.5% NP-40, 1mM PMSF, 0.5mM DTT,
1 mg/ml pepstatin, 1 mg/ml bestatin, 1mg/ml leupeptin).
One milligram of whole cell extract and 2 mg of anti-myc
antibody were used for subsequent immunoprecipitation.
The immunocomplexes were analyzed by standard west-
ern blot analysis using anti-acetylated Lysine antibody.
Membranes were reprobed with anti-myc antibody.
Lentiviral complementation of RelA/p65–/–MEFs
Virus production and transduction of RelA/p65–/– MEFs
were performed as described in (34). Briefly, HEK 293T
cells were transfected with 3.5mg of the envelope plasmid,
6.5mg of packaging plasmid, and 10 mg of pTV-myc-RelA/
p65 wild type, RelA/p65K/R mutants or the control pTV
vector. After 24 h the viral supernatant was harvested
and used to infect RelA/p65–/– MEFs. Thirty-six hours
post infection cells were split into selective medium
containing 2.5mg/ml Blasticidin (Sigma). Expression of
recombinant proteins in the complemented cells was
screened by western blot analysis. Pools of cells were
used for further analysis.
Electrophoretic mobility shift assay (EMSA)
Binding reactions were carried out in a total volume of
20 ml containing 10mM Tris–HCl pH 7.5, 50mM NaCl,
1mM DTT, 2mM PMSF, 0.25 mg poly dI-dC, 7% (v/v)
Ficoll/glycerol, 0.25 pmol HIV-LTR oligonucleotide
containing 2 kB binding sites labeled 50 with ATPg32P
and 7 mg of nuclear extract. The reaction was incubated
for 20min on ice and then resolved using a 5%
polyacrylamide gel in 0.5"TBE. The gel was run at
150V for 3 h, dried and subjected to autoradiography.
When supershifts were performed the binding reaction
was pre-incubated with the indicated antibody for 20min
on ice before the labeled oligonucleotide was added.
Immunohistochemistry
Cells were plated at the density of 45 000 cells per cham-
ber on poly-L-lysine (Sigma)-coated chamber slides
(LAB-TEK) and incubated overnight at 378C and 5%
CO2. Next day the cells were treated with 30 ng/ml of
TNFa for the indicated time. The cells were fixed in 4%
paraformaldehyde and then permeabilized with 0.2%
Triton-X-100/PBS. After blocking for 1 h in 2% BSA/
0.1% Triton-X-100/PBS slides were incubated with
anti-RelA/p65C-20 antibody (1:300 dilution) followed
by anti-rabbit Cy3 antibody (1:250 dilution, Jackson
Immunology). The samples were washed and Vectashield
mounting solution (Vector laboratories) was applied to
prevent bleaching. Cells were visualized using an Olympus
T50 microscope.
Whole cell extract preparation and immunoprecipitation
for RelA/p65-p300 interaction
The complemented cell lines were treated with TNFa
(30 ng/ml) for 30min. Whole cell extracts were prepared
(25mM Hepes pH 7.9, 300mM KAc, 1% NP-40, 1mM
PMSF, 1 mg/ml pepstatin, 1mg/ml bestatin, 1mg/ml
leupeptin, 50mM NaF, 20mM beta-glycerophosphate).
One milligram of whole cell extract was incubated with
2 mg of anti-p300 antibody or control IgG antibody for
2.5 h at 48C. The immunocomplexes were analyzed
by standard western blot analysis using anti-RelA/p65,
anti-p300 and anti-tubulin antibodies.
Nuclear extract preparation and immunoprecipitation
for in vivo acetylation of K310
Nuclear extracts were prepared as previously described in
(35). Two hundred micrograms of TNFa (30 ng/ml) and
HDAC inhibitor [TSA (2 mM), NAM (5mM)] treated
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nuclear extracts of complemented cells were incubated
with 2mg of anti-RelA/p65C-20 antibody for 2.5 h at 48C
rolling in binding buffer (20mM Hepes pH 7.9, 80mM
NaCl, 2.5mM MgCl2, 0.05% NP-40, 1mM PMSF, 1 mg/
ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin). After
incubation with protein G-sepharose beads (Amersham
Pharmacia) for another hour, the immunocomplexes
were extensively washed in washing buffer (20mM
Hepes pH 7.9, 100mM NaCl, 2.5mM MgCl2, 0.05%
NP-40, 1mM PMSF, 1 mg/ml pepstatin, 1 mg/ml bestatin,
1 mg/ml leupeptin). Proteins were boiled, resolved on
SDS–PAGE and analyzed by western blot using the
anti-RelA/p65ac310 antibody. Membranes were reprobed
with anti-RelA/p65 antibody.
Cell survival assay
The complemented cells (pTV empty vector control, RelA/
p65wt, RelA/p65K310R, RelA/p65K314/315R and RelA/
p65KTR) were plated in 12-well dishes at a density of
90 000 cells/ml. After 24 h of incubation, cells were starved
overnight with 0% FCS containing medium and then
treated with TNFa (30 ng/ml) or left untreated for
additional 10 h. The surviving cells were counted using
Trypan blue. The ratios of TNFa-treated and untreated
cells were calculated for each cell line. Each condition was
carried out in duplicate. A representative assay of three
independent experiments is shown.
RNA preparation
Total RNA was isolated three independent times from
TNFa-treated lysates from the different complemented
RelA/p65–/– MEFs with the ‘Total RNA isolation kit’
(Agilent Technologies). RNA quality was assessed with
the RNA 6000 Nano kit using the Bioanalyzer 2001
(Agilent Technologies). Purified RNAs were converted
into double-stranded cDNA and transcribed into Cy3-/
Cy5 (PerkinElmer/NEN Life Science)—labeled cRNA
using the ‘Low RNA Input Linear Amp Kit’ (Agilent
Technologies). cRNA from wild type RelA/p65 cells
was Cy5-labeled while the RelA/p65K/R mutant cRNAs
were Cy3-labeled. The purification of the labeled cRNAs
was performed with the RNeasy kit (Qiagen). Dye
incorporation was measured on the ND-1000
Spectrophotometer (NanoDrop Technologies)
Gene expression profiling
Gene expression profiling was performed in the Func-
tional Genomics Center Zurich using the two-colour
Agilent Microarray system (Agilent Technologies). 1 mg
of fragmented Cy5-labeled wild type and 1 mg of
Cy3-labeled mutant cRNA were each co-hybridized on
the Whole Mouse genome 60mer-oligo array (G4122A,
Agilent Technologies) according to manufacturers
protocol. The microarray analysis was performed in
triplicates. Slides were scanned using the Agilent DNA
microarray scanner and the scans were quantified with the
Agilent Feature Extraction software.
Data analysis
Data analysis was performed with GeneSpring software
(Silicon Genetics). For the statistical comparisons of the
RelA/p65 mutants and RelA/p65 wild type we only
considered genes that were present in either the mutant
or the wild type. We declared a gene as present in a
comparison, if the hybridisation intensity was in all
mutant replicates or in all wild type replicates above
200. Student’s t-test was used to compute the significance
of differential expression and 0.01 was used as significance
threshold. For each list of significant genes, the
Benjamini–Hochberg false discovery rate was computed
and is reported in the results section. Furthermore,
genes were filtered according to their fold change and
only genes exceeding a fold change of 1.5 up or down
are reported.
Quantitative real time RT-PCR
Total RNA from untreated or 45min TNFa-treated
cell lines (pTV, RelA/p65wt, RelA/p65K310R, RelA/
p65K314/315R and RelA/p65KTR) was reverse tran-
scribed using the high capacity cDNA Archive kit
according to manufacturers protocol (ABI). Real-time
PCR was performed using mouse-specific TaqMan probes
(Gene expression assays, ABI) for Ccl-7, Ifi-44, Ccl-20 and
Gpb-2. TaqMan probes for 18SrRNA and Rps6
were used to normalize for differences in RNA input.
Rotor-Gene3000A (Corbett) was used to perform the
real-time PCR reactions and the REST program was
applied for analysis (36). The figures show the averaged
results of three independent experiments.
TCA protein precipitation and Ccl-7 protein detection
Complemented cells (RelA/p65wt, RelA/p65K310R,
RelA/p65K314/315R and RelA/p65KTR) were starved
with 0% FCS containing medium for 1.5 h and then
treated with TNFa (30 ng/ml) or left untreated. After 4 h
of TNFa treatment, the medium was collected and 250 ng
of recombinant PCNA was added as a control for the
TCA protein precipitation. The medium was incubated
overnight at 48C with one-fourth volume of TCA (100%
w/v) and centrifuged. Pellets were washed twice with
acetone and lysed with lysis buffer (50mM Hepes pH 7.5,
420mM NaCl, 2mM EDTA, 0.5% NP-40, 15% glycerol,
1mM PMSF, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml
leupeptin). Forty micrograms of proteins were analyzed
by standard western blot analysis using anti-Ccl-7 and
anti-PCNA antibodies.
RESULTS
RelA/p65 is acetylated in vitro by p300 or CBP
Since RelA/p65 was reported to interact directly with
several histone acetyltransferases (HAT), we investigated
whether RelA/p65 could serve as a substrate in an in vitro
acetylation assay. We compared the ability of different
HATs to acetylate RelA/p65 in vitro. Full-length RelA/
p65 was incubated with recombinant p300, CBP, GCN5L,
P/CAF or Tip60 (all proteins expressed and purified from
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insect cells, Figure 1A) in the presence of radioactively
labeled acetyl-coenzyme A (acetyl-CoA) as a donor of the
acetyl group (Figure 1B). All tested HATs, except for
Tip60, acetylated RelA/p65 in vitro (Figure 1B). Calf
thymus core histones were used as a positive control of
acetylation (Figure 1C). p300 and CBP were the most
potent HATs for RelA/p65 in our system. This prompted
us to focus on p300 in this study.
RelA/p65 is acetylated in vitro by p300 or CBP
at lysine 310, 314 and 315
To identify the acetylation residues, in vitro acetylated
RelA/p65 by p300 was digested with trypsin and the
resulting peptides were analyzed by LC/MS/MS. 81.8% of
the K310 comprising peptides contained an acetylated
K310. 61.9% of K314 and 56.52% of K315 containing
peptides showed acetylated K314 and acetylated K315,
respectively. These data indicate that lysine 310, 314 and
315 were acetylated by p300. The identified lysine residues
are located close to the C-terminus of the Rel homology
domain (RHD) (Figure 2A). To confirm these findings,
the corresponding lysines were replaced with arginine
residues by site-directed mutagenesis. Substitution of
lysine to arginine maintains the positive charge of the
residue and may cause only minimal changes in the
local environment of the protein. Wild type or mutated
RelA/p65 harboring K310R, K314/315R or all three
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Figure 1. RelA/p65 is acetylated by p300 and CBP in vitro. (A) Recombinant histone acetyltransferases (HATs) expressed and purified from
insect cells were analyzed by SDS–PAGE and Coomassie staining. Molecular weight markers are shown on the left. (B) In vitro acetylation
assay using full-length RelA/p65 and indicated HATs. RelA/p65 was incubated in the presence of radioactively labeled [14C]-acetyl-CoA with 500 ng
of p300 or CBP or the equimolar amount of GCN5L, P/CAF or Tip60. Proteins were resolved on SDS–PAGE, stained with SyproRuby (left)
and exposed to X-ray films (right). RelA/p65 acetylation signals are indicated with an arrow. HATs or HAT autoacetylation signals are
indicated with an asterisk (#). (C) In vitro acetylation of histones. In vitro acetylation assay was performed as described in (B).
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K310/314/315R (KTR) substitutions were expressed and
purified from insect cells (Figure 2B). Subsequently,
all proteins were subjected to in vitro acetylation by
p300 or CBP (Figure 2C and Supplementary Figure 1).
Acetylation of RelA/p65 mutated at single K310 or
K314/315 was only slightly reduced compared to wild
type, while mutation of all three lysine residues abolished
acetylation of RelA/p65 (Figure 2C). When the purified
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protein substrates were tested only in the presence of
acetyl-CoA, no acetylation was observed confirming that
the acetylation was mediated by p300 and not by a
co-purified acetyltransferase. These results clearly indicate
that K310, K314 and K315 of RelA/p65 are the main
acetylation sites of p300 in vitro. To confirm that the
RelA/p65KTR mutant was still able to interact with
p300, GST-pull down experiments were performed using
GST-RelA/p65 wild type or GST-RelA/p65KTR as bait
proteins in the presence of purified p300. Subsequent
western blot analysis revealed that p300 was able to
equally directly interact with both RelA/p65 wild type and
the RelA/p65KTR mutant (Figure 2D). These results
indicate that abolished acetylation of the RelA/p65KTR
mutant was due to the lack of specific sites and not due to
the inability of this mutant to interact with p300.
Lysine 314 and 315 of RelA/p65 are acetylated
by p300 in cells
To examine if lysine residues 314 and 315 of RelA/p65
are acetylated in cells, myc-tagged wild type RelA/p65,
RelA/p65 acetylation-deficient mutants (RelA/p65K310R,
RelA/p65K314/315R, RelA/p65KTR) or myc-tagged
empty control vector were ectopically expressed in
HEK 293T cells together with the histone acetyltransfe-
rase p300. Previous experiments had revealed that over-
expressed RelA/p65 wild type can only be detected as
acetylated in the presence of ectopically expressed p300
[(29) and data not shown]. TNFa was applied to induce
NF-kB, while HDAC inhibitors (HDACi: TSA and
NAM) were used to inhibit histone deacetylases.
Subsequent immunoprecipitation analysis with anti-myc
antibody and western blot analysis using anti-acetylated
Lysine antibody revealed acetylation of RelA/p65 wild
type (Figure 3A). The acetylation of wild type RelA/p65
was already close to saturation before TNFa stimulation
most probably due to the activation of the NF-kB
pathway through overexpression of RelA/p65. However,
an increase of acetylation after TNFa stimulation is
detected in the RelA/p65K310R mutant, strongly suggest-
ing that lysine 314 and 315 are acetylated upon TNFa
induction. A significant decrease in acetylation was
detected in the RelA/p65 acetylation-deficient double
A
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Figure 3. RelA/p65 is acetylated in cells on lysine 314 and 315 by p300. (A) Wild type myc-RelA/p65 and myc-RelA/p65K/R mutants were
immunoprecipitated with anti-myc antibody from HDACi (TSA/NAM) and –/+ TNFa treated HEK 293T cells transfected with either empty
control vector or different CMV-myc-RelA/p65 vectors (wt, K310R, K314/315R or KTR) along with CMV-p300. Western blot analysis of the
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mutant (K314/315R). A small residual amount of
acetylation was still detected when the triple mutant
(KTR) of RelA/p65 was expressed in HEK 293T cells
indicating that also other lysine residues are acetylated by
p300 (Figure 3A).
To investigate if one of the previously reported sites
[K122, K123 (30) and K218, K221 and K310 (32)] is
acetylated in our system a variety of acetylation-deficient
point mutants of RelA/p65 were generated: RelA/
p65K122/123R, RelA/p65K218/221R, RelA/p65K218/
221/310R and a combinatorial mutant RelA/p65K218/
221/310/314/315R (RelA/p65KQR) harboring the acet-
ylation acceptor sites identified in this study and the
sites identified by Chen et al. after TNFa stimulation (32).
The different mutants of RelA/p65 were expressed in HEK
293T cells along with p300 in the presence of TNFa and
HDAC inhibitors. Anti-myc immunoprecipitation and
anti-acetylated Lysine western blot analysis revealed a
slight decrease in acetylation of the RelA/p65K122/123R
and RelA/p65K218/221R mutant when compared to wild
type RelA/p65 (Figure 3B). However, RelA/p65K218/221/
310R showed a higher reduction in acetylation while the
RelA/p65KQR mutant showed a decrease in acetylation
of 90% (when compared to the wild type) indicating that
K314 and K315 greatly contribute to the detected p300-
dependent acetylation level in RelA/p65 after TNFa
treatment. It also points out that K218 and K221 might
probably be the other lysine residues acetylated in cells by
p300 (Figure 3A). Together, these data indicate that RelA/
p65 is acetylated in cells mainly on lysine 314 and 315 by
p300.
Endogenous RelA/p65 is acetylated in vivo in TNFa
stimulated cells
To investigate the role of RelA/p65 acetylation of K310,
K314 and K315 in vivo, RelA/p65–/– NIH 3T3 mouse
embryonic fibroblasts (MEF) were genetically comple-
mented using lentiviruses encoding myc-RelA/p65 wild
type, myc-RelA/p65K310R, myc-RelA/p65K314/315R or
myc-RelA/p65KTR. After appropriate selection cells were
kept in pools and the expression of recombinant proteins
was analyzed by western blotting using an anti-RelA/p65
antibody (Figure 4A). The cells transduced with control
virus encoding the resistance gene [mock infected (pTV)]
and non-transduced wild type NIH 3T3 cells expressing
endogenous RelA/p65 protein were included as controls.
The expression levels of the recombinant wild type
and mutated RelA/p65 proteins were comparable to
that observed for endogenous RelA/p65 in NIH 3T3
cells. Furthermore, cell growth analysis revealed that
the proliferation rate was comparable between the tested
cell pools under normal growth conditions (data
not shown).
We and others showed that RelA/p65 is acetylated in
cells in a TNFa-dependent manner [Figure 3A and (29)].
In order to investigate whether endogenous RelA/p65
is acetylated at the identified lysine residues in vivo,
antibodies directed against RelA/p65 peptides acetylated
at residues 310, 314 or 315 were generated. Nuclear
extracts were prepared after treating the complemented
cells with TNFa and HDAC inhibitors (TSA and NAM).
Upon TNFa treatment RelA/p65 nuclear import was
induced in RelA/p65wt and RelA/p65 mutant comple-
mented cells (Figure 4B). Immunoprecipitation with an
anti-RelA/p65 antibody and subsequent western blot
analysis using the specific acetyl K310 antibody revealed
that RelA/p65 was indeed acetylated at this site upon
TNFa treatment (Figure 4C, left panel). TNFa induced
acetylation of RelA/p65 was further confirmed by
immunoprecipitating RelA/p65 from untreated and
TNFa stimulated cells (Figure 4C, right panel).
Acetylated RelA/p65 could only be detected in the extracts
stimulated by TNFa. Acetylation of RelA/p65 could not
be detected in the input lanes due to low detection
sensitivity of the anti-acetyl 310 antibody. Antibodies
raised against acetylated 314 and acetylated 315 were
found to be unspecific in this analysis (data not shown).
To investigate if the abolished acetylation of RelA/
p65K310R and RelA/p65KTR was due to their inability
to interact with endogenous histone acetyltransferase
p300, immunoprecipitation analyses with the different
mutants and p300 were performed. Whole cell extracts
were prepared from wild type and mutant RelA/p65
complemented cell lines after TNFa stimulation to induce
NF-kB. Immunoprecipitation with either anti-p300 or
control IgG antibody and subsequent western blot
analysis using anti-RelA/p65 antibody revealed that
endogenous RelA/p65K10R, RelA/p65K314/315R and
RelA/p65KTR are able to interact with endogenous
p300 upon TNFa stimulation to the same extend as wild
type RelA/p65 (Figure 4D).
K314/315R substitution mutation does not affect the
shuttling, the DNA-binding ability or the protection
against TNFa-induced cell death of RelA/p65
The complemented cells were treated with TNFa and
subcellular localization of the recombinant RelA/p65
proteins was analyzed by immunofluorescence analysis
at different time points (Figure 5A). Nuclear translocation
of the recombinant RelA/p65 wild type was detected
after 20min of TNFa treatment and relocation to the
cytoplasm after 60min. A similar shuttling kinetics was
observed for endogenous RelA/p65 protein in NIH 3T3
cells (data not shown). Analysis of the cells complemented
either with K310R, K314/315R or KTR revealed no
significant differences in the shuttling kinetics between
mutated RelA/p65 and RelA/p65 wild type proteins
(Figure 5A). This suggested that acetylation of RelA/
p65 at the three tested lysine residues was not essential for
the regulation of the RelA/p65 nuclear-cytoplasmic
redistribution. This observation is supported by our
findings that IkBa was able to bind to RelA/p65 wild
type and the acetylation-deficient mutants with similar
affinity (data not shown).
Next we investigated the influence of p300-mediated
RelA/p65 acetylation on the ability of RelA/p65 to bind
DNA. Nuclear extracts of the complemented cells treated
with TNFa were tested in an electro mobility shift assay
using an oligonucleotide containing two kB elements of
the HIV-LTR promoter. The experiments revealed that
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mutations of K310, K314 and K315 did not significantly
influence the TNFa-induced DNA binding of RelA/p65
(Figure 5B). Binding was substantially reduced by
competition with non-labeled oligonucleotides containing
a wild type kB site, but not a mutated kB site, indicating
that the binding was specific (data not shown).
The presence of RelA/p65 and p50 in the complex was
confirmed by supershift experiments using specific
anti-RelA/p65 and anti-p50 antibodies, respectively
(Figure 5B). Together, these findings show that the
acetylation-deficient mutants are able to translocate
to the nucleus and bind to DNA to the same extent as
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Figure 5. Mutation of the acetylation sites in RelA/p65 does not affect its nuclear translocation and DNA binding. (A) The complemented cells were
treated with TNFa and fixed with paraformaldehyde followed by immunostaining using anti-RelA/p65 antibodies. Subcellular localization of RelA/
p65 protein was analyzed by immunofluorescence microscopy. (B) Electro mobility shift assays were performed with nuclear extracts from the
untreated or TNFa treated cells using 32P-labeled oligonucleotide DNA containing 2kB sites. The bound complexes were characterized by anti-RelA/
p65 or anti-p50 supershift assays. Specific NF-kB complexes are indicated with an arrow, unspecific bands are marked with an asterisk (#). (C) Cell
viability assay after TNFa treatment. The different complemented cell lines (pTV, RelA/p65wt, K310R, K314/315R and KTR) were starved for 14 h
with 0% FCS medium and then left untreated or treated with TNFa (30 ng/ml) for 10 h. The number of surviving cells (%) after TNFa treatment
was calculated as described in ‘Material and methods’ section.
1674 Nucleic Acids Research, 2008, Vol. 36, No. 5
56
RelA/p65 wild type. These results are in accordance with
previously published data where K310 mutation to
arginine did not affect subcellular localization, DNA
binding or interaction with IkBa (32).
The deletion of the RelA/p65 gene in mouse cells is
known to render them vulnerable to TNFa-induced cell
death, stressing the important role of RelA/p65 in cell
survival (37). To investigate whether TNFa-induced
acetylation of RelA/p65 would affect the protective
function of RelA/p65, cell viability assays were performed.
The control cell line pTV (RelA/p65–/– cells comple-
mented with empty vector), RelA/p65 wild type and the
three different acetylation-deficient RelA/p65 mutant cell
lines were either left untreated or were stimulated with
TNFa for 10 h. The number of surviving cells after
treatment was determined using Trypan blue and com-
pared to the number of untreated cells (Figure 5C). As
expected, the pTV cells were not protected from TNFa-
induced cell death due to their lack of RelA/p65.
However, the non-acetylatable mutants of RelA/p65
(K310R, K314/315R and KTR) protected the cells from
cell death to the same extend as RelA/p65 wild type,
indicating that the acetylation of RelA/p65 at the three
mutated lysines does not affect substantially the tested
pathway or that a possible effect could be compensated by
the expression of RelA/p65-independent genes.
Determination of genes regulated by p300-mediated
acetylation of RelA/p65 on lysine 314 and 315
To investigate the functional relevance of lysine 314 and
315 acetylation, microarray analyses were performed
using the Agilent Whole Mouse Genome Array.
The complemented cell lines (RelA/p65 wild type, RelA/
p65K310R, RelA/p65K314/315R and RelA/p65KTR)
were treated for 45min with TNFa to induce NF-kB
and total RNA was isolated in three independent
replicates from these cells. RT-PCR for known TNFa-
dependent NF-kB target genes was performed to check
whether the TNFa induction was successful. The IkBa
mRNA was induced to the same extend in the wild type
and acetylation-deficient mutant cell lines (data not
shown). RNA was amplified and labeled. The RNA
from the different mutants (K310R, K314/315R and
KTR) was then each co-hybridized with wild type RNA
(RelA/p65 wild type cells) to the two-color whole
mouse genome array. Statistical analysis of the TNFa-
induced expression profiles aimed at identifying differen-
tially regulated genes when comparing the different
mutant cell lines with the wild type cell line. After
performing this comparison, we identified following
numbers of potentially regulated genes for K310R RelA/
p65 versus wild type RelA/p65: 1149 significantly
regulated genes with a P value $0.01 and a signal intensity
> 200 at a false discovery rate of 18.61%. Thereof 79 genes
were upregulated more than 1.5 times and 82 down-
regulated more then 1.5 times at a P value $ 0.01
(Supplementary Table S1). In the K314/315R RelA/p65
versus wild type RelA/p65 comparison we found 735
potentially regulated genes at P$ 0.01 (signal intensity
>200 and false discovery rate 28.43%). Ninety-seven
genes were found to be upregulated with a fold change
>1.5 and 54 downregulated with a fold change of <0.67
(P$ 0.01) (Supplementary Table S2). When we finally
analyzed the KTR mutant we found 1233 genes signifi-
cantly regulated with a signal >200 and P$ 0.01 at a false
discovery rate of 17% (i.e. 216 false positives). Of these
1233 regulated genes 150 were upregulated with a fold
change >1.5 and 116 downregulated with a fold change
<0.67 (P$ 0.01) when compared to wild type RelA/p65
(Supplementary Table S3). To investigate if common
regulated genes were present in the different cell lines
the overlap of the significantly downregulated and
upregulated genes was generated at a P value $0.01
(Figures 6A and 7A). The overlap of genes between the
different RelA/p65 mutants was small, possibly indicating
distinct sets of genes being regulated by the different
mutants.
To validate the results derived from the microarray
studies, and to confirm the p65 dependency and TNFa
induction of the analyzed genes, we performed quantita-
tive RT-PCR for some selected genes. The following genes
were chosen from the lists of overlapping differentially
regulated genes at P value $0.01: Ccl-20, Ccl-7, Ifi-44 and
Gbp-2. To perform quantitative real-time RT-PCR, RelA/
p65–/– cells complemented either with the empty vector
pTV, RelA/p65 wild type, RelA/p65K310R, RelA/
p65K314/315R or RelA/p65KTR mutant were left
untreated or were stimulated with TNFa for 45min.
Total RNA was isolated and reverse transcribed with
random hexamer primers to obtain cDNA. Gene expres-
sion of Ccl-20, Ifi-44 and Gbp-2 was highly dependent on
the acetylation of RelA/p65 at the identified sites, since
only low levels of expression of these genes could
be detected in cells expressing any of the mutants
(Figure 6B–D, right panel, black bars). On the other
hand, Ccl-7 expression was increased in cells expressing
the K314/315R (2-fold) and the KTR mutant (2.59-fold)
(Figure 7B, right panel). In the present analysis, the
expression profiles obtained by microarray analysis
were confirmed by quantitative RT-PCR analysis for all
tested genes. However, the two methods showed higher
correlation in the upregulated gene (Ccl-7; Figure 7B)
than in the downregulated genes (Ccl-20, Ifi-44 and
Gbp-2; Figure 6B–D).
In order to examine if these selected genes require RelA/
p65 to be induced upon TNFa treatment, we compared
their expression levels in the wild type cell line and in the
control cell line pTV upon TNFa treatment. The four
genes were upregulated in wild type cells, indicating that
they were RelA/p65-dependent (left panels in Figures 6B–
D and 7B). To determine the induction of these selected
genes after TNFa stimulation in the different complemen-
ted cell lines, expression levels upon TNFa treatment were
compared with unstimulated samples. All four genes were
induced upon TNFa stimulation in wild type cells (middle
panels from Figures 6B–D and 7B). However, among the
downregulated genes, only Ccl-20 was stimulated after
TNFa treatment in all acetylation-deficient mutants,
though to a reduced amount than in the wild type cell
line (Figure 6B–D). This suggests that gene expression of
Ccl-20, Ifi-44 and Gbp-2 can only be properly induced by
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Figure 6. Acetylation of RelA/p65 at lysine 310, 314 and 315 activates gene specific transcription. (A) Venn diagram showing the numbers of
common down regulated genes between the significantly regulated genes in the different RelA/p65 acetylation-deficient cell lines compared to the wild
type cell line found in the microarray analysis. (B–D) Quantitative real time RT-PCR validation for selected downregulated genes, Ccl-20 (B), Ifi-44
(C) and Gbp-2 (D). Left panels show the comparison of relative expression in the presence of TNFa (pTV was set as 1). Middle panels show the
TNFa fold induction of the different cell lines upon TNFa stimulation. Right panels show the comparison of relative expression of microarray (white
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TNFa when RelA/p65 is acetylatable by harboring lysines
at the position 310, 314 or 315. The Ccl-7 gene was induced
by TNFa in all cell lines (Figure 7B, middle panel).
To demonstrate that transcriptional changes in gene
expression correlate with changes in corresponding
protein expression, western blot analysis was performed
for Ccl-7 in the complemented cell lines. Upregulation of
Ccl-7 protein was detected in the RelA/p65 acetylation-
deficient mutant cell lines compared to wild type after 4 h
of TNFa stimulation (Figure 7C).
Taken together, the results obtained in the microarray
analysis could be confirmed by the complementary real
time RT-PCR method for four selected genes.
Interestingly, Ccl-7 protein expression analysis in the
distinct acetylation-deficient cell lines indicated that the
differential gene regulation detected in the microarray
analysis is indeed translated into protein expression.
Additionally, this analysis provides strong evidence that
acetylation of RelA/p65 at lysines 310, 314 and 315
positively or negatively regulates the transcription of
specific genes.
DISCUSSION
Increasing experimental evidence has indicated that
NF-kB-dependent gene expression is regulated by differ-
ent post-translational modifications including acetylation
(38,39). The acetylation-dependent NF-kB regulation
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was shown to occur via many different mechanisms (40).
For example acetylation of histones is known to
regulate NF-kB-dependent gene accessibility for the
transcriptional machinery (38). The direct acetylation of
NF-kB was reported to regulate the transcriptional
potential of NF-kB, the duration of the NF-kB response,
its DNA-binding activity as well as protein–protein
interactions with several transcription cofactors
(32,41,42).
In this study we have addressed the role of p300-
mediated acetylation of RelA/p65 in the regulation of gene
expression in vivo. We identified three lysines (K310, K314
and K315) in RelA/p65 as targets for the acetylation by
p300 in vitro and in cells upon TNFa stimulation
(Figures 2A and 3A). Interestingly, lysine 310 was
previously shown to be acetylated by p300 (32).
However, we additionally found two novel lysine residues,
lysine 314 and 315, acetylated in RelA/p65 not reported
before. It is important to mention that among the
previously reported acetylation sites by Kiernan et al.
and Chen et al. (30,32), we could only confirm the
acetylation of K310 in our experimental system
(Figure 3B). This could be due to the different experi-
mental procedures; stimuli (TNFa versus PMA) and cell
lines (HEK 293T cells versus Jurkat T cells) used in the
studies and could point towards a very specific stimulus
and cell-type-dependent regulation of RelA/p65 through
acetylation. However, our results suggest additional yet to
be identified p300 specific acetylation sites in RelA/p65
other than lysine 218, 221, 310, 314 and 315 (Figure 3C).
The relevance of the in vitro acetylation sites identified in
our study was confirmed by the ability of endogenous
RelA/p65 to be acetylated in vivo upon TNFa stimulation
using an acetylation site-specific antibody (Figure 4C).
To investigate the role of RelA/p65 acetylation in cells
we genetically complemented RelA/p65–/– fibroblasts
with a control vector (pTV) or cDNAs encoding for
RelA/p65 wild type, K310R, K314/315R and KTR
mutant (Figure 4A). Analysis of the complemented cells
revealed that the mutation of the acetylation sites did not
affect the kinetics of the cytoplasmic-nuclear redistribu-
tion of RelA/p65 upon TNFa stimulation (Figure 5A).
This implied that the upstream signalling events are not
regulated by the acetylation of RelA/p65 at the identified
sites. Furthermore, cell survival assays were performed to
examine whether the acetylation of RelA/p65 is involved
in the protection from TNFa-induced cell death. No
difference was seen in cell survival when RelA/p65–/– cells
complemented with wild type RelA/p65 were compared to
cells complemented with the acetylation-deficient mutants,
indicating that the acetylation of RelA/p65 on lysine 314
and 315 is not involved in the TNFa-dependent cell death
pathway (Figure 5C).
In order to elucidate the influence of RelA/p65
acetylation on gene expression in vivo we performed
genome-wide microarray analyses using total RNA
isolated from the complemented cells after TNFa stimula-
tion. We identified subsets of genes, which were specifi-
cally modulated depending on the ability of RelA/p65 to
be acetylated at lysine 310, 314 or 315 (Supplementary
Tables 1–3). The number of common significantly down
or upregulated genes found in the current analysis of the
different cell lines is small, indicating that acetylation of
RelA/p65 at lysine 310, 314 and 315 is possibly modulat-
ing the expression of only a subset of genes (Figures 6A
and 7A). Four genes from the distinct subsets of
differentially expressed genes were selected for validation:
Ifi-44, Ccl-20 (Mip-3a), Gbp-2 and Ccl-7 (MCP-3);
thereof Ccl-20 is a known NF-kB target gene (43).
Ifi-44, Ccl-20 and Gbp-2 gene expression showed to be
dependent on acetylation of RelA/p65 at lysine 310, 314
and 315. Expression of Ccl-7 was found to be repressed by
acetylated RelA/p65. This was supported by the protein
analysis performed for Ccl-7, which revealed induction of
Ccl-7 protein expression in the acetylation-deficient
mutant cell lines (Figure 7C). The increase in Ccl-7
protein only slightly correlated with the increase of
mRNA levels detected in the different mutants at 45min
of TNFa stimulation (compare Figure 7B, right panel).
This could be explained by the differences in stimulation
duration for mRNA (45min) and protein (4 h) detection
and by additional regulatory mechanisms (such as
secretion), which might influence the quantity of proteins.
When the induction of gene expression upon TNFa
stimulation was investigated, differences were detected
between the four genes. From the selected genes, the
chemokines Ccl-20 and Ccl-7 were the only genes induced
by TNFa in the mutant cell lines. Even though the
upstream events of TNFa-induced NF-kB signalling were
shown to be normal in our study, Ifi-44 and Gbp-2
gene expression was not induced by TNFa in the K/R
mutant cell lines suggesting that regulation by K310, 314
and 315 acetylation is essential for the first group of genes
(Ifi-44, Gbp-2) and required for the latter group (Ccl-20
and Ccl-7).
The results of the microarray analysis and the
quantitative real-time PCR revealed that the acetylation
of RelA/p65 does not always correlate with activation of
gene expression as has been suggested before (32). Rather,
we provide evidence that the p300-mediated acetylation of
RelA/p65 contributes to both gene-specific activation and
repression of transcription. It is unknown how RelA/p65
acetylation signals to activate certain genes while simulta-
neously suppressing the expression of others. One
hypothesis would be that the regulation of certain genes
by p300-mediated acetylation of RelA/p65 promotes the
recruitment of additional factors or stabilizes the forma-
tion of specific pre-initiation complexes at promoter sites.
Like this, acetylated RelA/p65 could serve as a factor that
regulates the recruitment of these proteins. It has been
previously reported that many proteins can specifically
recognize and bind acetylated lysine residues in histones
and transcription factors through their bromo domains
(44–46). Among them are well-characterized histone
acetyltransferases (e.g. p300, P/CAF and GCN5) (47),
subunits of chromatin remodelling complexes (e.g.
ATPases of SWI2/SNF2 and proteins of the WAL/BAZ
family of ISWI-associated proteins) (48) and a general
cofactor of the basal transcription machinery, TAF1 (49).
The nature of the recruited co-activator/co-repressor
would determine the response of the specific genes.
Another hypothesis would be that the presence of other
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cis-regulatory elements in a targeted gene and regulatory
proteins recruited to these elements might be critical for
the modulation of the acetylation dependent NF-kB
response. Acetylation is known to be a reversible protein
modification. In this regard HDAC-1, HDAC-2 and
HDAC-3 were reported to repress NF-kB-dependent
transcription upon treatment with inflammatory stimuli
(32,38,40). These histone deacetylases were also shown to
directly interact with several proteins involved in the
NF-kB signalling pathway, including NF-kB itself
(29,38,50). Deacetylation of RelA/p65 by HDAC-3 may
provide a counterpart mechanism for p300 function. The
exact molecular mechanism by which acetylation/deace-
tylation of RelA/p65 regulates the transcription activity of
RelA/p65 in the context of chromatin remains to be
investigated.
Together, acetylation of RelA/p65 presents an attractive
regulatory mechanism for the control of NF-kB-depen-
dent gene expression. The combination of acetylation with
other post-translational modifications will broaden even
more the potential of this regulation. Combinations of
different modifications have already been proposed to
serve as a ‘code’ for the interacting domains of different
proteins (51,52). Furthermore, acetylation can be regu-
lated by other post-translational modifications.
For example phosphorylation of RelA/p65 at serine 276
and 536 was shown to enhance the acetylation of lysine
310 (53). It cannot be excluded that other post-transla-
tional modifications of RelA/p65 can also regulate the
acetylation of this transcription factor. Our findings could
help to explain the diversity of NF-kB-dependent gene
expression upon different stimuli. We hypothesize that
unique combinations of post-translational markers and
the presence of cell-type-specific cofactors determine the
specific NF-kB-mediated response. Recruitment analyses
of RelA/p65 to the promoter region of the regulated
genes using chromatin immunoprecipitation will help to
understand how post-translational modifications of this
transcription factor influence gene expression of its
target genes.
In conclusion, our results support the hypothesis that
p300-mediated acetylation of distinct sites in the RelA/p65
protein is important to modulate the expression of defined
genes, thereby contributing to the specificity of the NF-kB
response.
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ABSTRACT (168 words) 
NF-κB regulates the expression of a large number of target genes involved in the immune 
and inflammatory response, apoptosis, cell proliferation, differentiation and survival. In 
this study, we describe that acetylated p65, a subunit of NF-κB, is recruited upon TNFα 
stimulation to promoters of specific genes whose expression is regulated by the 
acetylation status of p65. In addition, we identified SIRT2 as a novel deacetylase of p65. 
SIRT2 is a member of the family of sirtuins, which are NAD+-dependent deacetylases 
involved in several cellular processes. SIRT2 interacts with p65 in the cytoplasm and 
deacetylates p65 in vitro and in vivo at lysines 310, 314 and 315. Moreover, p65 is 
hyperacetylated at lysine 310 in Sirt2(-/-) cells after TNFα stimulation, which results in 
the dramatic increase in expression of a subset of p65 acetylation-dependent target genes. 
Together, our work provides strong evidence that p65 is deacetylated by SIRT2 in the 
cytoplasm after termination of the NF-κB response induced by TNFα, thus regulating the 
expression of specific NF-κB-dependent genes. 
 
Keywords: NF-κB/ SIRT2/ acetylation/ p65/RelA 
 
 
INTRODUCTION 
Nuclear factor kappa B (NF-κB) belongs to a family of inducible transcription factors 
that modulates gene expression in response to a variety of extracellular and intracellular 
stimuli (4, 14, 29). NF-κB plays a crucial role in the regulation of many genes involved in 
mammalian immune and inflammatory response, such as cytokines, cell adhesion 
molecules, complement factors, and a variety of immune receptors. It has additionally 
been implicated as an important regulator of cellular processes such as apoptosis, cell 
proliferation and differentiation. The mammalian NF-κB family includes five members, 
p65 (RelA), c-Rel, RelB, p105/p50 (NF-κB1) and p100/p52 (NF-κB2), encoded by 
RELA, REL, RELB, NFKB1 and NFKB2, respectively (12). These proteins form homo- or 
heterodimers. The most abundant heterodimer in the majority of cells consists of the two 
subunits p65 and p50. 
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 In most unstimulated cells, NF-κB is sequestered in the cytoplasm as an inactive 
transcription factor complex through physical association with one of the inhibitors of 
NF-κB (IκB, predominantly IκBα). NF-κB induction involves the rapid activation of 
IKKβ and NEMO-dependent phosphorylation and subsequent degradation of IκBs. 
Consequently, dissociation of IκBs from NF-κB unmasks the nuclear localization 
sequence (NLS) of p65, which leads to nuclear translocation and binding of NF-κB to 
specific κB consensus sequences in the chromatin, to regulate specific subsets of genes 
(11, 26). Interestingly, one consequence of NF-κB activation is the upregulation of IκBα 
gene expression, mediated by a κB consensus sequence within the IκBα promoter (28). 
Several lines of evidence suggest that newly synthesized IκBα enters the nucleus, 
displaces non-chromatin associated subunits of NF-κB, thereby mediating their export 
from the nucleus and re-establishing a cytoplasmic pool of inhibited complexes (17). 
Relocation of NF-κB into the cytoplasm and attenuation of NF-κB-mediated 
transcriptional activation therefore provides a feedback mechanism for modulating the 
extent and duration of inflammatory responses by cells. Nevertheless, if cells are 
continuously exposed to a specific stimulus, NF-κB translocates back to the nucleus after 
some time of the first wave of NF-κB induction to continue with transcriptional 
regulation of target genes (15). The duration of NF-κB response depends in part on the 
stimulus and on the type of cell.  
 NF-κB specificity is regulated at different levels in the cell (30). It is plausible 
that different stimuli induce distinct posttranslational modifications of p65, determining 
the outcome of p65-mediated transcriptional events. Several posttranslational 
modifications on p65 have been described, the most important ones being 
phosphorylation and acetylation (29). Phosphorylation of p65 enhances its interaction 
with its transcriptional coactivator CBP/p300 and with components of the general 
transcription machinery (44). Acetylation of p65 was reported to modulate its DNA-
binding capacity, its transcriptional activity, its interaction with IκB proteins and its 
subcellular localization (6, 20). We recently showed that p65 is acetylated by p300 not 
only at lysine 310, but also at lysine 314 and 315, two novel acetylation sites (5). 
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Microarray analysis of genetically complemented p65 knockout (-/-) cells treated with 
tumor necrosis factor α (TNFα) identified specific sets of genes differently regulated by 
acetylation deficient mutants of p65 compared to wild type cells. Together, these results 
showed that site-specific p300-mediated acetylation of p65 regulate the specificity of NF-
κB-dependent gene expression.  
 Reversible protein acetylation is an important posttranslational modification that 
regulates the function of histones and many other proteins (34). Acetylation has a rapid 
turnover due to the highly dynamic equilibrium between two different groups of 
enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). The 
balance between these two activities is key to regulate the appropriate cellular response to 
signals. Mammalian HDACs are divided into four main classes based on sequence 
similarity and cofactor dependency (Class I-IV) (42). Class III HDACs, also known as 
sirtuins, constitute a special class of enzymes because of their requirement for NAD+ as a 
cofactor in their deacetylation reaction. During the deacetylation reaction, nicotinamide 
(Nam) is cleaved from NAD+ and the acetyl group of the substrate is then transferred to 
ADP ribose, generating the novel metabolite 2’-O-acetyl-ADP ribose (OAADPr) (8). The 
sirtuin family consists of seven members in mammals (SIRT1–7) that contain a 
conserved catalytic core domain comprised of approximately 275 amino acids. They 
regulate a variety of cellular functions, such as genome maintenance, longevity, and 
metabolism (25, 39, 40). Up to date, all sirtuins have been described to have 
deacetylation activity except for SIRT4 (35). The SIRTs exhibit differential localization 
from nucleus to nucleolus, and from cytoplasm to mitochondria (33).  
SIRT2 is the counterpart of yeast Hst2p, both proteins localize to the cytoplasm 
(31). SIRT2 was found to bind HDCA6 and to deacetylate α -tubulin, thereby 
participating in the regulation of microtubule dynamics and possibly cell cycle 
progression (9, 24, 27). Presumably, SIRT2 regulates other cellular functions, as p53, 
p300 and histones (H3 and H4) have been identified as substrates (3, 13, 37). The 
apparent contradiction of a protein being cytoplasmically located, yet exhibiting 
specificity for a histone residue was resolved when SIRT2 localization was monitored 
during cell cycle progression. SIRT2 localized to the cytoplasm throughout the cell cycle 
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with the exception of prophase during G2/M transition, where it translocated to the 
nucleus to deacetylate histone H4 at lysine 16 (H4K16) (37). Moreover, MEFs derived 
from Sirt2(-/-) mice showed hyperacetylation of H4K16 during mitosis. 
Based on our recent findings, we extended our studies to further elucidate the 
molecular regulation of p65 acetylation. Here we identify additional genes regulated by 
p65 acetylation upon TNFα stimulation. Furthermore, we describe the characterization of 
SIRT2 as a novel deacetylase of p65. Gene expression analysis in SIRT2-deficient MEFs 
indicate that SIRT2-mediated p65 deacetylation is implicated in transcriptional regulation 
of a subset of genes. 
 
 
RESULTS 
 
Site-specific acetylation of p65 influences gene expression. 
We provided earlier evidence that acetylation of p65 at lysines 310, 314 and 315 is 
important for the expression of a defined subset of genes (5). These earlier studies 
provided a first glance of the functional relevance of p65 acetylation, since gene 
expression was measured only after 45 minutes of TNFα stimulation. In order to know if 
the requirement for site-specific acetylation is maintained for the same genes after longer 
exposure to TNFα, and to identify possible new genes regulated through p65 acetylation, 
we decided to extent our analysis to 3 hours of stimulation. For this, we used p65(-/-) 
MEFs complemented with non-acetylatable mutants described previously, where the 
target lysines for acetylation were mutated to arginines (5). p65(-/-) cells complemented 
either with wild type p65, an empty plasmid as control (pTV), the acetylation-deficient 
double mutant K314/315R or the triple mutant KTR (K310/314/315R), were stimulated 
by TNFα for 3 hours and total RNA was isolated in three independent replicates from 
these cells. RNA was amplified, labeled and hybridized to the Agilent Whole Mouse 
Genome Array. After statistical analysis of the expression profiles, differentially 
expressed genes were identified (Fig. S1A-B, and Tables SI and SII). We focused only on 
genes that required p65 for their proper induction, which were identified by comparing 
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gene expression profiles from wild type and pTV cells. These experiments revealed that 
the majority of genes were upregulated in the double mutant K314/315R compared to 
wild type cells (Fig. S1A). In contrast, the majority of differentially expressed genes in 
KTR mutant were downregulated compared to wild type cells (Fig. S1B). The 
observation that mutation of lysines 314/315 increases expression of certain genes (e.g. 
Mmp10 and Mmp13) suggests that either acetylation of these lysines represses gene 
expression or that acetylation would prevents modification of the same residues by 
another modification. Indeed, a recent study reported that these same two lysines 
(314/315) can by methylated by Set9 to induce ubiquitinylation of NF-κB and 
subsequently terminate gene expression (41). 
 Remarkably, only a few genes identified after 3 hours TNFα stimulation 
overlapped with the genes identified in our previous study after 45 minutes TNFα 
stimulation (data not shown), suggesting that acetylation is a very dynamic modification 
that regulates transcription accordingly. 
 We subsequently investigated the induction kinetics of several genes by real-time 
RT-PCR in the complemented cell lines stimulated by TNFα for different time points 
(between 20 and 360 minutes). Selection of these genes was based on their inducibility by 
TNFα, as well as their dependency on p65 and their regulation by acetylation of lysine 
310 or 314/315. Cfb, Mpa2l, NfkBie represented genes downregulated in KTR, while 
Mmp13 and Mmp10 were upregulated in lysines 314/315 in the microarray experiments. 
Overall, the absolute mRNA levels of Cfb, Mpa2l and NfkBie were decreased whenever 
lysine 310 was substituted with arginine (Fig. 1A-B and Fig. S1C), while the ones from 
Mmp10 and Mmp13 were increased in the K314/315R mutant (Fig. 1C-D), corroborating 
our microarray results. Interestingly, some of these dependences were already observed 
when the basal expression levels were compared. 
  
 
Chromatin-associated p65 is acetylated at lysines 310 and 314. 
To further assess the functional relevance of p65 acetylation in vivo, we generated 
different antibodies raised against the acetylated lysines 310, 314 or 315. All raised 
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antibodies recognized their specific p300-mediated acetylated residues on recombinant 
p65 acetylated in vitro (Fig. 2A) or on overexpressed p65 acetylated in vivo (Fig 2B). 
These experiments revealed additionally, that acetylation of lysines 310 or 314/315 are 
not functionally interconnected, but that these residues are rather acetylated 
independently of each other.  
From the above selected genes only Cfb was already described to contain a κB 
site in its promoter (18). We therefore searched for putative κB sites within the DNA 
sequence 1 kB upstream of the transcription start site (TSS) of the selected genes. This 
bioinformatic analysis identified several putative κB sites in the promoters of Mmp10 and 
Cfb, one site in the promoter of Mpa2l, and none for Mmp13 (Fig. S1D). Mmp13 was 
thus not further investigated. 
ChIP studies in p65(+/+) MEFs stimulated with TNFα for 20 and 180 minutes 
revealed that p65 was recruited to the promoters of Cfb and Mpa2l in a stimulus-
dependent manner, while no enrichment was observed in p65(-/-) MEFs (Fig. 2C). These 
recruitments were promoter-specific, since p65 occupancy to promoter of Glucagon, a 
negative control, was not induced upon TNFα stimulation. IP-10, a known NF-κB target 
gene with very well characterized κB sites at its promoter, served additionally as a 
positive control. Unfortunately, no p65 enrichment could be observed to the κB sites of 
Mmp10 (data not shown), indicating that p65 would activate this gene through other κB 
sites or other transcription factors.  
Moreover, ChIP experiments using the anti-acetyl K310 and acetyl K314 
antibodies showed that chromatin-associated p65 is indeed acetylated at lysines 310 and 
314 (Fig. 2D). Unfortunately, the antibody raised against acetyl K315 was not able to 
immunoprecipitate p65 under the tested conditions (data not shown). Interestingly, 
recruitment of acetylated p65 lysine 310 or 314 to the promoter of IP-10 was also 
observed. Together, these experiments identified Mpa2l as novel NF-κB target gene and 
provide strong evidence that p65 bound to chromatin is acetylated at lysines 310 and 314.  
 
p65 is deacetylated by SIRT1 and SIRT2 at  lysines 310, 314 and 315 in vivo and in 
vitro. 
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Since acetylation is a reversible posttranslational modification, we decided to investigate 
the kinetics of p65 acetylation in response to TNFα stimulation in vivo. p65(-/-) MEFs 
complemented with p65 wild type were stimulated for the indicated time points (20 to 90 
minutes). Western blot analysis of immunoprecipitated p65 from the nuclear fraction of 
the cells revealed that endogenous p65 was rapidly acetylated at lysine 310 after 20 
minutes of TNFα treatment (Fig. 3A). The signal dramatically decreased after 45 minutes 
of stimulation and was not detectable after 90 minutes, which correlates with the reported 
cytoplasmic relocalization of p65 in MEFs after TNFα stimulation (15). The sensitivity 
of the generated antibodies against acetyl K314 and acetyl K315 did unfortunately not 
allow the detection of endogenous p65 acetylated at those two lysines by western blot.  
 The reversed acetylation of p65 prompted us to investigate which enzyme is 
responsible for p65 deacetylation at the three lysine residues 310, 314 and 315. Initial 
experiments in HEK 293T cells overexpressing class I HDACs HDAC1, 2 and 3 did not 
reduce the acetylation levels of overexpressed p65 under the tested conditions (Fig. S2A). 
We therefore decided to focus on sirtuins. His-tagged SIRT1, 2, 6 and 7, known to 
localize either to the nucleus or to the cytoplasm, were overexpressed in HEK 293T cells 
(Fig. S2B), along with p65 and p300. Ectopic expression of p300 effectively led to p65 
acetylation (Fig. 3B, mock sample). Notably, overexpression of SIRT1 and SIRT2 
significantly reduced p65 acetylation at the three indicated lysine residues, while SIRT6 
and SIRT7 were not able to deacetylate p65 under the tested conditions (Fig. 3B). To 
verify that the deacetylase activity of both SIRT1 and SIRT2 was necessary for p65 
deacetylation, we overexpressed catalytically inactive SIRT1 and SIRT2 mutants (H363Y 
and H187Y, respectively), together with p65 and p300 in HEK 293T cells. Mutant SIRT1 
and SIRT2 were inactive on the p65 substrate (Fig. 3C). These results indicate that the 
enzymatic activity of SIRT1 and SIRT2 are required to deacetylate p65 at lysines 310, 
314 and 315 in vivo. 
To confirm that SIRT1 or SIRT2 would directly deacetylate p65, recombinant p65 
was acetylated in vitro by p300 and subsequently incubated with purified recombinant 
SIRT1, 2, 6 and 7 (Fig. S2C), in presence or absence of NAD+. Both SIRT1 and SIRT2 
were able to deacetylate p65 at lysine 310, 314 and 315 in vitro, as observed by western 
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blot analysis using the indicated antibodies (Fig. 3D).  As expected, SIRT6 or SIRT7 
were not able to deacetylate p65, in agreement with our previous results in HEK 293T 
cells (Fig. 3B). 
  
Hyperacetylation of p65 at lysine 310 is observed in Sirt2(-/-), but not in Sirt1(-/-) 
cells. 
SIRT1 has been previously reported to deacetylate p65 at lysine 310 (43). To further 
investigate the role of both SIRT1 and SIRT2 in p65 deacetylation in vivo, Sirt1(-/-) or 
Sirt1(+/+) and Sirt2(-/-) or Sirt2(+/+) MEFs were stimulated by TNFα and acetylation of 
endogenous p65 was analyzed by western blot. Only stimulation of Sirt2(-/-) cells by 
TNFα led to an increase in the acetylation of endogenous p65 at lysine 310 when 
compared with the other three cell lines (Fig. 3E). Protein levels of SIRT1 or SIRT2 were 
not altered in the analyzed MEFs when the other SIRT was knocked out (Fig. S2D). 
These results provide strong evidence that SIRT2 is the main enzyme responsible for p65 
deacetylation at lysine 310 after TNFα stimulation in vivo.  
 
SIRT2 interacts in vivo with p65 in the cytoplasm  
To investigate whether endogenous SIRT2 and p65 would interact in vivo, SIRT2 was 
immunoprecipitated from cytoplasmic or nuclear extracts of human unstimulated Jurkat 
T-cells. Although the immunoprecipitation efficiency of SIRT2 was poor, SIRT2 could 
be detected in the cytoplamic but not in the nuclear extract. Interestingly, p65 
coimmunoprecipitated with SIRT2 in the cytoplasmic extract (Fig. 4A).  
 
TNFα  stimulation does not induce nuclear translocation of SIRT2  
Although SIRT2 has been reported to be located almost exclusively in the cytoplasm, we 
decided to investigate if it would translocate to the nucleus upon TNFα stimulation. Due 
to the low expression levels of endogenous SIRT2, we overexpressed HA-tagged SIRT2 
in HeLa cells, followed by TNFα stimulation for 30 or 90 minutes. Consistent with our 
findings in Jurkat-T cells (Fig. 4A), immunofluorescence studies revealed that 
overexpressed SIRT2 and endogenous p65 localized to the cytoplasm in untreated cells 
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(Fig. 4B). Upon 30 minutes of TNFα stimulation, only p65 translocated to the nucleus 
and partly relocated to the cytoplasm after 90 minutes, while SIRT2 stayed in the 
cytoplasm throughout the experiment (Fig. 4B). 
  
SIRT2 deacetylates p65 in vivo in the cytoplasm.  
To provide further evidence for the cytoplasm as the cellular compartment where SIRT2 
deacetylates p65, HEK 293T cells were transfected with expression plasmids for different 
SIRT2 mutants containing an additional NLS or an NLS in combination with a NES 
deletion (NLSΔNES). While wild type SIRT2 was located exclusively in the cytoplasm, 
fusion of an NLS to SIRT2 slightly increased its nuclear localization (Fig. 4C). Complete 
nuclear localization of SIRT2 could be observed only upon additional deletion of the 
NES (NLSΔNES mutant). Importantly, analysis of the p65 acetylation status under the 
same conditions revealed that the nuclear localization of SIRT2 negatively correlated 
with p65 deacetylation (Fig. 4D). The mutation of SIRT2 to achieve nuclear localization 
(SIRT2 NLSΔNES mutant) did not abolish its deacetylation activity, since it was able to 
efficiently deacetylate H4K16 in the nucleus (data not shown). Collectively, these results 
suggest that SIRT2 interacts with p65 exclusively in the cytoplasm for its deacetylation. 
 
p65 deacetylation by SIRT2 contributes to regulation of NF-κB-dependent gene 
expression 
Since p65 acetylation influences NF-κB-dependent transcription, we decided to 
investigate whether the expression of NF-κB target genes upon TNFα was affected by 
SIRT2 depletion in vivo. Gene expression analysis by real-time RT-PCR in Sirt2(+/+) 
and Sirt2(-/-) MEFs after 3 hours TNFα stimulation uncovered a dramatic increase in 
Mpa2l induction in Sirt2(-/-) cells compared to Sirt2(+/+) cells (around 70 fold 
difference) (Fig. 5A). This correlates with our previous results showing that acetylation 
of p65 at lysine 310 is required for transcriptional activation of Mpa2l and that p65 is 
hyperacetylated in Sirt2(-/-) MEFs. Since TNFα stimulation was continuous throughout 
the experiment, we expect p65 to have shuttled several times from the cytoplasm to the 
nucleus during those 3 hours, as also reported previously (15).  
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Next, we analyzed the expression of Mmp13, a gene with increased expression  
upon mutation of lysines 314/315. Mmp13 induced gene expression was enhanced 3 fold 
in Sirt2(-/-) compared to Sirt2(+/+) cells (Fig. 5B). The induction of RELA, a gene that 
has neither been reported to be dependent on NF-κB nor to be a housekeeping gene 
(www.nf-kb.org), was not significantly different between the two genotypes (Fig. 5C). 
These data imply that the expression of genes that are particularly dependent on lysine 
310 acetylation are strongly induced in Sirt2(-/-) cells, as observed for the strong Mpa2l 
expression. Together, these data suggest that deacetylation of p65 by SIRT2 influences 
NF-κB-mediated expression of Mpa2l in vivo. 
 
 
DISCUSSION 
We have previously shown that p65 acetylation plays an important role in regulating NF-
κB-dependent transcription of a subset of genes. Our current results confirm those earlier 
findings by identifying new genes differentially regulated in the acetylation-deficient 
mutants compared to wild type cells. In addition, we report the identification of SIRT2 as 
a novel p65 deacetylase. SIRT2 deacetylates p65 in vitro and when overexpressed in cells 
after TNFα stimulation. Furthermore, endogenous p65 and SIRT2 interact in the 
cytoplasm of unstimulated cells. Subsequent TNFα treatment does not trigger SIRT2 
translocation to the nucleus, thus indicating that it deacetylates p65 in the cytoplasm. 
Moreover, p65 is hyperacetylated at lysine 310 in Sirt2(-/-) MEFs, which correlates with 
a strong increase in Mpa2l expression, a gene which is dependent on the acetylation of 
lysine 310. 
ChIP assays identified Mpa2l as a novel NF-κB target gene. Cfb was previously 
suggested to be a direct target of NF-κB by EMSA experiments (18). Here, we 
corroborated that p65 is recruited to this promoter in a TNFα-dependent manner in vivo. 
Mmp10 and Mmp13 were differentially expressed in acetylation-deficient mutant cells 
compared to wild type cells. However, we failed to detect p65 recruitment to the 
promoter of those genes. One explanation could be that p65 is recruited to the promoter 
region of these genes with a different kinetics than the one we investigated here. 
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Alternatively, p65 could bind to a regulatory element located far away from the promoter 
to regulate transcription, as has been shown for several NF-κB target genes (1, 10, 36). 
NF-κB is known to activate the expression of many transcription factors and their 
regulators (26); consequently, a third possibility is that p65 directly induces the 
expression of a protein that regulates the expression of these genes. Interestingly, NF-κB 
has been shown to directly activate the expression of the transcription factor Elk-1, which 
in turn induces Mmp13 gene expression (23). A plausible explanation for our 
observations is that acetylated p65 at lysines 314 and/or 315 would help to control the 
expression of Elk-1 in an acetylation-dependent manner, and thus expression of Mmp13. 
The requirement of intact acetylation site at K310 in p65 for correct gene 
expression of Cfb and Mpa2l and the observation that acetylated p65 at lysines 310 and 
314 is recruited to at least two of these promoters imply that p65 acetylation of K310 is 
required for transcriptional activation (Fig. 2D). The observed increase of acetylated p65 
recruited to chromatin between 20 minutes and 3 hours of TNFα stimulation (Fig. 2D), in 
contrast to the reduction of p65 acetylated at lysine 310 in nuclear extracts already 45 
minutes after stimulation (Fig. 3A), suggests that the pool of acetylated p65 bound to 
chromatin represents a minor fraction of the total p65 amount in the nucleus. 
Interestingly, our gene expression analysis indicated that the expression of Cfb and Mpa2l 
was not impaired in K314/315R mutant cells (Fig. 1A-B). Thus, it could well be that p65 
is acetylated by p300 at the promoter of many genes, but that the expression of only some 
of these genes is affected by p65 acetylation at distinct lysines. This could also be the 
reason why we unexpectedly observed binding of acetylated p65 to the promoter of IP-
10, a gene that did not show up in our microarray analysis to depend on p65 acetylation. 
Alternatively, p65 acetylation could be required for IP-10 expression, although we did 
not detect this in the microarray analysis using p65(-/-) MEFs complemented with p65 
wild type and non-acetylatable mutants. Indeed, we observed that TNFα does not induce 
NF-κB activity in the complemented MEFs as efficiently as in the parental p65(+/+) 
MEFs used for ChIP (data not shown). Therefore, although our complemented MEFs are 
useful to address the role of p65 acetylation in vivo, we might have identified only part of 
the genes influenced by p65 acetylation with the microarray screen. 
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Despite the identification of p65 acetylation, the exact mechanism by which 
acetylation of p65 regulates the expression remains to be further elucidated. By analogy 
with histone proteins, we can anticipate that the level of p65 acetylation reflects the 
competing influences of acetyltransferase(s) and deacetylase(s). An attractive possibility 
is that acetylated p65 creates docking sites for bromodomain-containing proteins that 
need to be recruited to promoters to modulate transcription. According to our findings, 
coactivators would bind to acetylated p65 at lysine 310.  Recently, Huang et al. reported 
that double bromodomain of Brd4 binds to acetylated lysine 310, which enhances 
transcriptional activation of NF-κB and the expression of a subset of NF-κB 
inflammatory genes in an acetylated lysine 310-dependent manner (16). Future 
experiments will focus on the possible binding between acetylated p65 and 
bromodomain-containing proteins. 
A recent study described methylation of p65 at lysines 314 and 315 and its 
involvement in the negative regulation of NF-κB-dependent transcription (41). Our ChIP 
experiments clearly show that chromatin-bound p65 is acetylated at lysine 310 as well as  
314 in a promoter-specific manner. Based on the observation that chromatin-bound p65 is 
acetylated at lysine 310 as well as at lysine 314 at the same promoter, we reason that 
acetylation at lysine 314/315 could prevent methylation-mediated repression of target 
genes and thus positively influence transcription, together with acetylated lysine 310. A 
direct evidence for methylated p65 at lysines 314/315 bound to chromatin is still missing. 
Whether the same genes are regulated by both posttranslational modifications should be 
further addressed. Alternatively, both posttranslational modifications might regulate 
distinct set of NF-κB-dependent genes and thus not influence each other. 
HDAC3 and SIRT1 have been previously described to deacetylate p65 (6, 43). 
However, we did not detect p65 deacetylation by overexpressed HDAC3 in HEK 293T 
cells (Fig. S2A). This disagreement in the results could be due to different experimental 
procedures, such as the use of HEK 293T cells instead of COS-7 cells. Deacetylation of 
lysine 310 by SIRT1 was shown under basal conditions in HEK 293T cells with 
overexpressed proteins and in vitro with recombinant proteins, which perfectly correlates 
with our results. SIRT1 and SIRT2 were both able to deacetylate p65 in vitro, but in 
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contrast to SIRT1 knock-out, only deficiency of SIRT2 was sufficient to induce 
hyperacetylation of p65 at lysine 310 upon TNFα stimulation in vivo. Our experiments 
with SIRT1(-/-)cells are in agreement with observations where RNAi of SIRT1 did not 
lead to changes in NF-κB target gene expression, unless cells were treated with 
resveratrol (43). These results suggest that SIRT1 and SIRT2 might function 
independently in p65 deacetylation and that they might regulate p65 in different cellular 
functions in response to different stimuli. Future experiments will address the role of p65 
acetylation in gene expression for different cellular processes such as apoptosis, 
inflammation or immunity. Recently, a study showed that SIRT6 does not deacetylate 
p65 in vitro or in vivo, in agreement with our results (Fig. 3B and D), but deacetylates 
histone H3K9 to attenuate NF-κB signaling (19).  
We observed that p65 was rapidly acetylated at lysine 310 in the nucleus of MEFs 
upon TNFα stimulation and that the signal was drastically reduced after 45 minutes of 
TNFα treatment (Fig. 3A). Immunostaining and EMSA experiments have previously 
shown that the majority of NF-κB shuttles back to the cytoplasm between 30 to 60 
minutes after TNFα stimulation in MEFs (5, 15). Strikingly, the timing of p65 
deacetylation at lysine 310 correlates with its reported export to the cytoplasm, 
supporting the idea that p65 is deacetylated in the cytoplasm.  
Our data suggest that in unstimulated cells, SIRT2 exists in a complex with p65 
and most probably p50 and IκBα, known to interact with p65 under basal conditions (Fig 
6). Upon TNFα stimulation, the complex dissociates and p65/p50 heterodimers 
translocate to the nucleus, while SIRT2 stays in the cytoplasm. Nuclear p65 binds to 
specific κB sites in the promoter or enhancer regions of target genes together with 
transcriptional coactivators, such as p300. Consequently, p65 is acetylated at lysines 310 
and 314/315 on the chromatin by p300, which influences its transcriptional activity, thus 
modulating the expression of a subset of target genes. Once the NF-κB response is 
terminated, p65/p50 heterodimer shuttles back to the cytoplasm, where SIRT2 
deacetylates p65 at all three lysines, thereby resetting the whole NF-κB response. Any 
p65 that would afterwards translocate to the nucleus again during continuous TNFα 
stimulation would have to be freshly acetylated by p300 to modulate gene expression, 
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thereby allowing a tight control of NF-κB-dependent transcription. 
 Gene expression analysis of Sirt2(-/-) MEFs revealed that the transcriptional 
activation of Mpa2l, whose expression was dependent on p65 acetylation at lysine 310 
(Fig. 1B), was dramatically increased in Sirt2(-/-) cells compared to other genes such as 
Mmp13 or RELA (Fig. 5). Therefore, we propose that SIRT2 regulates the expression of a 
subset of NF-κB-dependent genes by deacetylating p65 in the cytoplasm upon relocation 
of NF-κB to this cellular compartment after the first wave of NF-κB induction. Since NF-
κB is known to shuttle between nucleus and cytoplasm in 30-60 minutes periods in MEFs 
upon continuous TNFα stimulation (15), p65 would be hyperacetylated in Sirt2(-/-) cells 
after 3 hours of TNFα treatment, which would explain the observed differential Mpa2l 
gene regulation. Together, our results identify SIRT2 as a novel deacetylase of NF-κB 
and an important regulator of TNFα-induced NF-κB-dependent gene expression. 
 
 
MATERIALS AND METHODS 
 
Tissue culture 
Complemented p65(-/-) NIH 3T3 mouse embryonic fibroblasts (MEFs) stably expressing 
p65 wild type or the acetylation-deficient mutants were previously described in (5). They, 
as well as the p65(-/-) and (+/+) parental NIH 3T3 MEFs kindly provided by A. Beg (2), 
were maintained in DMEM supplemented with 10% FCS, 100 units/ml 
penicillin/streptomycin (Gibco) and non-essential amino acids (Gibco). Sirt2(-/-) and 
(+/+) MEFs were a generous gift from A. Vaquero. Those cells were originally generated 
in the lab of F. Alt (37). Sirt1(-/-) and (+/+) MEFs were kindly provided by F. Alt (7). 
Sirt1(-/-) , Sirt1(+/+), Sirt2(-/-) and Sirt2(+/+) MEFs were kept in DMEM supplemented 
with 15% FCS, 100 units/ml penicillin/streptomycin (Gibco), non-essential amino acids 
(Gibco), β-mercaptoethanol (Gibco) and Na-Pyruvate (Gibco). HEK 293T and HeLa 
cells were maintained in DMEM supplemented with 10% FCS and 100 units/ml 
penicillin/streptomycin; Jurkat T-cells in RPMI with 10% FCS and 100 units/ml 
penicillin/streptomycin. 
 
Plasmids  
Plasmids for the mammalian expression of human p65 wild type and mutants K310R, 
K314/315R and KTR were described elsewhere (5). Mammalian expression plasmids of 
human SIRT1, 2, 6 and 7 in the pcDNA-DEST40-V5/HIS background were kindly 
provided by I. Horikama (22). The enzymatic inactive mutant was generated by site-
directed mutagenesis of H187 to Y with pcDNA-DEST40-SIRT2 as template. The 
introduced mutation was verified by DNA sequencing. pcDNA3.1-SIRT1-MYC/HIS 
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wild type and the catalytically inactive mutant (H363Y) were a generous gift from T. 
Kouzarides (21). Plasmids for the expression of HA-tagged SIRT2 and HA vector control 
were described elsewhere (27). The GW-pHA-SIRT2-NLS vector was created by cloning 
the sequence 5’-GATCCCCAAAGAAGAAGCGAAAGGTAC into GW-pHA-SIRT2. 
Site-directed mutagenesis was performed to change the SIRT2 lysines K4 and K12 to 
alanines, creating the GW-pHA-SIRT2-NLSΔNES vector. The introduced sequence and 
mutations were verified by DNA sequencing. 
 
Reagents and antibodies 
Human tumor necrosis alpha (TNFα), Trichostatin A (TSA), Nicotinamide (Nam) and 
acetyl-Coenzyme A (acetyl Co-A) were purchased from Sigma. Recombinant mouse 
TNFα was either purchased from Sigma or generated in our laboratory. Sodium fluorid 
(NaF) and beta-glycerophosphate were obtained from Fluka. The acetyl-specific 
antibodies for p65 anti-acetyl K310 (ab19870), anti-acetyl K314 (ab18727) and anti-
acetyl K315 (ab19869) were generated by Abcam. The following antibodies were 
purchased from Santa Cruz Biotechnologies: anti-p65 (sc-372), anti-p300 (sc-585) and 
anti-SIRT2 (sc-20966 and sc-28298). The anti-SIRT1 antibody was from Millipore (07-
131). The anti-myc antibodies were either purchased from Roche (11-667-149-001) or 
purified from hybridoma cells. The anti-tubulin antibody was purchased from Sigma (T 
6199), the anti-his was from Qiagen (34670) and the anti-HA was from Covance (MMS-
101P). 
 
Generation of recombinant proteins  
The recombinant proteins were expressed by baculovirus in Sf21 cells using either the 
FastBac or the BacPAK systems (Clontech). His-tagged proteins were purified over Ni2+-
beads (ProBond, Invitrogen) and GST-tagged proteins over L-Glutathione beads (Sigma). 
The virus for expression of GST-SIRT1 was kindly provided by K. Chua. 
 
Microarray 
Complemented cell lines p65 wild type or acetylation-deficient mutants were starved 
overnight before either left untreated or stimulated with 30 ng/ml TNFα  for 3 hours. 
Total RNA from three biological replicates per sample was isolated at different days 
using the ‘Total RNA isolation mini kit’ (Agilent Technologies). RNA quality was 
measured on the 2100 Bioanalyzer (Agilent Technologies). Microarray experiments were 
performed using ‘Whole Mouse Genome (4x44K) Oligo Microarray Kit’ (Agilent 
Technologies) and ‘One-color microarray-based gene expression analysis’ (Agilent 
Technologies) following the manufacturer’s protocol. Cy3-labeled cRNA was purified 
with the RNeasy kit (Qiagen). Dye incorporation was assessed with the ND-1000 
Spectrophotometer (NanoDrop Technologies). Per sample, 1.65 µg cRNA from each of 
the three biological replicates was hybridized to independent arrays according to the 
manufacturer’s protocol. Hybridized slides were scanned with the Agilent DNA 
Microarray scanner and quantified using the Agilent Feature Extraction software. The 
data analysis was performed using ‘Rosetta Resolver® Gene Expression Data 
Management and Analysis System’ (Rosetta Biosoftware). Briefly, data was processed 
and normalized with default settings. Then, low-signal genes with signal intensities <0.1 
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were filtered out. Differential expression between two conditions was assessed based on 
the average ratio and significance. All genes with expression ratios <0.556 and >1.8, and 
a p-value <0.05 were selected to generate the tables of significantly regulated genes. 
These sequence data have been submitted to the GEO database 
(www.ncbi.nlm.nih.gov/geo) under accession number GSE15196. 
 
Gene expression by real-time RT-PCR 
Complemented MEFs were starved overnight before treatment with 30 ng/ml 
recombinant TNFα for different time points. Sirt2(+/+) and Sirt2(-/-)  MEFs were starved 
for 6 hours and then stimulated with 30 ng/ml recombinant TNFα for 3 hours or left 
unstimulated. Total RNA was isolated from at least two biological samples at different 
days with the ‘Total RNA isolation mini kit’ (Agilent Technologies). RNA was 
subsequently retro-transcribed using the ‘High-capacity cDNA reverse transcription kit’ 
(Applied Biosystems). Real-time PCR was performed using the Rotor-Gene 3000 
(Corbett Life Science, now Qiagen) and TaqMan assays from Applied Biosystems for 
Cfb, Mpa2l, Mmp10, Mmp13, NfkBie, Rps6 and CanX genes. The last two genes were 
used as internal controls to normalize for RNA input. In addition, gene expression of 
Mpa2l, Mmp13, RELA and Rps12 (as internal control) was assessed with SYBR Green 
using the following primers: Mpa2l_forward (GATGCTGAAGAAGCTAATGAAGG 
ATC), Mpa2l_reverse (CCTTGATGACATCTCTCAGTTGCTG), Mmp13_forward 
(GGACAAGCAGTTCCAAAGGCTACA) and Mmp13_reverse (GTCTTCATCGCCTG 
GACCATAAAG). RNA from at least two biological replicates per sample was measured 
and analyzed with REST (32). Each experiment was run three independent times, the 
mean value and ± SD was calculated and blotted into graphs with GraphPad Prism 
(GraphPad Software). 
 
Chromatin Immunoprecipitation 
p65(-/-) or (+/+) MEFs were stimulated with 10 ng/ml mouse TNFα for the indicated 
time points and fixed with 1% formaldehyde (Calbiochem) for 10 minutes. After 
extensive washing, the plasma membrane was first lysed with lysis buffer 1 (50mM Tris 
HCl pH8, 2mM EDTA pH8, 0.1% NP-40, 10% glycerol, 1 mM PMSF, 0.5 mM DTT, 
phosphatase and HDAC inhibitors) and then the nuclear membrane with lysis buffer 2 
(50mM Tris HCl pH8, 5 mM EDTA pH8, 1% SDS, 1 mM PMSF, 0.5 mM DTT, 
phosphatase and HDAC inhibitors). Chromatin fragmentation was achieved with the 
Bioruptor (Diagenode). Sonified chromatin was diluted with 9 volumes of dilution buffer 
(50mM Tris HCl pH8, 5mM EDTA pH8, 0.5% NP-40, 200mM NaCl and 1mM PMSF) 
and pre-cleared for 1 hour with Protein A Agarose/salmon sperm DNA (Millipore). 1% 
of input was saved and the remaining chromatin was then incubated overnight with the 
specific antibodies. After 30 additional minutes of incubation with Protein A 
Agarose/salmon sperm DNA, the immuno-complexes were extensively washed with 
washing buffer (20mM Tris HCl pH8, 2mM EDTA pH8, 1% NP-40, 0.1% SDS, 500mM 
NaCl and 1mM PMSF) and then with buffer TE (10mM Tris HCl pH8 and 1mM EDTA 
pH8). Chromatin was eluted with 2% SDS in TE buffer and incubated at 65°C for at least 
6 hours. DNA was purified with ‘QIAquick PCR purification kit’ (Qiagen) following the 
manufacturer’s recommendations and measured by real-time PCR using SYBR Green 
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and the Rotor-Gene 3000 (Corbett Life Science, now Qiagen). The following primers 
were used: Mpa2l_forward (CAGCCCCTTTTATAGTGAGTC), Mpa2l_reverse  (TAC 
AAAATCCGGGAGTATTGC), Cfb_forward (CACCTGTGAAGCAAGTCTCTCTCT), 
Cfb_reverse (TTTGTGCAGCAAGGACTCTGACCT), IP-10_forward (GCAATGCCCT 
CGGTTTACAG), IP-10_reverse (GGCTGACTTTGGAGATGACTCA), Glucagon_ 
forward (GAGTGGGCGAGTGAAATCAT) and Glucagon_reverse (TGAGCTGCGA 
ACAGGTGTAG). Samples were normalized to input chromatin and expressed as % 
input. Each experiment was independently repeated at least three times. Mean values ± 
SD of three independent real-time PCR runs from one independent ChIP are shown. 
 
In vitro acetylation assay 
1 µg of recombinant p65 wild type or the acetylation-deficient mutants were incubated 
with 500 ng recombinant p300 in HAT buffer (50 mM Tris HCl pH8, 100 mM NaCl, 
10% glycerol, 1mM PMSF, 1mM DTT, 1 µg/ml bepstatin, 1 µg/ml leupeptin, 1 µg/ml 
pepstatin and 1 mM sodium butyrate) with or without addition of 150 µM acetyl-CoA. 
After 1 hour at 30°C, samples were resolved on SDS-PAGE and analyzed by western 
blot. 
 
In vitro deacetylation assay 
500 ng recombinant p65 wild type was in vitro acetylated as described previously and 
then immunoprecipitated. The beads-bound p65 was incubated with 14 pmol of each 
recombinant SIRT in 100 µl deacetylation buffer (50 mM Tris HCl pH9, 4 mM MgCl2, 
0.2 mM DTT, 1 µg/ml bepstatin, 1 µg/ml leupeptin and 1 µg/ml pepstatin) supplemented 
or not with 1 mM NAD+ for 30 minutes with constant agitation. Proteins were 
subsequently resolved in SDS-PAGE and analyzed by western blot. Purified recombinant 
SIRTs were additionally resolved on SDS-PAGE and stained with coomassie blue. 
 
Acetylation and deacetylation assays in cells 
HEK 293T cells were transfected with expression plasmids for p300 and either myc-
tagged p65 wild type, the acetylation-deficient mutants or an empty vector, using the 
calcium phosphate precipitation method. After 23 hours, cells were treated with 10 ng/ml 
human TNFα for 30 minutes. Then, whole cell extracts were prepared and 40 µg protein 
was analyzed by SDS-PAGE and western blot. For the deacetylation assay in cells, 0.1 
pmol expression plasmid encoding the different sirtuins (wild type or mutants) or empty 
vector were additionally co-transfected in HEK 293T cells. 
 
Immunostaining 
Transfected HEK 293T cells or HeLa cells were stimulated with 10 ng/ml human TNFα 
for 30 minutes. They were fixed with 4% paraformaldehyde and then permeabilized with 
0.2% TritonX-100. Blocking solution (2% BSA and 0.1% TritonX-100 in PBS) was 
added for 1 hour before the slides were incubated with anti-HA and anti-p65 antibodies 
(1:250 each in blocking solution), followed by incubation with FITC-labeled anti-mouse 
and Cy3-labeled anti-rabbit antibodies (1:250 each in blocking solution, Jackson 
Immunology). The slides were washed, covered with Vectashield mounting solution 
(Vector laboratories) and visualized using a Leica SP 5 confocal microscope. 
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FIGURE LEGENDS 
 
Figure 1. Site-specific acetylation of p65 regulates the expression of distinct genes. 
Gene induction of Cfb (A), Mpa2l (B), Mmp10 (C) and Mmp13 (D) in a TNFα-dependent 
manner, as measured by real-time RT-PCR, from the following complemented cell lines: 
wild type (green), K310R (blue), K314/315R (brown), KTR (red) and pTV (black). 
Samples were normalized to Rps6 and CanX expression levels, and expressed as fold 
increase relative to wild type unstimulated. Two biological replicates were included. 
Shown are the means ± SD of three independent runs.  
 
Figure 2. Acetylated p65 is recruited to the promoter region of regulated genes upon 
TNFα  stimulation. (A-B) Characterization of specific antibodies against p65 acetylated 
at lysine 310, 314 or 315. (A) Purified recombinant p65 wild type and the acetylation-
deficient mutants were incubated with recombinant p300 in the presence (+) or absence (-
) of acetyl CoA. Proteins were resolved on SDS-PAGE and analyzed by western blot 
using the indicated antibodies. (B) HEK 293T cells were transfected with p65 wild type 
or mutants, with (+) or without (-) p300 co-transfection. Acetylation of p65 at specific 
lysines was assessed by western blot using the specific antibodies. * indicates a non-
specific band. Chromatin immunoprecipitation analysis of p65 (C) or acetylated p65 at 
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lysine 310 or 314 (D) from p65(+/+) MEFs kept unstimulated or treated with TNFα for 
20 or 180 minutes. Chromatin from p65(-/-) MEFs stimulated with TNFα for 180 
minutes was used as negative control. Recruitment to the indicated promoters was 
analyzed. Occupancy to IP-10 and Glucagon promoters was assessed as positive and 
negative control, respectively. Samples were normalized to input chromatin and 
expressed as % input. The result is representative of three independent experiments. 
Mean values ± SD of three independent runs are shown. 
 
Figure 3. SIRT2 deacetylates p65 at lysines 310, 314 and 315. (A). Endogenous p65 is 
rapidly and possibly transiently acetylated in the nucleus upon TNFα stimulation in vivo. 
Wild type complemented MEFs were treated with TNFα for the indicated time periods. 
p65 was immunoprecipitated from nuclear extracts and analyzed by western blot using 
anti-acetyl K310 antibody. PARP1 from 5% input was used as nuclear loading control. 
(B) Overexpressed SIRT1 and SIRT2 deacetylate p65 in HEK 293T cells. HEK 293T 
cells were transfected with the expression plasmids for the indicated his-tagged SIRTs 
along with p300 and myc-tagged p65. Whole cell extracts were prepared after 30 minutes 
of TNFα stimulation and analysed by western blot. (C) Deacetylase activity of SIRT1 
and SIRT2 is needed for p65 deacetylation in cells. SIRT1 and SIRT2 wild type and the 
enzymatic inactive mutants were overexpressed in HEK 293T cells together with p300 
and myc-tagged p65. The acetylation status of p65 after 30 minutes of TNFα stimulation 
was assessed with the indicated antibodies. (D) In vitro acetylated p65 wild type was 
incubated with recombinant sirtuins in the presence (+) or absence (-) of NAD+. Western 
blot analysis shows in vitro deacetylation of lysines 310, 314 and 315 by SIRT1 and 
SIRT2. (E) Endogenous p65 is hyperacetylated in Sirt2(-/-) cells. MEFs from the 
indicated genotypes were pre-treated with the HDAC inhibitors (HDACi) TSA and Nam 
for 30 minutes and then stimulated with TNFα for 1 hour before preparing whole cell 
extracts. Extracts were analyzed by western blot using anti-acetyl K310 antibody. The 
membrane was reprobed for p65, and tubulin was used as loading control. * indicates a 
non-specific band.  
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Figure 4. SIRT2 deacetylates p65 in the cytoplasm. (A) p65 and SIRT2 interact in the 
cytoplasm. Cytoplasmic (C) and nuclear (N) extracts were generated from unstimulated 
Jurkat T-cells, endogenous SIRT2 was immunoprecipitated and co-immunoprecipitated 
p65 was detected by western blot (upper panels). Levels of SIRT2, p65, PARP1 as 
nuclear control and tubulin as loading control from 5% input are shown in the lower 
panels. (B) p65 translocates to the nucleus in response to TNFα stimulation, while SIRT2 
stays in the cytoplasm. HeLa cells were transfected with HA-tagged SIRT2 and 
stimulated with TNFα for the indicated time points, followed by immunofluorescence 
detection of p65 and HA-SIRT2. Dapi staining shows the nucleus. Subcellular 
localization of p65 and HA-SIRT2 was analysed with a confocal microscope. (C) HEK 
293T cells were transfected with HA-tagged SIRT2 wild type, NLS mutant or NLSΔNES 
mutant. After 30 minutes of TNFα stimulation, cells were fixed and immunostained with 
anti-HA antibody to display cellular localization of SIRT2 wild type and mutant proteins, 
assessed with a confocal microscope. (D) p65 has a decreased deacetylation when nuclear 
SIRT2 mutant is expressed. The same constructs as in (C) were overexpressed in HEK 
293T cells along with p65 wild type and p300, followed by 30 minutes of TNFα 
stimulation, whole cell extracts preparation and western blot analysis with the indicated 
antibodies.   
 
Figure 5. Lack of SIRT2 increases TNFα-induced NF-κB-dependent transcriptional 
activation. Gene induction of Mpa2l (A), Mmp13 (B) and RELA (C) in Sirt2(+/+) and 
Sirt2(-/-) MEFs after 3 hours of TNFα stimulation, as measured by real-time RT-PCR. At 
least two biological replicates were analyzed. Shown are the means ± SD of three 
independent runs. 
 
Figure 6. p65 is acetylated in the nucleus to modulate gene expression and 
deacetylated in the cytoplasm by SIRT2. In unstimulated cells, p65 is in a complex 
with SIRT2 in the cytoplasm. Upon TNFα stimulation, the complex dissociates and 
p65/p50 heterodimers translocate to the nucleus, where they bind to promoters of 
regulated genes. Co-activator p300 binds to p65 and acetylates it at lysines 310, 314 and 
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315 to fine tune gene expression. Upon termination of the NF-κB response, p65/p50 
heterodimers shuttle back to the cytoplasm, where p65 is deacetylated by SIRT2.
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Figure S1. (A-B) Heat maps showing the gene expression profiles of K314/315R cells (A) or 
KTR cells (B) compared to wild type control at 3 hours after TNFα stimulation using whole 
mouse genome arrays. Each row represents a single gene, and each column represents a 
different cell line. Red or green represents up- or downregulation of genes relative to the 
mean on each row, respectively. Mean data from at least two biological replicates is 
displayed. Only genes upregulated in wild type cells compared to pTV control were taken 
into account (>2-fold, p-value <0.05). From these genes, only the ones with significant 
changes in expression levels (> 1.8-fold or < 0.556-fold, p-value < 0.05) between wild type 
and mutant cells are shown. (C) mRNA levels of NfκBie relative to wild type unstimulated 
sample, as measured by qPCR. Cells were stimulated with TNFα for the indicated time 
periods. Data was normalized to Rps6 and CanX expression levels. Shown are the means ± 
SD of three independent runs. (D) Promoters of Cfb, Mpa2l and Mmp10 have putative κB 
sites. Schematic representation of putative κB sites found in the indicated promoter regions. 
The distance in bp relative to the transcription start site (TSS) of every putative κB site is 
shown, as well as the sequence from the κB site chosen for analysis by ChIP. 
 
Figure S2. (A) Different myc-tagged HDACs were overexpressed in HEK 293T cells 
together with p300 and myc-tagged p65 and analyzed by western blot using anti-myc 
antibody (left panel) or anti-acetyl K310 antibody (right panel). (B) Western blot against his 
tag of overexpressed SIRT proteins to show expression levels of these proteins in HEK 293T 
cells. (C) Recombinant SIRT proteins used in the in vitro deacetylation assay were resolved 
by SDS-PAGE and stained with coomassie blue. (D) Western blot analysis of untreated 
samples showing no compensatory effect between SIRT1 and SIRT2 in the knock out cells. 
Tubulin served as loading control.  
 
Table SI. Lists of up- and downregulated genes in K314/315R cell line compared to wild 
type control after 3 hours of TNFα treatment, as measured by whole genome arrays. Average 
values from at least two biological replicates are shown.  
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Table SII. Lists of differentially regulated genes in KTR versus wild type control at 3 hours 
TNFα stimulation analyzed by microarrays. Average values from at least two biological 
replicates are shown. 
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CARM1 belongs to the protein arginine 
methyltransferase family. It was reported to 
methylate histone as well as non-histone 
proteins and thus to be involved in 
transcriptional activation and mRNA 
degradation/stability. Here we report the 
genetic complementation of carm1-/- cells with 
wild type CARM1 or an enzymatic inactive 
mutant of CARM1 to investigate the 
requirement of CARM1 and its enzymatic 
activity for NF-κB-dependent gene expression. 
Using custom micro array and real time RT-
PCR, we could define a subset of NF-κB target 
genes that required CARM1 for their proper 
expression. Although several TNFα  and 
PMA/Ionomycin induced NF-κB target genes 
are CARM1-dependent, CARM1 enzymatic 
activity was dispensable for gene expression. 
Interestingly, CARM1 was not required for the 
stimuli-dependent recruitment of NF-κB, 
suggesting that CARM1 is rather contributing 
in protein complex formation. Together, our 
results confirm the importance of CARM1 as 
transcriptional cofactor without the 
involvement of its catalytic activity.  
 The widely expressed and inducible 
transcription factor, nuclear factor-kappaB (NF-
κB), regulates the expression of many effectors 
and inducers that impact immune and 
inflammatory responses, apoptosis, differentiation, 
cell proliferation and transformation (1,2). NF-
κB/REL belongs to a family of five proteins, 
which share a conserved 300 amino acids region 
within their amino-termini, known as the Rel-
homology domain (RHD) that mediates 
dimerization, nuclear translocation, DNA-binding 
and interaction with inhibitory proteins (IκBs) (1). 
The best-studied NF-κB heterodimer is composed 
of RelA/p65 and p50/p105(NF-κB1) members. In 
most differentiated unstimulated cells, inactive 
NF-κB is sequestered in the cytoplasm by its 
physical association with inhibitory proteins IκBs. 
Treatment of cells with extra-cellular stimuli such 
as cytokines, bacterial lipopolysaccharides (LPS) 
or potent oxidants leads to the rapid degradation of 
the IκBs by the 26S proteasome pathway (3). 
Consequently, NF-κB accumulates in the nucleus, 
binds to specific κB DNA consensus sequences 
and activates specific target genes.  
 Gene expression requires the combinatorial and 
synchronized action of many transcriptional 
cofactors, which act as recruiting platform either 
directly by protein-protein interactions with 
secondary coactivators or via their enzymatic 
activity by modifying histone tails or coactivators 
(4,5). Specialized modules of coactivator proteins 
recognize modified residues on histone tails or 
coactivators (6,7). Like other transcription factors, 
NF-κB-dependent gene expression required many 
transcriptional coactivators, among which the 
histone acetyltransferases p300/CBP (CREB-
Binding Protein), pCAF (p300/CBP-Associated 
Factor), the p160 family of coactivator proteins, 
PARP1 (poly(ADP)-ribose polymerase1), PRMT1 
(Protein Arginine Methyltransferase 1) and 
CARM1/PRMT4 (Coactivator-Associated 
Arginine Methyltransferase 1/ Protein Arginine 
Methyltransferase 4) (8-11). 
 CARM1 belongs to the protein arginine 
methyltransferase family, which contains 10 
members, all sharing a specific signature motif 
(12). CARM1 acts as a coactivator of many 
transcription factors (11,13-15). Moreover, it was 
reported to methylate histone H3 at arginine 17 
(H3R17), which correlates with transcriptional 
activation (16), and a unique set of non-histone 
proteins (17-24). Furthermore, besides its role in 
transcription regulation, CARM1 affects also 
mRNA stability/degradation of some specific 
mRNAs bearing AU-rich elements (ARE) at their 
3’-untranslated regions (UTR) by methylating the 
protein HuD (23). CARM1 has also been 
implicated in the epigenetic programming of early 
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embryos (25). Cells from carm1-/- embryos have 
defective estrogen receptor, c-Fos, PPARγ and 
NF-κB pathways (11,15,26,27). The CARM1 
crystal structure was solved by two groups, 
providing insight into its mechanism of action 
(28,29). 
 Despite intensive investigations regarding the 
function of CARM1 as transcriptional co-
activator, the contribution of the protein itself or 
its enzymatic activity is still unclear and even 
controversial. In this report, we genetically 
complemented carm1-/- cells with CARM1 wild 
type or an enzymatic inactive CARM1 mutant to 
subsequently analyze expression of NF-κB target 
genes. Our experiments strongly provide evidence 
that CARM1 itself but not its enzymatic activity is 
required for NF-κB-dependent gene expression.  
 
Experimental Procedures 
Cell culture 
Carm1-/- mouse embryonic fibroblasts (kindly 
provided by Dr. Bedford (University of Texas)) 
(26) and the complemented Carm1-/-(+wt) and 
Carm1-/-(+mut) cells were maintained in DMEM 
(Invitrogen) containing 10% FCS, 100 units/ml 
penicillin/streptomycin and non-essential amino 
acids (GIBCO). Before stimulation with TNFα 
(10ng/ml) (Sigma) or phorbol-12-myristate-13-
acetate (PMA) (0.11 mg/ml)(Sigma)/Ionomycin 
(0.2µM) (Sigma), cells were grown for 12 hours in 
2% FCS-containing medium. Actinomycin D 
(Sigma) was used at a final concentration of 
5µg/ml. 
Lentiviral complementation of carm1-/- cells 
Virus production and transduction of carm1-/- 
cells was performed as described in (30). Briefly, 
HEK293T cells were transfected with 3.5 µg of 
the envelope plasmid, 6.5 µg of packaging 
plasmid, and 10 µg of pRRL-FlagCARM1 wild 
type, FlagCARM1 E267Q mutant. After 24 h the 
viral supernatant was harvested and used to infect 
carm1-/- MEFs. Thirty-six hours post infection 
cells were split into selective medium containing 
2.5 mg/ml Blasticidin (Sigma). Expression of 
recombinant proteins in the complemented cells 
was screened by western blot analysis. Pools of 
cells were used for further analysis. 
Proteins  
N-terminal 6xhis tagged CARM1 was expressed in 
Sf21 insect cells using baculovirus technology and 
purified in batch through Ni-NTA ProBond Resin 
(Invitrogen). GST-PABP was expressed in E.coli 
Bl21DE3 strain. The soluble protein was purified 
in batch through Glutathione Sepharose beads 
(Amersham Biosciences). 
Antibodies 
Anti-CARM1 (07-080) was purchased from 
Millipore, anti-PRMT1 (ab3768) from Abcam, 
anti-RelA/p65 (C20, sc372) and anti-tubulin (TU-
02, sc-8035) from Santa-Cruz Biotechnologies and 
anti-Flag M2 from Sigma.  
Plasmids 
The pRRL lentivirus transfer vector used in this 
study has been previously described (30). The 
enzymatic mutant form (E267Q) of CARM1 was 
created by site directed mutagenesis as described 
in (31) and verified by sequencing.  
In vitro methylation assay 
Assay using whole cell extracts was performed as 
described in (26).  
RNA isolation, Reverse-transcription 
Total RNAs were isolated from cells using Total 
RNA Isolation kit (Agilent Technologies) 
following manufacturer’s instructions. Purified 
RNAs were reverse-transcribed using Retroscript 
kit (Ambion).  
Real-time PCR 
Rotor-Gene3000A (Corbett) was used to perform 
the real-time PCR reactions. Real-time PCR was 
performed using SensimixPlusSYBR (Quantace) 
and specific primers encompassing the regions 
used in the micro array analysis (sequences 
available in suppl. table). The REST program was 
applied for gene expression analysis (32).  
Micro array  
RNA quality was assessed with the RNA 6000 
Nano kit using the Bioanalyzer 2001 (Agilent 
Technologies). Purified RNAs were converted into 
double-stranded cDNA and transcribed into 
AlexaFluor647/AlexaFluor555 labeled cRNA 
using the AminoAllyl MessageAmpTM II aRNA 
Amplification kit (Ambion). Dye incorporation 
was measured on the ND-1000 Spectrophotometer 
(NanoDrop Technologies).  
Activated CodeLink slides (GE Healthcare) were 
printed at the Functional Genomics Center Zurich 
(Switzerland). They contain 350 probes for 
previously identified or putative NF-κB-dependent 
genes and 174 probes for control genes. The 
probes were 60 nucleotides long. Hybridizations 
were performed at the Functional Genomics 
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Center Zürich (Switzerland). Equal amount of 
dye-labeled aRNAs was hybridized for 16 hours. 
Slides were scanned using the Agilent DNA micro 
array scanner and the scans were quantified with 
the Agilent Feature Extraction software. Data 
analysis was performed with GeneSpring software 
(Silicon Genetics).  
Chromatin immunoprecipitation 
ChIP on cross-linked chromatin was performed as 
described in (11). All ChIP experiments were 
performed several times on independent chromatin 
preparations. Immunoprecipitated DNA and input 
DNA were analyzed by real-time PCR using 
specific primers (sequences available in suppl. 
table). Microarray data have been deposited in the 
ArrayExpress under accession numbers A-MEXP-
1502 (array design) and E-MEXP-2020 
(experiment data). 
 
RESULTS 
Genetic complementation of carm1-/- cells with 
wild type and enzymatic inactive CARM1. 
 In a previous study, we could show that 
CARM1 is a transcriptional coactivator of NF-κB-
dependent gene expression (11). To assess the 
contribution of the presence of CARM1 and of its 
methyltransferase activity for the transcriptional 
coactivation function, we genetically 
complemented carm1-/- MEF cells by retroviral 
transduction, either with wild type CARM1 
(carm1-/-(+wt)) or with the enzymatic inactive 
E267Q mutant  of CARM1 (carm1-/-(+mut)) (31).  
 Protein expression levels of the complemented 
CARM1 (wt and mut) were comparable to the 
CARM1 expression levels in a rescued cell line, in 
which CARM1 expression was restored by 
transfection of flp-recombinase (26) (Fig.1A). 
Complementing cells did not alter the expression 
level of PRMT1 protein or of p65 (Fig.1A and 
data not shown). To confirm that CARM1 in 
carm1-/-(+mut) cells was indeed enzymatic 
inactive, we performed a radioactively labeled in 
vitro methylation assay using whole cell extracts 
from the different complemented cell lines and 
GST-PABP as a CARM1 specific substrate. 
Arginine methylation was controlled with a 
recombinant purified active CARM1 as positive 
control. While GST-PABP was in vitro arginine-
methylated in the presence of the recombinant 
protein and in the presence of cell extracts from 
carm1-/-(+wt) cells, no methylation of the target 
protein was observed when carm1-/- or carm1-/-
(+mut) extracts were used (Fig.1B). Together 
these experiments confirmed that carm1-/- cells 
were complemented comparable to wild type cells. 
A subset of TNFα-induced NF-κB-dependent 
genes required CARM1 for their expression. 
 Previously, we could show by conventional 
RT-PCR that some selected NF-κB dependent 
genes were differentially expressed in carm1+/+ 
and carm1-/- cells. To have a broader view of 
which genes required CARM1 for their proper 
expression, global NF-κB-dependent gene 
expression was analyzed using a customized micro 
array with 350 sequences of previously identified 
or putative NF-κB target genes. Total RNA was 
isolated from carm1-/-, carm1-/-(+wt) or carm1-/-
(+mut), which were either untreated or stimulated 
for 3 hours with TNFα. RT-PCR for IκBα, a well 
known TNFα-dependent NF-κB target gene, 
revealed that IκBα expression was induced to the 
same extend in all three cell lines, thus confirming 
signal pathway activation by TNFα stimulation 
(data not shown). Amplified and labeled RNAs 
were subsequently co-hybridized in different 
combination to the customized micro array. First, 
we compared non-stimulated and TNFα-
stimulated carm1-/-(+wt) cells. 28 genes were 
found to be up-regulated more than 2-fold upon 
stimulation (Fig.2A and 2B). No gene was found 
to be down-regulated upon TNFα stimulation. 
Comparison of the gene expression profile of 
TNFα-stimulated carm1-/- and carm1-/-(+wt) 
cells revealed that 26 genes were upregulated 
more than 2-fold in carm1-/-(+wt) compared to 
carm1-/- indicating that CARM1 is required for 
their expression (data not shown). From these 26 
CARM1-dependent genes, only 7 genes were also 
dependent on TNFα stimulation (indicated in bold 
in Fig.2B) while the others were not induced by 
TNFα.  
Next, we assessed the contribution of 
CARM1’s enzymatic activity for the expression of 
NF-κB-dependent genes. Comparison of gene 
expression profiles of TNFα-stimulated carm1-/-
(+wt) and carm1-/-(+mut) cells revealed that gene 
expression profiles were highly similar. Gene 
expression was subsequently confirmed for some 
genes by q-RT-PCR (TNFα-stimulated cells in 
Fig.3A and B and data not shown). Together these 
results provide strong evidence that CARM1 is 
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required for the expression of a subset of NF-κB 
target genes but the enzymatic activity of CARM1 
is dispensable.  
Induction of NF-κB by PMA/Ionomycin neither 
requires the enzymatic activity of CARM1.  
 The NF-κB response is in part dependent on 
the stimulus (33). To investigate whether CARM1 
is also indispensable for the expression of a subset 
of NF-κB target genes when the complemented 
carm1-/- MEF cells are treated with another 
stimulus, experiments were repeated and cells 
stimulated for 3 hours either with TNFα or 
PMA/Ionomycin. IκBα and Cox2, two genes 
identified earlier in our studies as CARM1-
independent genes (Fig.2), were induced upon 
TNFα stimulation in all three cell lines to about 8-
fold or 5-fold, and upon PMA/Ionomycin 
stimulation to 2-fold or 20-fold, respectively, 
suggesting that cells were indeed stimulated by the 
treatment and confirmed CARM1 independency of 
these genes (Fig.3A). 
 We subsequently investigated the expression of 
four CARM1-dependent genes after TNFα 
stimulation by q-RT-PCR (Mpa2l, Cxcl5, IL6 or 
MIP2). While Mpa2l and Cxcl5 were induced in a 
CARM1 and TNFα-dependent manner (20-fold 
for Mpa2l and 4 fold for Cxcl5), PMA/Ionomycin 
treatment of the cells was not able to induce their 
expression (Fig.3B), thus not allowing the 
assessment of the influence of the 
PMA/Ionomycin stimulus. However, IL6 was 
induced 15-fold upon TNFα or PMA/Ionomycin 
stimulation in carm1-/-(+wt) cell line and MIP2 
was induced by TNFα by 100-fold, while 
PMA/Ionomycin induced gene expression only by 
20-fold (Fig.3B). Both genes were expressed at a 
very low level in carm1-/- cells upon stimulation 
with both stimuli, re-confirming that the 
expression was dependent on CARM1. Moreover, 
measurement of IL6 and MIP2 gene expression in 
carm1-/-(+mut) cells revealed that the expression 
levels were comparable to the ones measured in 
carm1-/-(+wt) cells, confirming that the 
methyltransferase activity is dispensable after 
TNFα but also after PMA/Ionomycin stimulation 
for both tested NF-κB dependent genes. 
Together, these results indicate that the 
level of gene expression for a given gene is 
dependent on the stimulus, but that the 
dependency for CARM1 is not altered by the 
stimulation. 
The enzymatic activity of CARM1 reduces MIP2 
mRNA degradation. 
The measured expression levels by qRT-
PCR represent equilibrium of mRNA synthesis 
and degradation. CARM1 was shown to increase 
mRNA degradation of some specific mRNAs 
bearing AU-rich elements (ARE) at their 3’-
untranslated regions (UTR) by methylating HuD 
(23). Many cytokines and chemokines mRNA 
harbors AREs at their 3’-UTR. Thus, we explored 
the possible role of CARM1 in the stability of two 
CARM1-dependent genes, MIP2 and Cxcl5. Cells 
were stimulated for 1 hour with TNFα before the 
addition of actinomycin D (Fig.4). Total RNAs 
were purified at different time points, reverse-
transcribed and analyzed by qRT-PCR. Cxcl5 
mRNA was really stable in the three different cell 
lines with a half-life of more than 2 hours 
(Fig.4A). However, MIP2 mRNA was less stable 
in the carm1-/-(+wt) cells (half-life of less than 30 
minutes) compared to the stability in carm1-/- and 
carm1-/-(+mut) cells (half life of 1 hour, Fig.4B). 
These results indicate that although CARM1’s 
enzymatic activity is not required for transcription, 
it has an effect in the MIP2 mRNA stability.  
RelA/p65 recruitment to chromatin is stimulus-
dependent but independent on CARM1.  
 To investigate whether CARM1 would regulate 
the recruitment of NF-κB to its target genes, we 
performed chromatin immunoprecipitation (ChIP) 
experiments of RelA/p65 to the promoter of NF-
κB-dependent genes in carm1-/- cells, carm1-/-
(+wt) and in carm1-/-(+mut) cells after TNFα 
stimulation. Recruitment to the promoter of 
CARM1-dependent (MIP2 and Mpa2l) and 
CARM1-independent genes (Cox2 and IP10) or 
control gene (glucagon) was analyzed by qPCR 
using specific primers. RelA/p65 was similarly 
recruited to promoters of CARM1-independent or 
dependent genes in all cell lines (Cox2, IP10, and 
Mpa2l, Fig.5A). Only at the MIP2 promoter in 
carm1-/- cells, RelA/p65 recruitment was delayed 
indicating that CARM1 protein might stabilize the 
binding of NF-κB to this gene. As a control, 
RelA/p65 was not recruited to the glucagon 
promoter (Fig.S1). 
Wild type and enzymatically inactive CARM1 are 
recruited to the same extent to NF-κB target 
genes.  
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 To control that both complemented forms of 
CARM1 would be recruited to comparable levels, 
we repeated ChIP experiments for CARM1 and 
the indicated promoters (Fig.5B and Fig.S1). Wild 
type and mutant CARM1 were recruited to the 
same extent after 30 minutes of stimulation to all 
tested promoters. The recruitment would increase 
over time (highest at 60 minutes) for wild type 
CARM1 and slightly decreases, although not 
significantly, at the later time point for mutant 
CARM1 (Fig.5B). As a control, CARM1 was not 
recruited to the glucagon promoter (Fig.S1). 
 
DISCUSSION 
 
To further characterize CARM1 as a 
transcriptional coactivator, carm1-/- cells were 
stably complemented by viral transduction with 
wild type or with an enzymatic inactive mutant of 
CARM1. Cells were subsequently stimulated by 
TNFα or PMA/Ionomycin and gene expression 
analyzed using either a custom micro array with 
NF-κB-target genes or by qRT-PCR. Both 
analyses reveal that CARM1 is required for the 
correct expression of certain NF-κB-target genes 
but that the enzymatic activity of CARM1 is 
dispensable. The absence of the enzymatic activity 
did neither affect the recruitment of RelA/p65 nor 
the one of CARM1 to distinct promoters. 
However, the enzymatic activity affected the 
mRNA stability of MIP2. 
 So far, functional contribution of CARM1 upon 
induced gene expression was never analyzed on a 
global level. Here, CARM1’s functional role as a 
transcriptional coactivator was analyzed in more 
details using a customized micro array for NF-κB 
target genes. This global approach revealed that 
only a subset of genes required the presence of the 
protein (independently of its enzymatic activity) 
probably dependent on the promoter context. 
Furthermore, few studies analyzed the in vivo 
expression of certains genes by RT-PCR in 
knockout or knockdown cells (14,15,27,34,35). 
Thus, further studies will be necessary to extend 
the view that CARM1 is necessary only for a 
subset of target genes and to define which 
promoter context requires CARM1. Additionally, 
we found that complementation of carm1-/- cells 
with wt or inactive CARM1 changed the 
expression profile in part independent on TNFα 
(Fig.2 and data not shown), indicating that 
CARM1 might influence the composition of the 
chromatin on a general level. 
Interestingly, CARM1 was not required 
for the recruitment of NF-κB upon TNFα 
stimulation, since NF-κB was recruited after 30 
and 60 min to three different promoters (Cox2, 
MPa2l and IP10) in all tested cells lines in a 
stimuli-dependent manner to the same extent and 
only slightly delayed to the MIP2 promoter. These 
results suggests, that while CARM1 is influencing 
the initial recruitment of NF-κB to its response 
elements (11), CARM1 does not influence the 
chromatin binding of NF-κB upon longer 
stimulation with TNFα. Interestingly, the binding 
of NF-κB itself to these promoters was not 
sufficient to induce gene expression in carm1-/- 
cells (Fig.3B). Furthermore, CARM1 was 
recruited in a stimuli-dependent manner, 
independent whether it was an active or inactive 
protein, suggesting that CARM1 is important for 
transcriptional coactivator complex formation 
and/or stabilization of this complex.  
 Comparable to TNFα, also PMA/Ionomycin 
induced NF-κB-dependent gene expression was 
not dependent on CARM1’s enzymatic activity, 
suggesting that the observed dispensability might 
be generally valid. We can however, not exclude, 
that other stimuli or cell types might depend on the 
enzymatic activity of CARM1 and that also the 
promoter context might influence the requirement 
of protein methylation by CARM1. Further studies 
are needed to extend our observations. 
Despite intensive investigation regarding 
the involvement of CARM1’s enzymatic activity 
for its role as transcriptional coactivator, its 
contribution is still not clear and even 
controversial. Methylation of p300 by CARM1 
could be beneficial (17) or could attenuate 
transcriptional responses (18). On the other hand, 
methylation of SRC3/AIB1/p/CIP attenuated 
estrogen receptor transcriptional response by 
destabilizing complex association (19,24). This is 
the first report providing genetical evidences that 
the enzymatic activity is not required for the 
transcriptional activation of genes. The 
contribution of CARM1’s enzymatic activity was 
so far investigated by comparing gene expression 
profiles from carm1-/- and carm1+/+ cells, which 
does not allow deciphering between requirement 
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of the protein or its enzymatic activity 
(11,15,26,27). Additionally, the requirement of 
CARM1 enzymatic activity to coactivate gene 
expression was mainly analyzed by 
overexpressing CARM1 and using transiently 
transfected reporter gene expression assay as 
readout (13,31). This latter approach, however, 
suffers major drawbacks such as the transfection 
of multiple plasmids, which are poorly 
chromatinized and the overexpression of proteins 
that could impair the balance of proteins in the 
cell. Consequently, the results of such experiment 
might not reflect the in vivo functional relevance 
of CARM1. In the context of multiple protein-
protein complexes present at the promoters during 
the initiation step of transcription, the requisite of 
CARM1 protein might not be compensated by 
other proteins. CARM1 possesses a unique C-
terminal extension that bears an autonomous 
activation domain (36) which suggests that 
CARM1 may interact with downstream 
components of the transcriptional machinery. 
Since the presence of CARM1 is important to 
induce a proper expression of NF-κB-dependent 
genes, it might be through the recruitment of other 
important coactivator or stabilization of 
complexes. Few proteins are known to interact 
with full-length CARM1 such as Brg1 within the 
NUMAC complex (37), p300 (8,11,18), SRCAP, 
which shares homology with the SNF2 family of 
proteins (38) or β-catenin (39). A recent study 
revealed that CARM1 could facilitate the 
recruitment of Brg1 at late genes during muscle 
differentiation (40). Interestingly, not only wild-
type but also the enzymatic mutant of CARM1 
was reported to synergistically activate together 
with Brg1 ER-dependent transcription (37). 
Further studies are needed to identify and 
characterize the proteins that are dependent on 
CARM1 and that participate in the appropriate 
expression of NF-κB-dependent genes. 
Moreover, besides its role as a 
transcriptional coactivator, CARM1 was shown to 
affect mRNA stability/degradation of some 
specific mRNAs bearing AU-rich elements (ARE) 
at their 3’-untranslated regions (UTR) by 
methylating HuD (23). Many cytokines and 
chemokines mRNA harbors AREs at their 3’-
UTR. Experiments of gene expression in presence 
of actinomycin D indeed revealed that MIP2 
mRNA was less stable in the carm1-/-(+wt) cell 
line (Fig.4). Thus, the enzymatic activity of 
CARM1 might not be required for transcriptional 
coactivation, but might rather influence mRNA 
stability. mRNA stability was recently reported to 
be a key determinant controlling the kinetic 
patterns of TNFα-induced gene expression (41). 
Overexpression of CARM1 was observed 
in hormone-independent prostate carcinoma, 
suggesting that overexpressed CARM1 could lead 
to tumor formation by stabilizing coactivator 
complexes at the androgen receptor target genes 
(42,43). The contribution of the enzymatic activity 
has to be further investigated, but based on our 
observation the overexpression of CARM1 alone 
might be sufficient to tumorigenesis. 
 Together, the presented results strongly support 
an essential role of the CARM1 as transcriptional 
coactivator. Moreover, our results suggest that the 
enzymatic activity of CARM1 is dispensable for 
NF-κB-dependent gene expression.  
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FIGURE LEGENDS 
 
Fig. 1. Genetic complementation of carm1-/- cells. A Whole cell extracts of the different cell lines were 
analyzed by western blot using anti-CARM1 and anti-PRMT1 antibodies, B purified GST-PABP was 
incubated with 14C-SAM and whole cell extracts from carm1-/-, carm1-/-(+wt) and carm1-/-(+mut) cells 
as a source of CARM1 or purified recombinant CARM1. Pull-down GST-PABP was loaded on a SDS-
PAGE and analyzed by autoradiography. 
 
Fig. 2. CARM1 is required for the expression of a subset of NF-κB-dependent genes. A Venn diagram 
showing upregulated genes found in the micro array analysis when non-stimulated carm1-/-(+wt) cells 
and TNFα-stimulated carm1-/- cells were compared to TNFα-stimulated carm1-/-(+wt) cells. B List of 
genes found in the micro array analysis. CARM1-dependent genes are indicated in bold. The fold 
induction after TNFα stimulation represents the increase in gene expression obtained when comparing 
non-stimulated and TNFα-stimulated carm1-/-(+wt) cells. CARM1 dependency was determined by 
comparing TNFα-stimulated carm1-/-(+wt) and carm1-/- cells. 
 
Fig. 3. Enzymatic activity of CARM1 is not required for the expression of NF-κB target genes. Carm1-/-, 
carm1-/-(+wt) and carm1-/-(+mut) cells were left unstimulated (white bars), stimulated with TNFα 
(black bars) or with PMA/Ionomycine (grey bars). A The relative mRNA expression of two CARM1-
independent genes (IκBα and Cox2) and B four CARM1-dependent genes (IL6, MIP2, Mpa2l and Cxcl5) 
are shown. Results are representative of three biological replicates. 
 
Fig. 4. MIP2 mRNA stability is influenced by CARM1’s enzymatic activity. Cells were stimulated for 
one hour with TNFα (time 0) and mRNA synthesis was inhibited by actinomycin D for different time 
points. A Expression level of remaining MIP2 and B Cxcl5 in carm1-/- (), carm1-/-(+wt) () and 
carm1-/-(+mut) () mRNAs was determined and calculated relative to time 0 (set at 100%). 
 
Fig. 5. p65 recruitment is not impaired in carm1-/- cells. Fold increase in the recruitment of A RelA/p65 
and B Flag-CARM1 at promoters of two CARM1-dependent genes (MIP2 and Mpa2l) and of two 
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CARM1-independent genes (Cox2 and IP10) was analyzed by ChIP experiments in non-treated cells 
(white bars), after 30’ (black bars) or 60’ (grey bars) stimulation with TNFα.  
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Supplementary Tables 
 
Table1: Sequences of the oligonucleotides used for gene expression and for ChIP 
analysis 
 
Oligonucleotides used for gene expression analysis 
 Primer Primer Sequences 
Rps12 Fw GAAGCTGCCAAAGCCTTAGA 
 Rev AACTGCAACCAACCACCTTC 
Cox2 Fw AGGGCCCTACCAAGATGCTAGAAA 
 Rev CCCTATTGCCCAGAACTACTCACA 
IκBα Fw AAATCTCCAGATGCTACCCGAGAG 
 Rev ATAATGTCAGACGCTGGCCTCCAA 
IL6 Fw TCACTTTGAGATCTACTCGGCAAACC 
 Rev TCTGACCACAGTGAGGAATGTCCA 
MIP2 Fw ACATCCCACCCACACAGTGAAAGA 
 Rev TCCTTCCATGAAAGCCATCCGACT 
Cxcl5 Fw GCTGCTGTGTCATGCAGAAACCTA 
 Rev GACATTATGCCATACTACGAAGACATC 
Mpa2l Fw CTTGGAGAAGCCTACTTCGTCTCT 
 Rev AAATCTGCCAGCAGACCCTAACCT 
 
Oligonucleotides used for ChIP analysis 
 Primer Primer Sequences 
IP10 Fw GCAATGCCCTCGGTTTACAG  
 Rev GGCTGACTTTGGAGATGACTCA 
Cox2 Fw AGTACAGATGTGGACCCTGACAGAG 
 Rev GGCCTAAAAGCTCAAGAGTGTCACAG 
Mpa2l Fw CAGCCCCTTTTATAGTGAGTC 
 Rev TACAAAATCCGGGAGTATTGC 
MIP2 Fw CCCAGGGTCCCATAGTGGAA 
 Rev CCGCCCCTAAGCTGAGT 
Glucagon Fw GAGTGGGCGAGTGAAATCAT 
 Rev TGAGCTGCGAACAGGTGTAG 
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Supplementary Figure Legend 
Fig.S1 RelA/p65 and Flag-CARM1 are not recruited at the glucagon promoter 
Fold increase in the recruitment of RelA/p65 (A) and Flag-CARM1 (B) at the 
promoter of glucagon gene was analyzed by ChIP experiments in non-treated cells 
(white bars), after 30’ (black bars) or 60’ (grey bars) stimulation with TNFα.  
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7 Unpublished data 
 
7.1 Acetylation of p65 in response to TNFα  and IL-1β  stimulation 
Proinflammatory cytokines such as TNFα and IL-1β trigger the classical NF-κB pathway 
[266]. The finding that p65 is acetylated after TNFα stimulation prompted us to test whether 
this was also the case after IL-1β treatment. Indeed, p65 acetylation can be observed in p65-/- 
MEFs complemented with p65 wild type after stimulation with IL-1β, as revealed by western 
blot using the specific antibody against acetylated K310 from p65 (Figure 8). The observed 
signal is stronger than the one after TNFα stimulation. Together, this data suggest that p65 
acetylation is in general important for gene expression. 
 
 
Figure 8. Endogenous p65 acetylation at K310 upon TNFα and IL-1β stimulation in vivo. Wild type 
complemented MEFs were treated with or without HDAC inhibitors (HDACi) TSA and Nam for 30 minutes 
before stimulation with TNFα or IL-1β for 45 minutes. Total cell extracts were prepared, p65 was 
immunoprecipitated and samples were analyzed by western blot using α-acetyl K310 antibody. The membrane 
was reprobed for p65. Tubulin from 5% extracts was used as loading control. 
 
 
7.2 Characterization of α-acetyl K314/315 p65 specific antibody 
Since we were able to detect acetylation at K314 and K315 in vitro and when p65 and p300 
were overexpressed in HEK 293T cells, but not with endogenous proteins with the specific 
antibodies against acetylated K314 or acetylated K315, we decided to generate an antibody 
that recognizes both acetylated lysines. This antibody was generated by Eurogentec using the 
following peptide for immunization: SIM K(Ac)K(Ac)S PFS GPC, acetylated at both lysines. 
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Recombinant p65 protein was acetylated in vitro by p300 and analyzed by western blot with 
purified α-acetyl K314/315 antibody (Figure 9A). To determine if the signal was specific, 
p65 K314/315R mutant protein was used as a negative control. The antibody detected 
acetylated p65 only when p65 wild type protein was used. In addition, the antibody 
specifically recognized acetylated p65 overexpressed in HEK 293T cells together with p300 
(Figure 9B). However, the antibody failed to detect endogenous acetylated p65 from nuclear 
or total cell extracts (Figure 9C and 9D, respectively). In both experiments, no band from the 
size of p65 was observed, although complemented cells were treated with HDACi to 
facilitate the detection of endogenous acetylated p65, as has been done for detection of 
acetylated K310. 
 
 
 
Figure 9. Characterization of purified α-acetyl K314/315 antibody. (A) Recombinant purified p65 wild type 
and K314/315R mutant were acetylated in vitro by p300 and analyzed by western blot with α-acetyl K314/315 
antibody. The membrane was reprobed with α-p65 antibody. (B) Myc-tagged p65 wild type and p65 KTR 
mutant were overexpressed in HEK 293T cells with or without co-expression of p300. Total cell extracts were 
prepared and analyzed by western blot with the indicated antibodies. (C) Complemented cells were treated with 
TSA and Nam for 1 hour prior TNFα stimulation for 20 minutes. Nuclear extracts were prepared, p65 was 
immunoprecipitated and analyzed by western blot. (D) Complemented cells were treated with TSA and Nam for 
2.5 hours before stimulation with TNFα for 30 minutes. p65 was immunoprecipitated from total extracts and 
analyzed by western blot with α-acetyl K314/315 antibody. The membrane was reblotted with α-p65 antibody. 
118
Results 
 
 
Furthermore, the α-acetyl K314/315 serum was tested for the recognition of 
endogenous p65 in its native form. Immunostaining with the α-acetyl K314/315 serum in the 
wild type complemented cells showed a different staining pattern than the one obtained with 
the α-p65 antibody (Figure 10). The cross-reactivity of the antibody was further confirmed 
when pTV cells were used (p65-/- complemented with the empty vector), since the same 
unspecific signal was observed in both wild type and pTV cells. This result suggests that the 
α-acetyl K314/315 serum recognizes a different nuclear protein than p65, which is 
acetylated, since the signal was increased after treatment with HDACi. This serum might thus 
be used to study a perhaps so far unidentified acetylated protein in MEFs. 
 
 
 
Figure 10. Immunostaining using the α-acetyl K314/315 serum. p65-/- MEFs complemented with p65 wild type 
(upper panel) or with the empty vector (lower panel) were either left untreated, treated with HDACi alone, or 
with both HDACi and TNFα. Cells were fixed and immunostained using α-acetyl K314/315 serum or α-p65 
antibody. 
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7.3 Searching for acetylation-dependent interacting partners of p65 
In order to modulate the transcription of target genes, p65 interacts with distinct coactivators 
and corepressor. In some cases, the interaction has been shown to depend on posttranslational 
modifications, such as the requirement of p65 phosphorylation at serines 276 and 536 for the 
binding with p300/CBP [260]. To determine whether p65 acetylation regulates NF-κB-
dependent gene expression by modulating the ability of p65 to interact with specific 
coregulatory proteins, we performed several acetylation-dependent interaction studies. We 
focused on bromodomain-containing proteins, since bromodomains have been reported to 
bind acetyl lysines and are found in chromatin associated proteins and HATs [114]. 
 
7.3.1 p300 
The bromodomain of p300 has been reported to bind to acetylated proteins including p53 and 
MyoD [267, 268]. To determine if p300 preferentially binds to acetylated p65 compared to 
non-acetylated one, we performed pull-down experiments using in vitro translated p300 
bromodomain and GST-p65 wild type or KTR mutant. In contrast to what we expected, we 
observed an increased interaction with the non-acetylated p65 wild type or KTR mutant 
(Figure 11), suggesting that acetylation of p65 is not important for binding to p300. 
 
Figure 11. In vitro interaction between GST-p65 and His-p300 BD. GST-p65 was acetylated in vitro by p300 
(ac) or left non-acetylated (non-ac). Pull-down assays were performed with radioactively labeled His-p300 
bromodomain (His-p300 BD) and detected by autoradiography. 10% of His-p300 BD used for the pull-downs 
was kept as control. GST-p65 wild type or KTR mutant were either stained with coomassie as loading control or 
analyzed by western blot using α-acetyl K310 antibody. 
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7.3.2 TAF1 
TAF1, the largest TAF of TFIID, contains two bromodomains that have been shown to 
interact with acetylated Histone H4 and p53 [95, 269]. Pull-down experiments between GST-
TAF1 double bromodomain (GST-TAF1 BD) and recombinant p65 wild type revealed that 
these two proteins interact in vitro in an acetylation-dependent manner (Figure 12, lower 
panel). However, when p65 acetylation-deficient mutants were used for this experiment, we 
did not observe any decrease in the binding to TAF1 double bromodomain, suggesting that 
this interaction is not mediated by acetylation on lysines 218, 221, 310, 314 or 315 from p65. 
 
 
Figure 12. Pull-down assays between TAF1 double bromodomain and purified p65. Recombinant p65 wild type 
(wt) or acetylation deficient mutants KTR (K310/314/315R) or KQR (K218/221/310/314/315R) were acetylated 
in vitro by p300 in the presence of acetyl-CoA, as revealed by western blot analysis using α-acetyl K310 
antibody or left non-acetylated (upper panel). Recombinant p65 proteins (wt or mutants, acetylated or non-
acetylated) were incubated with GST-tagged TAF1 double bromodomain bound to beads (lower panel). 
Samples were washed with binding buffer containing 200 or 800 mM NaCl and analyzed by western blot using 
α-p65 antibody. Membranes were stained with Ponceau to detect GST-TAF1 BD. 10% input of recombinant 
p65 proteins were kept as positive control, GST-TAF1 BD bound to beads (B) alone was used as negative 
control. 
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To confirm that the binding between p65 and TAF1 depends on the bromodomains of 
TAF1, pull-down experiments with wild type or mutant double bromodomain were 
performed (Figure 13). Interaction was lost when the bromodomains were mutated, 
indicating that the integrity of the double bromodomain of TAF1 is required for its 
interaction with acetylated p65. 
 
 
Figure 13. Recombinant p65 wild type was acetylated in vitro by p300 and subsequently incubated with GST-
TAF1 BD wild type or mutant. Samples were analyzed by western blot against p65.  
 
 
Because p65 was acetylated by p300 in vitro before interaction studies were 
performed, p300 was present during the pull-down experiments. To determine whether the 
observed binding between p65 and GST-TAF1 BD is mediated by p300, pull-down 
experiments were performed in the presence or absence of p300 or acetyl-CoA. Recombinant 
p65 wild type expressed in insect cells was already slightly acetylated at K310 without the 
addition of acetyl-CoA, independent on the presence of p300, probably due to acetylation in 
insect cells (Figure 14, upper panel). After incubation with p300 and acetyl-CoA, p65 
acetylation was dramatically increased. Incubation of these different samples with GST-
TAF1 BD revealed that the binding between p65 and TAF1 increases in the presence of 
acetyl-CoA and p300 (Figure 14, lower panel). 
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Figure 14. Recombinant purified p65 wild type was incubated alone, with p300 alone or with both p300 and 
acetyl-CoA (upper panel). These different samples were subsequently incubated with GST-TAF1 BD wild type, 
washed with binding buffer containing 600 or 1200 mM NaCl and analyzed by western blot (lower panel). 
 
 
7.3.3 Brd4 
Brd4 is a mammalian protein that contains two tandem bromodomains and binds to 
acetylated histones H3 and H4 [270]. We investigated whether p65 and Brd4 bind in an 
acetylation-dependent manner in vivo by performing co-immunoprecipitation of myc-tagged 
p65 from the complemented cell lines pTV, wt and KTR treated with HDACi and TNFα. 
Western blot analysis with an α-Brd4 antibody revealed that Brd4 was unspecifically co-
immunoprecipitated even in pTV cells, which do not contain myc-tagged p65 (Figure 15).  
 
 
Figure 15. In vivo interaction between Brd4 and p65. Complemented MEFs pTV, wt and KTR were treated for 
1.5 hour with HDACi TSA and Nam before additional 20 minutes of TNFα stimulation. Nuclear extracts were 
prepared and myc-tagged p65 was immunoprecipitated form there. Co-immunoprecipitated Brd4 was analyzed 
by western blot.  
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The experiment was repeated using α-p65 or α-Brd4 antibodies for the 
immunoprecipitation, but unfortunately similar results were generated (data not shown). 
Thus, under the tested conditions, we did not detect a specific interaction between p65 and 
Brd4 in vivo. 
 
 
7.4 Gene expression in Sirt2-/- MEFs 
We identified SIRT2 as a novel p65 deacetylase (see section 6.2). Since p65 acetylation 
influences NF-κB-dependent transcription [245], we decided to investigate whether the 
expression of NF-κB target genes is affected in Sirt2-/- cells in vivo. In the submitted 
manuscript “Deacetylation of p65 by cytoplasmic SIRT2 regulates NF-κB” we describe the 
misregulation of Mpa2l, RELA and Mmp13 in Sirt2-/- MEFS compared to Sirt2+/+ MEFs. 
Here, we analyzed the expression of three additional NF-κB target genes: IP10, Cox2 and 
Nos2 (Figure 17). In agreement with our reported results, the TNFα-mediated induction of 
these three genes was higher in Sirt2-/- cells as well. 
 
 
Figure 17. Misregulated gene expression in Sirt2-/- cells. mRNA levels from Sirt2+/+ and Sirt2-/- MEFs were 
measured by real-time RT-PCR in response to TNFα. The mean value of at least two biological replicates is 
shown in the graphs ± SD. 
 
 
7.5 PARP1 protein levels in SIRT1 and SIRT2 knock out MEFs 
During western blot analysis of lysates from Sirt1+/+, Sirt1-/-, Sirt2+/+ and Sirt2-/- MEFs, we 
realized that the levels of PARP1 were lower in SIRT1 and SIRT2 knock out cells (Figure 
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18). The major difference was observed between Sirt2+/+ and Sirt2-/- cells (Figure 18, left 
panel), suggesting that PARP1 protein expression might be affected by SIRT1 and SIRT2. 
 
 
 
Figure 18. (Left panel) Total cell extracts were prepared from unstimulated Sirt2+/+, Sirt2-/- and HEK 293T 
cells and analyzed by western blot using the indicated antibodies. (Right panel) Nuclear (NE) and cytoplasmic 
(CE) extracts from Sirt1+/+and Sirt1-/- MEFs left untreated or treated for 20 minutes with TNFα were resolved 
on SDS-PAGE and analyzed by western blot. Tubulin served as loading control. 
 
 
7.6 Materials and methods 
 
7.6.1 Endogenous p65 acetylation at K310 after TNFα and IL-1β 
Wild type complemented MEFs were starved overnight in medium containing 0% FCS. Cells 
were left untreated or treated with HDACi (HDACi: 2 mM TSA, 5mM NAM) for 30 minutes 
before stimulation with 30 ng/ml TNFα or 10 ng/ml IL-1β for 45 additional minutes. Total 
cell extracts were prepared and used for immunoprecipitation of p65. Samples were resolved 
on SDS-PAGE and analyzed by western blot using α-acetyl K310 antibody. The membranes 
were reprobed with α-p65 antibody. 
 
7.6.2 In vitro acetylation assay  
One microgram of recombinant human wild type or mutant p65 was incubated with or 
without 0.5 µg recombinant p300 in HAT buffer (50 mM Tris–HCl pH 8.0, 100 mM NaCl, 
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10% glycerol, 1 mM DTT, 1 mM PMSF, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml 
leupeptin, 1 mM sodium butyrate) supplemented with or without 5 mM cold acetyl CoA for 1 
hour at 30°C. Reactions were stopped by adding 10x Laemmli-buffer and proteins resolved 
on SDS–PAGE with subsequent western blot analysis using α-acetyl K314/315 or α-acetyl  
K310 antibodies. The membranes were reprobed for p65. 
 
7.6.3 p65 acetylation in cells 
Myc-tagged p65 wild type or K314/315R mutant were co-expressed with p300 in HEK 293T 
cells. After 24 hours of transfection, cells were treated with HDACi (2 mM TSA, 5mM 
NAM) for 40 minutes and subsequently stimulated with 10 ng/ml human TNFα (SIGMA) for 
30 additional minutes. Whole cell extracts were prepared (50 mM Hepes pH 7.9, 420 mM 
NaCl, 0.5% NP-40, 1 mM PMSF, 0.5 mM DTT, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 
mg/ml leupeptin, 5 mM TSA, 0.5 M Nam). 30 µg of whole cell extract was resolved on SDS-
PAGE and analyzed by standard western blot using α-acetyl K314/315 antibody, followed by 
reprobe with α-myc antibody. 
 
7.6.4 Immunostaining 
Complemented cells were plated at the density of 80 000 cells per chamber. After 6 hours, 
cells were either left untreated, treated with HDACi (0.5 mM TSA and 0.5 M Nam) alone for 
1 hour, or treated with HDACi for 40 minutes and 20 additional minutes with 30 ng/ml 
mouse TNFα. Cells were fixed with 4% paraformaldehyde and then permeabilized with 0.2% 
Triton-X-100/PBS. After blocking for 1 hour in 2% BSA/0.1% Triton-X-100/PBS, samples 
were incubated with α-p65 antibody (1:250 dilution, Santa Cruz) or α-acetyl K314/315 
serum (1:250 dilution), followed by α-rabbit Cy3 antibody (1:250 dilution, Jackson 
Immunology). The samples were washed and Vectashield mounting solution (Vector 
laboratories) was applied to prevent bleaching. Cells were visualized using an Olympus T50 
microscope. 
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7.6.5 GST pull-downs 
GST-tagged fragment of the double bromodomain from TAF1 (GST-TAF1 BD) was 
expressed in bacteria. GST-TAF1 BD (wild type or mutant) was immobilized on glutathione 
beads (Amersham Pharmacia) and incubated with in vitro acetylated recombinant p65 (wild 
type, KTR or KQR mutants) in binding buffer (50 mM Tris pH 8, 120 mM NaCl, 0.5% NP-
40, 1mM PMSF and 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin, 5 mM Nam, 1 
mM TSA) for 2 h at 4°C rolling. Glutathione beads were washed with binding buffer 
containing distinct NaCl concentrations. Proteins were boiled, resolved on SDS–PAGE and 
subjected to western blot analysis using α-p65 antibody (C-20, Santa Cruz). 
 GST-tagged full-length p65 was expressed in insect cells, immobilized on glutathione 
beads (Amersham Pharmacia) and in vitro acetylated by p300. After several washes to get rid 
of p300, GST-p65 was incubated with His-p300 BD in binding buffer (50 mM Tris pH 8, 120 
mM NaCl, 0.5% NP-40, 1mM PMSF and 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml 
leupeptin, 5 mM Nam, 1 mM TSA) for 3 h at 4°C rolling. Glutathione beads were washed 
with binding buffer; proteins were boiled and resolved on SDS–PAGE. The gel was fixed, 
dryed and exposed to X-ray films (Contatyp) at –80°C. 
 
7.6.6 In vitro translation 
His-tagged p300 bromodomain (His-p300 BD) was in vitro translated using the ‘TNT 
coupled reticulocyte lysate systems’ (Promega) following the manufactures instructions. 
 
7.6.7 mRNA quantification by real-time RT-PCR  
Total RNA from untreated or 3 hours TNFα-treated Sirt2+/+ and Sirt2-/- MEFs was reverse 
transcribed using the High Capacity cDNA Archive Kit (ABI) according to manufacturers 
protocol. Real-time RT-PCR was performed using mouse-specific TaqMan probes (Gene 
expression assays, ABI) for IP-10, Nos2 and Cox2. TaqMan probe for Rps6 was used to 
normalize for differences in RNA input. Rotor-Gene3000A (Corbett Life Science, now 
Qiagen) was used to perform the real-time RT-PCR reactions and the REST program was 
applied for analysis. The graphs show the mean values of at least two biological replicates ± 
standard error. 
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DISCUSSION 
 
8 Summary of results 
 
The aim of this thesis was to examine the role of p65 acetylation; more specifically, its 
influence on NF-κB-dependent gene expression. We showed that p300 acetylates p65 at 
lysines 310, 314 and 315 in vitro and in vivo in response to TNFα. Furthermore, using p65-/- 
MEFs genetically complemented with non-acetylatable mutants, we demonstrated that site-
specific acetylation of p65 regulates the expression of particular subsets of NF-κB target 
genes. Gene expression analysis of the different complemented cell lines suggested that 
acetylation of K310 is required for the full activation of specific genes, while lysines K314/ 
K315 are needed for the reduced expression of another subset of genes. Importantly, 
acetylated p65 was recruited to the promoter of some of these genes, thus providing 
additional evidence that p65 acetylation is implicated in gene-specific transcriptional 
regulation. 
 In the second manuscript (submitted), we also describe SIRT2 as a novel p65 
deacetylase after TNFα-induced NF-κB activation. Since we detected the interaction of both 
endogenous proteins in the cytoplasm and since we showed that SIRT2 stays in that cellular 
compartment during NF-κB activation by TNFα, our data strongly suggest that p65 is 
deacetylated by SIRT2 in the cytoplasm after termination of the first wave of NF-κB 
activation. 
 In the last manuscript (submitted), the role of CARM1 as a transcriptional coactivator 
of NF-κB was studied. Custom microarray and real-time RT-PCR experiments identified a 
subset of NF-κB-dependent genes that require CARM1 for their proper expression. Its 
enzymatic activity was dispensable, suggesting that CARM1 might be required for the 
recruitment of other important coactivator or for stabilization of complexes, rather that for 
methylation of histones or non-histone proteins. 
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9 Acetylation of p65 and its influence on NF-κB-dependent transcription 
 
The investigation of the effect of p65 acetylation on the NF-κB induction started many years 
ago in our lab. To study the functional relevance of p65 acetylation, p65-/- MEFs were 
genetically complemented with p65 wild type or acetylation deficient mutants, including a 
single mutant (K310R), a double mutant (K314/315R) and a triple mutant (KTR). To hinder 
acetylation in these mutants, the acetylation sites were mutated to arginines. Using these 
cells, it was shown that p65 acetylation does not affect NF-κB DNA binding, nuclear 
translocation or IκBα degradation. Interestingly, a difference in gene expression upon TNFα 
treatment was observed in the different mutants compared to wild type cells (see section 9.1). 
As already stated in section 4.4, two other groups have identified additional 
acetylation sites of p65. Cheng et al. reported acetylation at lysines 218, 221 and 310; while 
the Benkirane group reported lysines 122 and 123 to be modified [244, 261]. Both groups 
described particular effects on p65 activity by acetylation at the different lysine residues. The 
discrepancy in the identification of acetylated lysines in p65 by the distinct groups may be 
explained by the use of different experimental approaches (mass spectrometry vs. peptide 
mapping analysis), stimuli (TNFα vs. PMA and unstimulated) and cell lines (MEFs vs. HEK 
293T, HeLa and Jurkat T-cells). 
Although we have demonstrated that lysines 310, 314 and 315 are acetylated in vitro 
and in vivo when p300 is co-expressed, we could show p65 acetylation at endogenous levels 
only for K310 after TNFα stimulation, but not for K314 or K315 acetylation. This suggests 
that either the quality and sensitivity of the different antibodies is not comparable, that K310 
is the major acceptor site for acetylation upon TNFα treatment in MEFs and that acetylation 
at K314/315 cannot be detected by western blot, or that these lysines are methylated (see 
section 9.2). 
 
9.1 Regulation of NF-κB-dependent transcription by p65 acetylation 
Genome-wide microarray studies revealed that specific genes were either up- or 
downregulated in the triple mutant KTR compared to wild type cells after 45 minutes of 
stimulation. In addition, when the cells were stimulated for a longer period, 3 hours, the list 
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of differentially expressed genes changed, suggesting that transcriptional regulation through 
p65 acetylation is a dynamic process. 
When gene expression profiles of pTV (p65-/- MEFs complemented with the empty 
vector) and wild type cells were compared, we found that the transcriptional activation of 
several differentially expressed genes between the acetylation-deficient mutants and wild 
type MEFs did not depend on p65. This could be due to the partly redundancy in gene 
activation observed between the different NF-κB family members [204].  For example, some 
genes have been shown to recruit all NF-κB proteins with no apparent specificity to their 
promoters in dendritic cells [212]. In contrast, another study described that some NF-κB 
target genes have remarkably different requirements for NF-κB proteins [208]. To avoid any 
misinterpretation of our results, we decided to focus only on genes whose expression requires 
p65. 
Interestingly, p65 acetylation did not always correlate with transcriptional activation; 
some of the genes appeared to be less induced in wild type cells compared to non-
acetylatable mutants. Although the majority of evidence describes p65 as a transcriptional 
activator, it has been shown that it can also act as a transcriptional repressor [271, 272].  
Gene expression analysis by real-time RT-PCR revealed that the expression of specific genes 
was increased in the double mutant K314/315R relative to wild type cells, while expression 
of another subset of genes was reduced when lysine 310 was mutated to arginine (in K310R 
or KTR cell lines) compared to wild type cells. The requirement of an intact acetylation site 
at K310 suggests that acetylation at this lysine is needed for full activation of a subset of 
genes. On the contrary, lysines 314 and/or 315 appear to be required for the tight control of 
expression of specific genes after induction. Together, acetylation of p65 seems to have 
opposing effects on gene transcription depending on the lysine residues that are modified. 
The possible mechanism how this can take place will be further discussed in section 9.2. 
 The majority of genes found to depend on p65 acetylation were not previously 
described as NF-κB target genes. However, the impaired induction of several of these genes 
in pTV suggested that these might be novel NF-κB-dependent genes. To confirm this 
hypothesis, we performed ChIP assays using primers directed to putative κB sites identified 
by bioinformatic analysis on the promoters of three genes. In response to TNFα, p65 was 
recruited to the promoters of Mpa2l and Cfb. Using antibodies against acetyl K310 and acetyl 
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K314, we demonstrated that chromatin-associated p65 is acetylated at these two lysines, 
further implying that acetylation of p65 is involved in transcriptional regulation. ChIP assays 
with anti-acetyl K315 antibody were unsuccessful. The fact that p65 was found to be 
acetylated at lysine 314 at the promoters of Cfb and Mpa2l although the expression of these 
two genes was not impaired in K314/315R cells suggests that p65 might be acetylated at 
many more promoters than the ones that really require this modification for proper gene 
expression.  
Our gene expression analysis showed that some genes were regulated by p65 
acetylation although it was not recruited to their promoters. Because several transcriptional 
regulators are among the target genes of NF-κB, it is known that this family of transcription 
factors influences the expression of many more genes than its direct targets [196]. One 
example is Mmp13, whose transcriptional activation has been shown to require the NF-κB-
dependent expression of the transcription factor Elk-1 [273]. Therefore, acetylation of p65 
might indirectly regulate the expression of some genes. Mmp10 appears to be such a gene, 
since we failed to detect an enrichment of p65 at its promoter. Alternatively, it could be that 
p65 is recruited to Mmp10 promoter with a different kinetics than the one we investigated; or 
that p65 binds to an enhancer element localized far away from the TSS of Mmp10 or even at 
another chromosome. 
 
9.2 Possible mechanisms of transcriptional regulation by p65 acetylation 
The transcriptional activity of several transcription factors has been reported to be modulated 
by acetylation; the best example of this is p53 [274]. How can the acetylation status of p65 
influence the expression of specific NF-κB target genes? This regulation most probably takes 
place at the chromatin level, since we showed that p65 acetylated at K310 and K314 is bound 
to chromatin. 
 Acetyl lysines are known to be recognized by bromodomains. Several transcriptional 
regulators, such as components of chromatin-remodeling complexes, general transcription 
factors and HATs, have been reported to get recruited to chromatin through binding of their 
bromodomains to acetylated histones or other acetylated chromatin-bound proteins 
(discussed in section 3.3) [114]. The investigation of the interaction between acetyl lysines 
and bromodomains is difficult to perform, since these interactions are thought to be transient 
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due to the reversible nature of lysine acetylation. Notably, the affinity of several 
bromodomain binding to acetyl lysines is generally much weaker than that of chromodomain 
or PHD finger to methyl lysines [275]. Acetylated p53 is an example of a modified protein 
recognized by bromodomains. Acetylation of p53 at two lysines has been shown to facilitate 
the recruitment of TAF1, a subunit of TFIID, to the p21 promoter through its bromodomains 
[269]. A similar mechanism could be predicted for p65 acetylation. According to our results, 
we would expect a transcriptional coactivator to bind to acetylated K310. However, 
interaction studies between acetylated p65 and TAF1 bromodomains in section 7.3.2 revealed 
that although p65 binding to TAF1 bromodomains increased upon acetylation and was 
dependent on the integrity of TAF1 double bromodomain, this interaction was not mediated 
by p65 acetylation at lysines 218, 221, 310, 314 and 315. It could be that TAF1 double 
bromodomain recognizes p65 acetylated at yet unidentified lysines. Further experiments need 
to be performed to clarify this issue.  
In addition to TAF1, we investigated the interaction between acetylated p65 and the 
bromodomain of p300. We unexpectedly observed a preferred binding of non-acetylated p65 
over acetylated p65 to this bromodomain (section 7.3.1). It could be that the bromodomain of 
p300 preferentially recognizes non-acetylated lysines of p65, in analogy to the preferential 
binding of PHD finger of BHC80 to unmethylated H3K4 [98]. Nevertheless, co-
immunoprecipitation studies revealed that full-length p300 interacted with p65 wild type at 
the same extent as with p65 acetylation-deficient mutants [245], suggesting that the 
acetylation status of p65 is not important for the binding to full-length p300 in vivo. 
Moreover, the bromodomain of p300 is located in the middle of the protein, but p65 has been 
described to bind to the N-terminal part of p300, further suggesting that acetylation of p65 
does not influence binding to p300 in vivo. 
Recently, Huang et al. reported that bromodomains of Brd4 bind to acetylated K310, 
which enhances transcriptional activation of NF-κB and the expression of a subset of NF-κB 
inflammatory genes in an acetylated K310-dependent manner [242]. Our results shown in 
section 7.3.3 failed to confirm this interaction in vivo, since we always observed an 
unspecific band in our negative control pTV. It should be noted that this control is missing in 
the mentioned study by Huang et al. 
 Another possibility to explain how p65 acetylation modulates gene expression is that 
site-specific acetylation of p65 interferes with stabilization of the general transcription 
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machinery, coactivators or corepressors. Furthermore, crosstalk between p65 acetylation and 
another posttranslational modification in p65 could influence regulation of gene expression. 
For example, phosphorylation of serine 276 and 536 in p65 have been shown to be needed 
for binding to p300 [260], and thus required for subsequent acetylation at K310 [262]. Two 
additional phosphorylation sites in p65 (S311 and S316) are located directly adjacent to the 
identified acetylated lysine residues, which could influence acetylation at K310, K314 or 
K315. Moreover, during the writing of this thesis, K314/315 were described to be methylated 
by Set9 to negatively regulate NF-κB-dependent transcription [276]. Thus, in addition to 
acetylation, lysines 314 and 315 might be subjected to methylation. This raises the possibility 
that a crosstalk between these two posttranslational modifications at K314/315 exists, which 
could influence regulation of gene expression. Our ChIP experiments clearly show that 
chromatin-bound p65 is acetylated at K310 and K314 in a promoter-specific manner. Based 
on this observation, we reason that acetylation at K314/315 could prevent methylation-
mediated repression of target genes and thus positively influence transcription, together with 
acetylated lysine 310. A direct evidence for methylated p65 at K314/315 bound to chromatin 
is still missing, making the interpretation of the results difficult. Importantly, K314/315R 
mutant MEFs from the mentioned study show increased gene expression compared to wild 
type cells, which correlates with our results. Whether the same genes are regulated by both 
posttranslational modifications should be further studied. Alternatively, both posttranslational 
modifications might regulate distinct set of NF-κB-dependent genes and thus not influence 
each other. 
 
 
10 Deacetylation of p65 by SIRT2 
 
Lysine acetylation is a very dynamic process, the steady-state equilibrium of which is 
regulated by the opposing activities of HATs and HDACs [277]. p65 is not an exception of 
this: its acetylation status changes rapidly over time. Western blot analysis of p65-/- MEFs 
complemented with p65 wild type and stimulated with TNFα for different time periods 
uncovered that p65 is acetylated rapidly in the nucleus at lysine 310 (after 20 minutes of 
stimulation). Acetylation levels were dramatically decreased only 25 minutes after this 
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observation (after 45 minutes of TNFα treatment). This observation prompted us to 
investigate which enzyme is responsible for p65 deacetylation. 
To explore this, we performed deacetylation assays with overexpressed proteins in 
HEK 293T cells and with recombinant proteins in vitro using class I HDAC members 
(HDAC1, 2 and 3) and SIRT1, 2, 6 and 7. We chose class I HDAC members because they are 
known to localize exclusively to the nucleus [144]. SIRT1, 2, 6 and 7 were selected because 
these class III HDACs have been reported to localize to nucleus and cytoplasm, but not to 
mitochondria, as SIRT3, 4 and 5 [163]. In vitro deacetylation assays with class I HDACs 
were not performed, since they are known to catalyze deacetylation reactions only in 
complex with other proteins. In the tested conditions, we observed deacetylation of p65 at all 
three lysines only by SIRT1 and SIRT2. In contrast to our results, HDAC3 has been 
previously reported to deacetylate p65 when overexpressed in COS-7 cells [227]. The 
difference in cell lines used for this and our experiment could explain the discrepancy in both 
results. Recently, a study showed that SIRT6 does not deacetylate p65 in vitro or in vivo, in 
agreement with our results, but deacetylates histone H3K9 to attenuate NF-κB signaling 
[169]. Our observation that both SIRT1 and SIRT2 were able to deacetylate p65 in vitro, but 
that only deficiency of SIRT2 (but not SIRT1) was sufficient to induce hyperacetylation of 
p65 at K310 upon TNFα stimulation in vivo, suggests that SIRT2 is the main deacetylase of 
p65 in MEFs upon TNFα stimulation. Consistent with our results, SIRT1 has been shown to 
deacetylate p65 at K310 in vitro and when overexpressed in HEK 293T cells [159]. Thus, it 
is possible that endogenous SIRT1 plays a major role in deacetylating p65 in other cell types 
or after NF-κB induction with another stimuli than TNFα. The in vivo study of p65 
deacetylation by SIRT2 was only possible for acetylated K310, since we were not able to 
detect endogenous p65 acetylation at K314 or K315 with specific antibodies in MEFs. Thus, 
we can currently not exclude that another enzyme deacetylates p65 at K314 or K315 in vivo. 
Several studies have reported that SIRT2 localizes to the cytoplasm, where it 
deacetylates α-tubulin [161]. Despite its initial description as a cytoplasmic protein, it was 
later shown that SIRT2 deacetylates nuclear proteins as well, including p53, p300, H3 and 
H4 [162, 166, 278]. Immunostaining experiments revealed that SIRT2 constantly shuttles 
between nucleus and cytoplasm during interphase, due to a putative NES found in the N-
terminal part of SIRT2, which causes the active export of this sirtuin from the nucleus in a 
Crm1-dependent manner [164]. Another study described that SIRT2 translocates to the 
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nucleus at prophase during G2/M transition to deacetylate histone H4 at lysine 16 (H4K16), 
which results in compaction of the chromatin [162]. Knowing that SIRT2 is predominantly a 
cytoplasmic protein that can potentially localize to the nucleus, we decided to investigate in 
which cellular compartment is p65 deacetylated by SIRT2. Due to the nuclear localization of 
acetylated p65, we investigated whether SIRT2 would translocate to the nucleus upon TNFα, 
the stimulus that induces p65 acetylation. Immunostaining revealed that this is not the case, 
SIRT2 stays in the cytoplasm while p65 shuttles to the nucleus upon TNFα stimulation to 
activate transcription. In addition, we observed that these two proteins interact in the 
cytoplasm, suggesting that SIRT2 deacetylates p65 in that cellular compartment. 
TNFα is known to activate the canonical NF-κB pathway, where p65/p50 
heterodimers translocate to the nucleus after IκBα proteosomal degradation. p65/p50 then 
bind to κB sites in the promoter and enhancer region of regulated genes and recruit 
coactivators to activate transcription, such as p300. We have shown that p65 is rapidly 
acetylated by p300 in the nucleus, most probably after the first interaction between these two 
proteins. Immunostaining and EMSA experiments have shown that the majority of NF-κB 
shuttles back to the cytoplasm between 30 to 60 minutes after TNFα stimulation in MEFs 
[245, 279]. This time correlates with the observed decrease in p65 acetylation at K310 with 
western blot analysis, supporting the idea that p65 is deacetylated in the cytoplasm. Thus, an 
attractive possibility is that SIRT2 deacetylates p65 when NF-κB shuttles back to the 
cytoplasm, to reset the NF-κB response. Any p65 that would afterwards translocate to the 
nucleus again during persistent TNFα stimulation would have to be freshly acetylated by 
p300 to modulate gene expression, thereby allowing a tight control of NF-κB-dependent 
transcription.  
If SIRT2 is the major enzyme deacetylating p65 after termination of the first wave of 
NF-κB activation by TNFα, and knowing that p65 acetylation modulates transcription of 
target genes, then NF-κB-dependent gene expression should be misregulated in the absence 
of SIRT2. This is indeed the case in Sirt2-/- MEFs, where induction of Mpa2l is drastically 
increased in response to TNFα compared to Sirt2+/+ cells. Since acetylation of p65 at lysine 
310 was shown to be required for full activation of this gene and since p65 is hyperacetylated 
at that lysine in Sirt2-/- MEFs, our data suggests that p65 deacetylation by SIRT2 influences 
NF-κB-dependent transcription of specific genes in vivo. Gene expression analysis of a 
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number of genes by real-time RT-PCR revealed that the induction of all these genes except 
the control genes Rps6 and Rps12 was slightly higher (around 3 fold) in Sirt2-/- cells after 
TNFα treatment compared to Sirt2+/+ cells (see section 7.5). Considering that SIRT2 has been 
shown to deacetylate H4K16 to condense chromatin [162], a plausible explanation is that 
Sirt2-/- MEFs possess a more open chromatin structure than wild type MEFs, which would 
moderately facilitate the recruitment of transcription regulators to chromatin templates.  
 
 
11 Perspectives 
 
The exact mechanism behind the regulation of NF-κB-dependent transcription by p65 
acetylation should be further investigated at the chromatin level. It would be interesting to 
elucidate by ChIP whether p65 recruits specific bromodomain-containing coactivators or 
corepressor through its acetyl lysines to the promoters or enhancers of the regulated genes. 
Interaction studies between acetylated p65 and bromodomain-containing proteins would 
further help to characterize this interaction. As mentioned above, acetylated K310 could be 
recognized by the bromodomain of a coactivator needed for the full transcription of Mpa2l 
and Cfb, for example. Conversely, acetylation at K310 could hinder the binding of a 
corepressor to these promoters. Although EMSA studies showed that p65 binding to DNA is 
not impaired in the acetylation-deficient mutants, the stability of p65/DNA complex should 
be further addressed in vivo by ChIP in the p65-/- MEFs complemented with p65 wild type or 
the acetylation-deficient mutants. It is possible that p65 is not properly recruited to the 
promoters of Mpa2l and Cfb when it is not acetylated at K310. In this regard, p65 K314/315R 
mutant has recently been suggested to bind stronger to chromatin than p65 wild type [276], 
which should be confirmed in our system. In addition, it may be important to investigate 
whether there is a crosstalk between the newly described methylation of K314/315 and 
acetylation at all three lysines 310, 314 and 315. 
To understand how general the regulation of NF-κB-dependent transcription by p65 
acetylation is, ChIP-chip could be performed using the specific antibodies against acetyl 
K310 and acetyl K314. This would allow the identification of new genes regulated by p65 
acetylation, although we have evidence that acetylated p65 is recruited to many more 
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promoters than the ones that strictly require it. Furthermore, genome-wide expression 
analysis after IL-1β stimulation would reveal if p65 acetylation regulates the expression of 
different genes when distinct stimuli are used. Both TNFα and IL-1β are known to activate 
the NF-κB response, though in addition, these different cytokines also activate distinct 
cellular pathways. Thus, it would be interesting to investigate the possible overlap of genes 
regulated by p65 acetylation upon TNFα and IL-1β. In addition, it should be addressed 
whether SIRT2 or another enzyme deacetylates p65 after NF-κB activation through IL-1β 
stimulation. An additional remaining question is whether p65 is acetylated during the non-
canonical NF-κB pathway and whether this regulates NF-κB-dependent transcription as well. 
Our gene expression analysis in Sirt2-/- and Sirt2+/+ MEFs suggested that overall gene 
expression is higher in the absence of SIRT2. To confirm this hypothesis, genome-wide 
expression analysis should be performed with cells from both genotypes, both under basal 
conditions and after stimulation. In addition, recruitment of acetylated p65 to promoters of 
regulated genes should be compared in both cell lines, as well as the levels of acetylated 
H4K16. The difference in chromatin structure between Sirt2+/+ and Sirt2-/- cells could further 
be studied with MNase protection assays. 
It should be noted that when using PARP1 as a nuclear loading control, we 
unexpectedly observed less expression of this nuclear protein in Sirt2-/- cells compared to 
wild type cells. PARP1 binding to nucleosomes was both reported to promote the formation 
of compact and transcriptionally repressed chromatin [280], and to correlate with gene 
expression when it binds to nucleosomes in the promoter of transcribed genes [281]. It would 
be interesting to investigate why and how PARP1 protein expression is decreased in Sirt2-/- 
MEFS, and whether this observation is linked to chromatin structure in Sirt2-/- cells. 
NF-κB sustained activation has been correlated with occurrence of some cancers 
[177]. Specifically, high expression of p65 has been linked to pancreatic cancer [176]. 
Currently, whether p65 acetylation is involved and even required for tumorogenesis is not 
known. Future experiments that analyze the acetylation status of p65 in different tumor 
biopsies should be able to provide insights into this process. 
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